



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : <b>C07C 45/27, 49/21, 49/203, C07D 305/14, 307/93, 317/70</b>		A1	(11) International Publication Number: <b>WO 95/03265</b> (43) International Publication Date: <b>2 February 1995 (02.02.95)</b>
(21) International Application Number: <b>PCT/US94/08350</b>		Douglas [US/US]; 109 Herb Morgan Building, 2035 East Paul Dirac Drive, Tallahassee, FL 32310 (US). SMITH, Chase [US/US]; 109 Herb Morgan Building, 2035 East Paul Dirac Drive, Tallahassee, FL 32310 (US). LIANG, Feng [CN/US]; 109 Herb Morgan Building, 2035 East Paul Dirac Drive, Tallahassee, FL 32310 (US). MURTHI, Krishna [IN/US]; 109 Herb Morgan Building, 2035 East Paul Dirac Drive, Tallahassee, FL 32310 (US).	
(22) International Filing Date: <b>20 July 1994 (20.07.94)</b>		(74) Agents: HEJLEK, Edward, J. et al.; Senniger, Powers, Leavitt and Roedel, 16th floor, One Metropolitan Square, St. Louis, MO 63102 (US).	
(30) Priority Data: 08/095,161 20 July 1993 (20.07.93) US 08/138,229 15 October 1993 (15.10.93) US 08/189,058 27 January 1994 (27.01.94) US		(81) Designated States: AU, CA, CN, CZ, FI, HU, JP, KR, NO, NZ, PL, RU, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).	
(71) Applicant (for all designated States except US): FLORIDA STATE UNIVERSITY [US/US]; 109 Herb Morgan Building, 2035 East Paul Dirac Drive, Tallahassee, FL 32310 (US).		Published <i>With international search report.</i> <i>With amended claims.</i>	
(72) Inventors; and (75) Inventors/Applicants (for US only): HOLTON, Robert, A. [US/US]; 109 Herb Morgan Building, 2035 East Paul Dirac Drive, Tallahassee, FL 32310 (US). SOMOZA, Carmen [AR/US]; 109 Herb Morgan Building, 2035 East Paul Dirac Drive, Tallahassee, FL 32310 (US). KIM, Hyeong, B. [KR/US]; 109 Herb Morgan Building, 2035 East Paul Dirac Drive, Tallahassee, FL 32310 (US). SHINDO, Mitsuru [JP/JP]; 109 Herb Morgan Building, 2035 East Paul Dirac Drive, Tallahassee, FL 32310 (US). BIEDIGER, Ronald, J. [US/US]; 109 Herb Morgan Building, 2035 East Paul Dirac Drive, Tallahassee, FL 32310 (US). BOATMAN, P.,			
(54) Title: <b>SYNTHESIS OF TAXOL AND ITS DERIVATIVES</b>			
(57) Abstract  Process for the synthesis of taxol and other tricyclic and tetracyclic taxanes.			

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				


### Synthesis of Taxol and its derivatives.

This invention was made with Government support under NIH Grant #CA 42031 awarded by the National Institutes of Health. The United States Government has certain rights in the invention.

#### BACKGROUND OF THE INVENTION

The present invention is directed to a process for the synthesis of taxol and other tricyclic and tetracyclic taxanes and novel intermediates thereof.


The taxane family of terpenes, of which taxol is a member, has attracted considerable interest in both the biological and chemical arts. Taxol is a promising cancer chemotherapeutic agent with a broad spectrum of antileukemic and tumor-inhibiting activity. Taxol has the following structure:



wherein Ac is acetyl.


The supply of taxol is presently being provided by the bark from Taxus brevifolia (Western Yew). However, taxol is found only in minute quantities in the bark of these slow growing evergreens. Consequently, chemists in recent years have expended their energies in trying to find a viable synthetic route for the preparation of taxol. To date, the results have not been entirely satisfactory.

A semi-synthetic approach to the preparation of taxol has been described by Greene, et al. in JACS 110, 5917 (1988), and involves the use of a congener of taxol, 10-deacetyl baccatin III which has the structure of formula II shown below:




10-deacetyl baccatin III is more readily available than taxol since it can be obtained from the needles of Taxus baccata. According to the method of Greene et al., 10-deacetyl baccatin III ("10-DAB") is converted to taxol by attachment of the C-10 acetyl group and by attachment of the C-13  $\beta$ -amido ester side chain through the esterification of the C-13 alcohol with a  $\beta$ -amido carboxylic acid unit.


15 Denis et al. in U.S. Patent No. 4,924,011 disclose another process for preparing derivatives of baccatin III or of 10-deactylbaccatin III of general formula



in which R' denotes hydrogen or acetyl. As reported, an acid of general formula:



in which R<sub>1</sub> is a hydroxy-protecting group, is condensed with a taxane derivative of general formula:



in which  $R_2$  is an acetyl hydroxy-protecting group and  $R_3$  is a hydroxy-protecting group, and the protecting groups  $R_1$ ,  $R_3$  and, where appropriate,  $R_2$  are then replaced by hydrogen.


remote corners of the world and the extraction of 10-DAB and/or baccatin III therefrom.

SUMMARY OF THE INVENTION


5 Among the objects of the present invention, therefore, is the provision of a process for the synthesis of taxol and other tetracyclic taxanes; the provision of such a process which is highly diastereoselective; the provision of such a process which proceeds in relatively high yield; and the provision of 10 key intermediates and processes for their preparation.

Briefly, therefore, the present invention is directed to a process for the preparation of taxol and other tricyclic and tetracyclic taxanes.

15 In accordance with one aspect of the present invention, the process comprises reacting a compound having the formula



20 with  $\text{BrMgN}(\text{iPr})_2$ , an aldehyde (or ketone), followed by phosgene and an alcohol to form a compound having the formula:



wherein

R<sub>1</sub> is hydrogen or protected hydroxy; R<sub>2</sub> is hydrogen or protected hydroxy;

5 R<sub>3</sub> is oxo;

R<sub>7b</sub> is hydrogen, alkyl, cyano, hydroxy, protected hydroxy, or -OCOR<sub>36</sub>, or together with R<sub>3</sub> or R<sub>9</sub> is a carbonate;

10 R<sub>7c</sub> and R<sub>7d</sub> are independently hydrogen, alkyl, alkenyl, alkynyl, aryl or heteroaryl;


R<sub>9</sub> is hydrogen, protected hydroxy, or oxo;

R<sub>10</sub> is -OP<sub>10</sub>;


R<sub>13</sub> is -OP<sub>13</sub>; and

P<sub>10</sub> and P<sub>13</sub> are hydroxy protecting groups.

15 In accordance with another aspect of the present invention, the process comprises reacting a compound having the formula



with lithium tetramethylpiperidide to form a compound having the formula:



wherein


5 R<sub>1</sub> is hydrogen or protected hydroxy;

R<sub>7c</sub> is hydrogen, alkyl, alkenyl, alkynyl, aryl or heteroaryl;


R<sub>9</sub> is hydrogen, protected hydroxy, or oxo; and

P<sub>10</sub> and P<sub>13</sub> are hydroxy protecting groups.

10 In accordance with another aspect of the present invention, the process comprises reacting a compound having the formula:




15 with lithium tetramethylpiperidide and camphosulfonyl oxaziridine to form a compound having the formula:




;

wherein R<sub>9</sub> is hydrogen, protected hydroxy, or oxo; R<sub>7c</sub> is hydrogen, alkyl, alkenyl, alkynyl, aryl or heteroaryl; and P<sub>10</sub> and P<sub>13</sub> are hydroxy protecting groups.

5 In accordance with another aspect of the present invention, the process comprises reacting a compound having the formula:




10 with a hydride reducing agent, preferably Red-Al, to form a compound having the formula:




;

wherein R<sub>9</sub> is hydrogen, protected hydroxy, or oxo; R<sub>7c</sub> is hydrogen, alkyl, alkenyl, alkynyl, aryl or heteroaryl; and P<sub>10</sub> and P<sub>13</sub> are hydroxy protecting groups.

5 In accordance with another aspect of the present invention, the process comprises reacting a compound having the formula:



with lithium diisopropylamide to form a compound having the formula:




10


15

wherein R is lower alkyl, R<sub>1</sub> is hydrogen, protected hydroxy or R<sub>1</sub> and R<sub>2</sub> together form a carbonate, R<sub>2</sub> is hydrogen, protected hydroxy or R<sub>1</sub> and R<sub>2</sub> together form a carbonate, R<sub>9</sub> is hydrogen, protected hydroxy, or oxo; R<sub>7c</sub> is hydrogen, alkyl, alkenyl, alkynyl, aryl or heteroaryl; and P<sub>10</sub> and P<sub>13</sub> are hydroxy protecting groups.

In accordance with another aspect of the present invention, the process comprises reacting a compound having the formula:



with DBU to form a compound having the formula:



wherein

5                   R<sub>1</sub> is hydrogen, hydroxy, protected hydroxy or -OCOR<sub>30</sub>, or together with R<sub>2</sub> is a carbonate;

10                  R<sub>2</sub> is hydrogen, hydroxy, protected hydroxy, oxo, or -OCOR<sub>31</sub>, or together with R<sub>1</sub> is a carbonate;

15                  R<sub>4a</sub> is hydrogen, alkyl, hydroxy, or protected hydroxy, or together with R<sub>2</sub> is a carbonate;

                    R<sub>4b</sub> is hydroxymethylene;

                    R<sub>5</sub> is -OMs, -OTs or a bromide;

                    R<sub>7a</sub> is hydrogen, protected hydroxy, or -OCOR<sub>34</sub>, or together with R<sub>9</sub> is a carbonate;

                    R<sub>9</sub> is hydrogen, oxo, hydroxy, protected hydroxy, or -OCOR<sub>33</sub>, or together with R<sub>7a</sub> or R<sub>10</sub> is a carbonate;


                    R<sub>10</sub> is hydrogen, oxo, hydroxy, protected hydroxy, or -OCOR<sub>29</sub>, or together with R<sub>9</sub> is a carbonate;

10


$R_{13}$  is hydrogen, hydroxy, protected hydroxy, or  $-OCOR_{35}$ ;

$R_{29}$ ,  $R_{33}$ ,  $R_{34}$  and  $R_{35}$  are independently hydrogen, alkyl, alkenyl, alkynyl, alkoxy, aryloxy,  $-NX_8X_{10}$ ,  $-SX_{10}$ , 5 monocyclic aryl or monocyclic heteroaryl;


In accordance with another aspect of the present invention, the process comprises reacting a compound having the formula:



10 with  $KOtBu$  and  $(PhSeO)_2O$  to form a compound having the formula:



15 which rearranges in the presence of additional  $KOtBu$ , silica gel, or other acids or bases, or with heat to a compound having the formula:



wherein

R<sub>1</sub> is hydrogen, hydroxy, protected hydroxy, or together with R<sub>2</sub> is a carbonate;

5 R<sub>2</sub> is hydrogen, protected hydroxy, or -OCOR<sub>31</sub>, or together with R<sub>1</sub> or R<sub>4a</sub> is a carbonate;

R<sub>4a</sub> is hydrogen, alkyl, hydroxy, protected hydroxy, or -OCOR<sub>27</sub>, together with R<sub>4b</sub> is an oxo, or together with R<sub>2</sub>, R<sub>4b</sub>, or R<sub>5</sub> is a carbonate;

10 R<sub>4b</sub> is hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl, or cyano, together with R<sub>4a</sub> is an oxo, together with R<sub>4a</sub> or R<sub>5</sub> is a carbonate, or together with R<sub>5</sub> and the carbons to which they are attached form an oxetane ring;

15 R<sub>5</sub> is hydrogen, protected hydroxy, -OCOR<sub>33</sub>, together with R<sub>4a</sub> or R<sub>4b</sub> is a carbonate, or together with R<sub>4b</sub> and the carbons to which they are attached form an oxetane ring;


20 R<sub>7a</sub> is hydrogen, halogen, protected hydroxy, or -OCOR<sub>34</sub>; and

R<sub>27</sub>, R<sub>29</sub>, R<sub>30</sub>, R<sub>31</sub>, R<sub>33</sub>, R<sub>34</sub>, R<sub>35</sub> and R<sub>37</sub> are independently hydrogen, alkyl, alkenyl, alkynyl, alkoxy, aryloxy, -NX<sub>8</sub>X<sub>10</sub>, -SX<sub>10</sub>, monocyclic aryl or monocyclic heteroaryl.

25 X<sub>8</sub> is hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterosubstituted alkyl, alkenyl, alkynyl, aryl or heteroaryl;

$X_{10}$  is alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterosubstituted alkyl, alkenyl alkynyl, aryl or heteroaryl;

In general, the process of the present invention may be used to prepare taxanes having the formula:



(1)

wherein

$R_1$  is hydrogen, hydroxy, protected hydroxy, or  $-OCOR_{30}$ ;

$R_2$  is hydrogen, hydroxy,  $-OCOR_{31}$ , or oxo;

$R_{4a}$  is hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl, cyano, hydroxy,  $-OCOR_{27}$ , or together with  $R_{4b}$  forms an oxo, oxirane or methylene;

$R_{4b}$  is hydrogen, together with  $R_{4a}$  forms an oxo, oxirane or methylene, or together with  $R_5$  and the carbon atoms to which they are attached form an oxetane ring;

$R_5$  is hydrogen, halogen, hydroxy, protected hydroxy,  $-OCOR_{37}$ , oxo, or together with  $R_{4b}$  and the carbon atoms to which they are attached form an oxetane ring;


$R_{7a}$  is hydrogen, halogen, hydroxy, protected hydroxy,  $-OCOR_{34}$ , oxo, or  $-OR_{28}$ ;

$R_9$  is hydrogen, hydroxy, protected hydroxy, acyloxy, or oxo;

$R_{10}$  is hydrogen,  $-OCOR_{29}$ , hydroxy, protected hydroxy, or oxo;

$R_{13}$  is hydroxy, protected hydroxy,  $MO^-$  or

13



$R_{28}$  is a functional group which increases the solubility of the taxane;

5  $R_{27}$ ,  $R_{29}$ ,  $R_{30}$ ,  $R_{31}$ ,  $R_{34}$  and  $R_{37}$  are independently hydrogen, alkyl, alkenyl, alkynyl, monocyclic aryl or monocyclic heteroaryl;

$X_1$  is  $-OX_6$ ,  $-SX_7$ , or  $-NX_8X_9$ ;

10  $X_2$  is hydrogen, alkyl, alkenyl, alkynyl, aryl, or heteroaryl;

$X_3$  and  $X_4$  are independently hydrogen, alkyl, alkenyl, alkynyl, aryl, or heteroaryl;

15  $X_5$  is  $-COX_{10}$ ,  $-COOX_{10}$ ,  $-COSX_{10}$ ,  $-CONX_8X_{10}$ , or  $-SO_2X_{11}$ ;

$X_6$  is hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl, hydroxy protecting group, or a functional group which increases the water solubility of the taxane derivative;

20  $X_7$  is alkyl, alkenyl, alkynyl, aryl, heteroaryl, or sulfhydryl protecting group;

$X_8$  is hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterosubstituted alkyl, alkenyl, alkynyl, aryl or heteroaryl;

$X_9$  is an amino protecting group;


25  $X_{10}$  is alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterosubstituted alkyl, alkenyl alkynyl, aryl or heteroaryl;

$X_{11}$  is alkyl, alkenyl, alkynyl, aryl, heteroaryl,  $-OX_{10}$ , or  $-NX_8X_{14}$ ;

30  $X_{14}$  is hydrogen, alkyl, alkenyl, alkynyl, aryl, or heteroaryl; and

$M$  comprises ammonium or is a metal.

The present invention is additionally directed to an intermediate for use in the preparation of a tricyclic or tetracyclic taxane having the formula:



5 wherein

R<sub>1</sub> is hydrogen, hydroxy, protected hydroxy or -OCOR<sub>30</sub>, or together with R<sub>2</sub> is a carbonate;

R<sub>2</sub> is hydrogen, hydroxy, protected hydroxy, oxo, or -OCOR<sub>31</sub>, or together with R<sub>1</sub> is a carbonate;

10 R<sub>3</sub> is hydrogen, hydroxy, protected hydroxy, -OCOR<sub>32</sub>, or oxo;

R<sub>8</sub> is hydrogen, alkyl, alkenyl, alkynyl, aryl or heteroaryl;

15 R<sub>9</sub> is hydrogen, hydroxy, protected hydroxy, oxo, or -OCOR<sub>33</sub>, or together with R<sub>10</sub> is a carbonate;

R<sub>10</sub> is hydrogen, hydroxy, protected hydroxy, oxo, or -OCOR<sub>29</sub>, or together with R<sub>9</sub> is a carbonate;

R<sub>13</sub> is hydrogen, hydroxy, protected hydroxy, -OCOR<sub>35</sub> or MO-;


20 R<sub>29</sub>, R<sub>30</sub>, R<sub>31</sub>, R<sub>32</sub>, R<sub>33</sub>, and R<sub>35</sub> are independently hydrogen, alkyl, alkenyl, alkynyl, alkoxy, aryloxy, -NX<sub>8</sub>X<sub>10</sub>, -SX<sub>10</sub>, monocyclic aryl or monocyclic heteroaryl;

X<sub>8</sub> is hydrogen, alkyl, alkenyl, alkynyl, aryl, or heteroaryl;

25 X<sub>10</sub> is alkyl, alkenyl, alkynyl, aryl, or heteroaryl; and

M comprises ammonium or is a metal.

The present invention is further directed to an intermediate for use in the preparation of a tricyclic or tetracyclic taxane having the formula:



5 wherein

R<sub>1</sub> is hydrogen, hydroxy, protected hydroxy or -OCOR<sub>30</sub>, or together with R<sub>2</sub> is a carbonate;

R<sub>2</sub> is hydrogen, hydroxy, protected hydroxy, oxo, or -OCOR<sub>31</sub>, or together with R<sub>1</sub> is a carbonate;

R<sub>3</sub> is hydrogen, hydroxy, protected hydroxy, -OCOR<sub>32</sub>, or oxo, or together with R<sub>7b</sub> is a carbonate;

R<sub>7b</sub> is hydrogen, alkyl, cyano, hydroxy, protected hydroxy, or -OCOR<sub>36</sub>, or together with R<sub>3</sub> or R<sub>9</sub> is a carbonate;

R<sub>7c</sub> and R<sub>7d</sub> are independently hydrogen, alkyl, alkenyl, alkynyl, aryl or heteroaryl;

R<sub>9</sub> is hydrogen, hydroxy, protected hydroxy, oxo, or -OCOR<sub>33</sub>, or together with R<sub>7b</sub> or R<sub>10</sub> is a carbonate;

R<sub>10</sub> is hydrogen, hydroxy, protected hydroxy, oxo, or -OCOR<sub>29</sub>, or together with R<sub>9</sub> is a carbonate;

R<sub>13</sub> is hydrogen, hydroxy, protected hydroxy, -OCOR<sub>35</sub> or MO-;


R<sub>29</sub>, R<sub>30</sub>, R<sub>31</sub>, R<sub>32</sub>, R<sub>33</sub>, R<sub>35</sub> and R<sub>36</sub> are independently hydrogen, alkyl, alkenyl, alkynyl, alkoxy, aryloxy, -NX<sub>8</sub>X<sub>10</sub>, -SX<sub>10</sub>, monocyclic aryl or monocyclic heteroaryl;

$X_8$  is hydrogen, alkyl, alkenyl, alkynyl, aryl, or heteroaryl;

$X_{10}$  is alkyl, alkenyl, alkynyl, aryl, or heteroaryl; and

5 M comprises ammonium or is a metal.

The invention is further directed to an intermediate for use in the preparation of a tricyclic or tetracyclic taxane having the formula:



10 wherein

$R_1$  is hydrogen, hydroxy, protected hydroxy or  $-OCOR_{30}$ , or together with  $R_2$  is a carbonate;

15  $R_2$  is hydrogen, hydroxy, protected hydroxy, oxo, or  $-OCOR_{31}$ , or together with  $R_1$  is a carbonate;

$R_3$  is hydrogen, hydroxy, protected hydroxy, or  $-OCOR_{32}$ ;

20  $R_{7b}$  is hydrogen, alkyl, cyano, hydroxy, protected hydroxy, or  $-OCOR_{36}$ , or together with  $R_3$  or  $R_9$  is a carbonate;

$R_{7c}$  is hydrogen, alkyl, alkenyl, alkynyl, aryl or heteroaryl;

25  $R_9$  is hydrogen, hydroxy, protected hydroxy, oxo, or  $-OCOR_{33}$ , or together with  $R_{10}$  is a carbonate;

$R_{10}$  is hydrogen, hydroxy, protected hydroxy, oxo, or  $-OCOR_{29}$ , or together with  $R_9$  is a carbonate;

$R_{13}$  is hydrogen, hydroxy, protected hydroxy,  $-OCOR_{35}$  or  $MO-$ ;


$R_{29}$ ,  $R_{30}$ ,  $R_{31}$ ,  $R_{32}$ ,  $R_{33}$ , and  $R_{35}$  are independently hydrogen, alkyl, alkenyl, alkynyl, alkoxy, aryloxy,  $-5 NX_8X_{10}$ ,  $-SX_{10}$ , monocyclic aryl or monocyclic heteroaryl;

$X_8$  is hydrogen, alkyl, alkenyl, alkynyl, aryl, or heteroaryl;

$X_{10}$  is alkyl, alkenyl, alkynyl, aryl, or heteroaryl; and

10  $M$  comprises ammonium or is a metal.

The present invention is further directed to an intermediate for use in the preparation of a tricyclic or tetracyclic taxane having the formula:



15 wherein

$R$  is  $C_1 - C_8$  alkyl,

$R_1$  is hydrogen, hydroxy, protected hydroxy or  $-OCOR_{30}$ , or together with  $R_2$  is a carbonate;

20  $R_2$  is hydrogen, hydroxy, protected hydroxy, oxo, or  $-OCOR_{31}$ , together with  $R_1$  is a carbonate, or together with  $R_4$  is a carbonate;

$R_{4a}$  is hydrogen, alkyl, hydroxy, protected hydroxy, or  $-OCOR_{27}$ , or together with  $R_2$  is a carbonate;

25  $R_{7a}$  is hydrogen, halogen, hydroxy, protected hydroxy,  $-OCOR_{34}$ , or together with  $R_9$  is a carbonate;

$R_9$  is hydrogen, oxo, hydroxy, protected hydroxy,  $-OR_{28}$ , or  $-OCOR_{33}$ , or together with  $R_{7a}$  or  $R_{10}$  is a carbonate;

5                   R<sub>10</sub> is hydrogen, oxo, hydroxy, protected hydroxy, -OR<sub>28</sub>, or -OCOR<sub>29</sub>, or together with R<sub>9</sub> is a carbonate;

$R_{13}$  is hydrogen, hydroxy, protected hydroxy,  $-OCOR_{35}$  or  $MO-$ ;

10 R<sub>28</sub> is a functional group which increases the solubility of the taxane derivative;


$R_{27}$ ,  $R_{29}$ ,  $R_{30}$ ,  $R_{31}$ ,  $R_{33}$ ,  $R_{34}$ , and  $R_{35}$  are independently hydrogen, alkyl, alkenyl, alkynyl, alkoxy, aryloxy,  $-NX_8X_{10}$ ,  $-SX_{10}$ , monocyclic aryl or monocyclic heteroaryl;

15                    $X_8$  is hydrogen, alkyl, alkenyl, alkynyl, aryl,  
or heteroaryl;

$X_{10}$  is alkyl, alkenyl, alkynyl, aryl, or heteroaryl; and

M comprises ammonium or is a metal.

20 The invention is further directed to an intermediate for use in the preparation of a tricyclic or tetracyclic taxane having the formula:



wherein

25 R<sub>1</sub> is hydrogen, hydroxy, protected hydroxy or  
-OCOR<sub>30</sub>, or together with R<sub>2</sub> is a carbonate;

R<sub>2</sub> is hydrogen, hydroxy, protected hydroxy, oxo, or -OCOR<sub>31</sub>, or together with R<sub>1</sub> or R<sub>4a</sub> is a carbonate;

R<sub>4a</sub> is hydrogen, alkyl, hydroxy, protected hydroxy, or -OCOR<sub>27</sub>, together with R<sub>4b</sub> is an oxo, or together with R<sub>2</sub>, R<sub>4b</sub>, or R<sub>5</sub> is a carbonate;

R<sub>4b</sub> is hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl, or cyano, together with R<sub>4a</sub> is an oxo, together with R<sub>4a</sub> or R<sub>5</sub> is a carbonate, or together with R<sub>5</sub> and the carbons to which they are attached form an oxetane ring;


R<sub>5</sub> is hydrogen, hydroxy, protected hydroxy, -OCOR<sub>28</sub>, oxo, together with R<sub>4a</sub> or R<sub>4b</sub> is a carbonate, or together with R<sub>4b</sub> and the carbons to which they are attached form an oxetane ring;

R<sub>7a</sub> is hydrogen, halogen, hydroxy, protected hydroxy, -OR<sub>28</sub>, or -OCOR<sub>34</sub>, or together with R<sub>9</sub> is a carbonate;

R<sub>9</sub> is hydrogen, oxo, hydroxy, protected hydroxy, -OR<sub>28</sub>, or -OCOR<sub>33</sub>, or together with R<sub>7a</sub> or R<sub>10</sub> is a carbonate;

R<sub>10</sub> is hydrogen, oxo, hydroxy, protected hydroxy, -OR<sub>28</sub>, or -OCOR<sub>29</sub>, or together with R<sub>9</sub> is a carbonate;

R<sub>13</sub> is hydrogen, hydroxy, protected hydroxy, -OCOR<sub>35</sub>, MO- or



R<sub>28</sub> is a functional group which increases the solubility of the taxane derivative;

$R_{27}$ ,  $R_{29}$ ,  $R_{30}$ ,  $R_{31}$ ,  $R_{33}$ , and  $R_{35}$  are independently hydrogen, alkyl, alkenyl, alkynyl, alkoxy, aryloxy, -  
 $NX_8X_{10}$ , - $SX_{10}$ , monocyclic aryl or monocyclic heteroaryl;

5  $X_1$  is - $OX_6$ , - $SX_7$ , or - $NX_8X_9$ ;

$X_2$  is hydrogen, alkyl, alkenyl, alkynyl, aryl, or heteroaryl;

$X_3$  and  $X_4$  are independently hydrogen, alkyl, alkenyl, alkynyl, aryl, or heteroaryl;

10  $X_5$  is - $COX_{10}$ , - $COOX_{10}$ , - $COSX_{10}$ , - $CONX_8X_{10}$ , or - $SO_2X_{11}$ ;

$X_6$  is hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl, hydroxy protecting group, or a functional group which increases the water solubility of the taxane derivative;

15  $X_7$  is alkyl, alkenyl, alkynyl, aryl, heteroaryl, or sulfhydryl protecting group;

$X_8$  is hydrogen, alkyl, alkenyl, alkynyl, aryl, or heteroaryl;

20  $X_9$  is an amino protecting group;

$X_{10}$  is alkyl, alkenyl, alkynyl, aryl, or heteroaryl;

$X_{11}$  is alkyl, alkenyl, alkynyl, aryl, heteroaryl, - $OX_{10}$ , or - $NX_8X_{14}$ ;

25  $X_{14}$  is hydrogen, alkyl, alkenyl, alkynyl, aryl, or heteroaryl; and

$M$  comprises ammonium or is a metal.

Other objects and features of this invention will be in part apparent and in part pointed out hereinafter.

30 DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

As used herein "Ar" means aryl; "Ph" means phenyl; "Me" means methyl; "Et" means ethyl; "iPr" means isopropyl; "tBu" and "t-Bu" means tert-butyl; "R" means lower alkyl unless otherwise defined; "Ac" means acetyl; "py" means pyridine; "TES" means triethylsilyl; "TMS"

means trimethyl-silyl; "TBS" means  $\text{Me}_2\text{t-BuSi-}$ ; "Tf" means  $-\text{SO}_2\text{CF}_3$ ; "BMDA" means  $\text{BrMgNiPr}_2$ ; "Swern" means  $(\text{COCl})_2\text{Et}_3\text{N}$ ; "LTMP" means lithium tetramethylpiperidide; "MOP" means 2-methoxy-2-propyl; "BOM" means benzylloxymethyl; "LDA" means lithium diisopropylamide; "LAH" means lithium aluminum hydride; "Red-Al" means sodium bis(2-methoxyethoxy) aluminum hydride; "Ms" means  $\text{CH}_3\text{SO}_2^-$ ; "TASF" means tris(diethylamino)sulfonium-difluorotrimethylsilicate; "Ts" means toluenesulfonyl; "TBAF" means tetrabutyl ammonium hydride; "TPAP" means tetrapropyl-ammonium perruthenate; "DBU" means diazabicycloundecane; "DMAP" means p-dimethylamino pyridine; "LHMDS" means lithium hexamethyldisilazide; "DMF" means dimethylformamide; "AIBN" means azo-(bis)-isobutyronitrile; "10-DAB" means 10-desacetylbaaccatin III; "FAR" means 2-chloro-1,1,2-trifluorotriethylamine; "mCPBA" means metachloroperbenzoic acid; "DDQ" means dicyanodichloroquinone; "sulphydryl protecting group" includes, but is not limited to, hemithioacetals such as 1-ethoxyethyl and methoxymethyl, thioesters, or thiocarbonates; "amine protecting group" includes, but is not limited to, carbamates, for example, 2,2,2-trichloroethylcarbamate or tertbutylcarbamate; "protected hydroxy" means  $-\text{OP}$  wherein P is a hydroxy protecting group; and "hydroxy protecting group" includes, but is not limited to, acetals having two to ten carbons, ketals having two to ten carbons, ethers such as methyl, t-butyl, benzyl, p-methoxybenzyl, p-nitrobenzyl, allyl, trityl, methoxymethyl, methoxyethoxymethyl, ethoxyethyl, tetrahydropyranyl, tetrahydrothiopyranyl, and trialkylsilyl ethers such as trimethylsilyl ether, triethylsilyl ether, dimethylarylsilyl ether, triisopropylsilyl ether and t-butyldimethylsilyl ether; esters such as benzoyl, acetyl, phenylacetyl, formyl, mono-, di-, and trihaloacetyl such as chloroacetyl, dichloroacetyl,

trichloroacetyl, trifluoro-acetyl; and carbonates including but not limited to alkyl carbonates having from one to six carbon atoms such as methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl; isobutyl, and n-pentyl; alkyl carbonates having from one to six carbon atoms and substituted with one or more halogen atoms such as 2,2,2-trichloroethoxymethyl and 2,2,2-tri-chloroethyl; alkenyl carbonates having from two to six carbon atoms such as vinyl and allyl; cycloalkyl carbonates having from three to six carbon atoms such as cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl; and phenyl or benzyl carbonates optionally substituted on the ring with one or more C<sub>1-6</sub> alkoxy, or nitro. Other hydroxyl, sulfhydryl and amine protecting groups may be found in "Protective Groups in Organic Synthesis" by T. W. Greene, John Wiley and Sons, 1981.

The alkyl groups described herein are preferably lower alkyl containing from one to six carbon atoms in the principal chain and up to 15 carbon atoms. They may be straight or branched chain and include methyl, ethyl, propyl, isopropyl, butyl, hexyl and the like. They may be hydrocarbon or heterosubstituted with the various substituents defined herein, including heteroalkyl, alkenyl, heteroalkenyl, alkynyl, heteroalkynyl, aryl, heteroaryl, and heterosubstituted heteroaryl.

The alkenyl groups described herein are preferably lower alkenyl containing from two to six carbon atoms in the principal chain and up to 15 carbon atoms. They may be straight or branched chain and include ethenyl, propenyl, isopropenyl, butenyl, isobutenyl, hexenyl, and the like. They may be hydrocarbon or heterosubstituted with the various substituents defined herein, including alkyl, heteroalkyl, heteroalkenyl, alkynyl, heteroalkynyl, aryl, heteroaryl, and heterosubstituted heteroaryl.

5                   The alkynyl groups described herein are preferably lower alkynyl containing from two to six carbon atoms in the principal chain and up to 15 carbon atoms. They may be straight or branched chain and include ethynyl, propynyl, butynyl, isobutynyl, hexynyl, and the like. They may be hydrocarbon or heterosubstituted with the various substituents defined herein, including alkyl, heteroalkyl, alkenyl, heteroalkenyl, heteroalkynyl, aryl, heteroaryl, and heterosubstituted heteroaryl.

10

15                   The aryl moieties described herein contain from 6 to 15 carbon atoms and include phenyl. They may be hydro-carbon or heterosubstituted with the various substituents defined herein, including alkyl, heteroalkyl, alkenyl, heteroalkenyl, alkynyl, heteroalkynyl, heteroaryl, and heterosubstituted heteroaryl. Phenyl is the more preferred aryl.

20                   The heteroaryl moieties described herein contain from 5 to 15 atoms and include, furyl, thienyl, pyridyl and the like. They may be hydrocarbon or heterosubstituted with the various substituents defined herein, including alkyl, heteroalkyl, alkenyl, heteroalkenyl, alkynyl, heteroalkynyl, aryl, and heterosubstituted heteroaryl.

25                   The acyl moieties described herein contain alkyl, alkenyl, alkynyl, aryl or heteroaryl groups.


                         The alkoxy carbonyloxy moieties described herein comprise lower alkyl, alkenyl, alkynyl or aryl groups.


30                   The hydrocarbon substituents described herein may be alkyl, alkenyl, alkynyl, or aryl, and the hetero-substituents of the heterosubstituted alkyl, alkenyl, alkynyl, aryl, and heteroaryl moieties described herein contain nitrogen, oxygen, sulfur, halogens and/or one to six carbons, and include lower alkoxy such as methoxy, ethoxy, butoxy, halogen such as chloro or fluoro, and nitro, heteroaryl such as furyl or thienyl, alkanoxy,


35


hydroxy, protected hydroxy, acyl, acyloxy, nitro, amino, and amido.


An exemplary synthesis of baccatin III or 10-DAB is depicted hereinbelow in Reaction Scheme A. The starting material, diol 2, can be prepared from patchino (commonly known as B-patchouline epoxide) which is commercially available. The patchino is first reacted with an organo-metallic, such as lithium t-butyl followed by oxidation with an organic peroxide, such as t-butylperoxide in the presence of titanium tetraisopropoxide to form a tertiary alcohol. The tertiary alcohol is then reacted with a Lewis acid, such as boron trifluoride at low temperature, in the range from 40°C to -100°C; in the presence of an acid, such as trifluoromethane sulfonic acid. A graphical depiction of this reaction scheme along with an experimental write-up for the preparation of diol 2 can be found in U.S. Patent No. 4,876,399.


Reaction Scheme A

















In Reaction Scheme A,  $P_5$  is TMS,  $P_7$  is MOP or BOM,  $P_{10}$  is TES,  $P_{13}$  is TBS, and R is ethyl in compounds 6 and 7, methyl in compounds 15, 16, and 17, Ms in compounds 24aa and 26a, and Ts in compound 26aa. It should be understood, however, that  $P_5$ ,  $P_7$ ,  $P_{10}$ , and  $P_{13}$  may be other hydroxy protecting groups and R may comprise other lower alkyl substituents in compounds 6, 7, 15, 16 and 17.

Reaction Scheme A may be varied between compounds 18 and 29 as set forth below in Reaction Scheme A', with the reactions leading to compound 18 and following compound 29 being as set forth in Reaction Scheme A.


Reaction Scheme A'






In Reaction Scheme A',  $P_5$  is TMS or Ac,  $P_7$  is MOP or BOM,  $P_{10}$  is TES,  $P_{13}$  is TBS and  $P_{520}$  is acetal or ketal, preferably acetonide. It should be understood, however, that  $P_5$ ,  $P_7$ ,  $P_{10}$ , and  $P_{13}$  and  $P_{520}$  may be other hydroxy protecting groups.


In general, tricyclic and tetracyclic taxanes bearing C13 side chains may be obtained by reacting a  $\beta$ -lactam with alkoxides having the taxane tricyclic or tetracyclic nucleus and a C-13 metallic oxide substituent to form compounds having a  $\beta$ -amido ester substituent at C-13. The  $\beta$ -lactams have the following structural formula:



wherein  $X_1$  -  $X_5$  are as defined above. The alkoxides having the tricyclic or tetracyclic taxane nucleus and a C-13 metallic oxide or ammonium oxide substituent have the following structural formula:



wherein  $R_1$ ,  $R_2$ ,  $R_{4a}$ ,  $R_{4b}$ ,  $R_5$ ,  $R_6$ ,  $R_{6a}$ ,  $R_{7a}$ ,  $R_9$ , and  $R_{10}$  are as previously defined,  $R_{13}$  is  $-OM$  and  $M$  comprises ammonium or is a metal optionally selected from Group IA, IIIA, transition (including lanthanides and actinides), IIB, IIIA IVA, VA, or VIA metals (CAS version). If  $M$  comprises ammonium, it is preferably tetraalkylammonium and the alkyl component of the tetraalkylammonium substituent is preferably  $C_1$  -  $C_{10}$  alkyl such as methyl or butyl. Most preferably, the alkoxide has the tetracyclic taxane nucleus and corresponds to the structural formula:



wherein M, R<sub>2</sub>, R<sub>4a</sub>, R<sub>7a</sub>, R<sub>9</sub>, and R<sub>10</sub> are as previously defined.

As set forth in Reaction Scheme A, taxol may be prepared by converting 7-protected Baccatin III 35 to the corresponding alkoxide and reacting the alkoxide with a  $\beta$ -lactam in which X<sub>1</sub> is protected hydroxy, X<sub>3</sub> is phenyl and X<sub>5</sub> is benzoyl. Protecting groups such as 2-methoxypropyl ("MOP"), 1-ethoxyethyl ("EE") are preferred, but a variety of other standard protecting groups such as the triethylsilyl group or other trialkyl (or aryl) silyl groups may be used. Taxanes having alternative side chain substituents may be prepared through the use of  $\beta$ -lactams which comprise the alternative substituents.


Taxanes having alternative C9 substituents may be prepared by selectively reducing the C9 keto substituent of taxol, 10-DAB, Baccatin III or one of the other intermediates disclosed herein to yield the corresponding C9  $\beta$ -hydroxy derivative. The reducing agent is preferably a borohydride and, most preferably, tetrabutylammoniumboro-hydride (Bu<sub>4</sub>NBH<sub>4</sub>) or triacetoxyborohydride.

As illustrated in Reaction Scheme 1, the reaction of baccatin III with Bu<sub>4</sub>NBH<sub>4</sub> in methylene chloride yields 9-desoxo-9 $\beta$ -hydroxybaccatin III 5. After the C7 hydroxy group is protected with the triethylsilyl protecting group, for example, a suitable side chain may

be attached to 7-protected-9 $\beta$ -hydroxy derivative 6 as elsewhere described herein. Removal of the remaining protecting groups thus yields 9 $\beta$ -hydroxy-desoxo taxol or other 9 $\beta$ -hydroxytetracyclic taxane having a C13 side chain.

5


REACTION SCHEME 1



Alternatively, the C13 hydroxy group of 7-protected-9 $\beta$ -hydroxy derivative 6 may be protected with trimethylsilyl or other protecting group which can be selectively removed relative to the C7 hydroxy protecting group as illustrated in Reaction Scheme 2, to enable further selective manipulation of the various substituents of the taxane. For example, reaction of

10


7,13-protected-9 $\beta$ -hydroxy derivative 7 with KH causes the acetate group to migrate from C10 to C9 and the hydroxy group to migrate from C9 to C10, thereby yielding 10-desacetyl derivative 8. Protection of the C10 hydroxy group of 10-desacetyl derivative 8 with triethylsilyl yields derivative 9. Selective removal of the C13 hydroxy protecting group from derivative 9 yields derivative 10 to which a suitable side chain may be attached as described above.

REACTION SCHEME 2

As shown in Reaction Scheme 3, 10-oxo derivative **11** can be provided by oxidation of 10-desacetyl derivative **8**. Thereafter, the C13 hydroxy

protecting group can be selectively removed followed by attachment of a side chain as described above to yield 9-acetoxy-10-oxo-taxol or other 9-acetoxy-10-oxotetraacylic taxanes having a C13 side chain. Alternatively, the C9 acetate group can be selectively removed by reduction of 10-oxo derivative **11** with a reducing agent such as samarium diiodide to yield 9-desoxo-10-oxo derivative **12** from which the C13 hydroxy protecting group can be selectively removed followed by attachment of a side chain as described above to yield 9-desoxo-10-oxo-taxol or other 9-desoxo-10-oxotetraacylic taxanes having a C13 side chain.

### REACTION SCHEME 3




15 Reaction Scheme 4 illustrates a reaction in which 10-DAB is reduced to yield pentaol **13**. The C7 and

C10 hydroxyl groups of pentaol **13** can then be selectively protected with the triethylsilyl or another protecting group to produce triol **14** to which a C13 side chain can be attached as described above or, alternatively, after further modification of the tetracyclic substituents.

5


REACTION SCHEME 4



Taxanes having C9 and/or C10 acyloxy substituents other than acetate can be prepared using 10-DAB as a starting material as illustrated in Reaction Scheme 5. Reaction of 10-DAB with triethylsilyl chloride in pyridine yields 7-protected 10-DAB **15**. The C10 hydroxy substituent of 7-protected 10-DAB **15** may then be readily acylated with any standard acylating agent to

yield derivative **16** having a new C10 acyloxy substituent. Selective reduction of the C9 keto substituent of derivative **16** yields 9 $\beta$ -hydroxy derivative **17** to which a C13 side chain may be attached. Alternatively, the C10 and C9 groups can be caused to migrate as set forth in Reaction Scheme 2, above.

REACTION SCHEME 5



Taxanes having alternative C2 and/or C4 esters can be prepared using baccatin III and 10-DAB as starting materials. The C2 and/or C4 esters of baccatin III and 10-DAB can be selectively reduced to the corresponding alcohol(s) using reducing agents such as LAH or Red-Al, and new esters can thereafter be substituted using


standard acylating agents such as anhydrides and acid chlorides in combination with an amine such as pyridine, triethylamine, DMAP, or diisopropyl ethyl amine.

Alternatively, the C2 and/or C4 alcohols may be converted to new C2 and/or C4 esters through formation of the corresponding alkoxide by treatment of the alcohol with a suitable base such as LDA followed by an acylating agent such as an acid chloride.

Baccatin III and 10-DAB analogs having different substituents at C2 and/or C4 can be prepared as set forth in Reaction Schemes 6-10. To simplify the description, 10-DAB is used as the starting material. It should be understood, however, that baccatin III derivatives or analogs may be produced using the same series of reactions (except for the protection of the C10 hydroxy group) by simply replacing 10-DAB with baccatin III as the starting material. 9-desoxo derivatives of the baccatin III and 10-DAB analogs having different substituents at C2 and/or C4 can then be prepared by reducing the C9 keto substituent of these analogs and carrying out the other reactions described above.

In Reaction Scheme 6, protected 10-DAB **3** is converted to the triol **18** with lithium aluminum hydride. Triol **18** is then converted to the corresponding C4 ester using  $\text{Cl}_2\text{CO}$  in pyridine followed by a nucleophilic agent (e.g., Grignard reagents or alkyllithium reagents).

Scheme 6




Deprotonation of triol **18** with LDA followed by introduction of an acid chloride selectively gives the C4 ester. For example, when acetyl chloride was used, triol **18** was converted to 1,2 diol **4** as set forth in Reaction Scheme 7.

10 Triol **18** can also readily be converted to the 1,2 carbonate **19**. Acetylation of carbonate **19** under vigorous standard conditions provides carbonate **21** as described in Reaction Scheme 8; addition of alkylolithiums or Grignard reagents to carbonate **19** provides the C2

45


ester having a free hydroxyl group at C4 as set forth in Reaction Scheme 6.

Scheme 7




5

Scheme 8



As set forth in Reaction Scheme 9, other C4 substituents can be provided by reacting carbonate **19** with an acid chloride and a tertiary amine to yield carbonate **22** which is then reacted with alkylolithiums or Grignard reagents to provide 10-DAB derivatives having new substituents at C2.


Scheme 9




Alternatively, baccatin III may be used as a starting material and reacted as shown in Reaction Scheme 10. After being protected at C7 and C13, baccatin III is reduced with LAH to produce 1,2,4,10 tetraol **24**. Tetraol **24** is converted to carbonate **25** using  $\text{Cl}_2\text{CO}$  and pyridine, and carbonate **25** is acylated at C10 with an acid chloride.

and pyridine to produce carbonate **26** (as shown) or with acetic anhydride and pyridine (not shown). Acetylation of carbonate **26** under vigorous standard conditions provides carbonate **27** which is then reacted with alkyl lithiums to provide the baccatin III derivatives having new substituents at C2 and C10.

5

Scheme 10




10-desacetoxy derivatives of baccatin III and 10-desoxy derivatives of 10-DAB may be prepared by reacting baccatin III or 10-DAB (or their derivatives) with samarium diiodide. Reaction between the tetracyclic taxane having a C10 leaving group and samarium diiodide may be carried out at 0°C in a solvent such as tetrahydrofuran. Advantageously, the samarium diiodide selectively abstracts the C10 leaving group; C13 side chains and other substituents on the tetracyclic nucleus remain undisturbed. Thereafter, the C9 keto substituent may be reduced to provide the corresponding 9-desoxo-9 $\beta$ -hydroxy-10-desacetoxy or 10-desoxy derivatives as otherwise described herein.


5

10


C7 dihydro and other C7 substituted taxanes can be prepared as set forth in Reaction Schemes 11, 12 and 12a.

REACTION SCHEME 11



REACTION SCHEME 12

## REACTION SCHEME 12a



As shown in Reaction Scheme 12, Baccatin III may be converted into 7-fluoro baccatin III by treatment with FAR at room temperature in THF solution. Other baccatin derivatives with a free C7 hydroxyl group behave similarly. Alternatively, 7-chloro baccatin III can be prepared by treatment of baccatin III with methane sulfonyl chloride and triethylamine in methylene chloride solution containing an excess of triethylamine hydrochloride.


5

10

5 Taxanes having C7 acyloxy substituents can be prepared as set forth in Reaction Scheme 12a, 7,13-protected 10-oxo-derivative 11 is converted to its corresponding C13 alkoxide by selectively removing the C13 protecting group and replacing it with a metal such as lithium. The alkoxide is then reacted with a  $\beta$ -lactam or other side chain precursor. Subsequent hydrolysis of the C7 protecting groups causes a migration of the C7 hydroxy substituent to C10, migration of the C10 oxo substituent to C9, and migration of the C9 acyloxy substituent to C7.

10

15 As shown in Reaction Scheme 13, 7-O-triethylsilyl baccatin III can be converted to a tricyclic taxane through the action of trimethyloxonium tetrafluoroborate in methylene chloride solution. The product diol then reacts with lead tetraacetate to provide the corresponding C4 ketone.

REACTION SCHEME 13

The subprocesses of Reaction scheme A can be applied at various stages. For example, the process for the conversion of compound 30 to compound 33 can be applied to any intermediate having a hydroxyl group at C-10 and two hydrogens at C-9, e.g., the process for introducing C9 and C10 carbonyl and hydroxyl groups can be applied to suitably protected intermediates 4 through 29.

Likewise, the process for introduction of C1 and C2 oxygen-containing functional groups (conversion of 6 to 13 in Reaction Scheme A) can be applied to any intermediate having a C3 carbonyl group.

Similarly, the process for introducing C2 and C4 acyl groups as exemplified in Reaction Schemes 6 through 10 can be applied to any intermediate having a C1, C2 carbonate.

5 Also, the process for forming the oxetane ring, as exemplified in the conversion of 24a to 27a in Reaction Scheme A, can be applied to a variety of intermediates having a C4 carbonyl group.

10 The aldol process exemplified in the conversion of 5 to 6 in Reaction Scheme A can be applied to any suitably protected intermediate having a C3 carbonyl group and a C8a hydrogen. A variety of ketones or aldehydes can be used as a reactant in this process.

15 Formation of a cyclic carbonate from any 1,2 or 1,3 diol subunit in any intermediate can be carried out by using phosgene as a reactant. Carbonyl groups can be reduced by hydride reagents or metallic species to the corresponding alcohols. Alcohols can be oxidized using a variety of oxidizing agents as exemplified in the 20 Reaction Schemes, to the corresponding carbonyl groups.

25 The compounds disclosed in this application have several asymmetric carbons and may exist in diastereomeric, racemic, or optically active forms. All of these forms are contemplated within the scope of this invention. More specifically, the present invention includes the enantiomers, diasteriomers, racemic mixtures, and other mixtures of the compounds disclosed herein.

30 The following examples illustrate the invention.

## EXAMPLES

## REACTION SCHEME A

Triethylsilyloxy alcohol 3. To a solution of diol 2 (3.16 g, 13.4 mmol) and DMAP (70 mg, 0.57 mmol) in  $\text{CH}_2\text{Cl}_2$  (65 mL) at room temperature was added triethylamine (3.7 mL, 26.6 mmol) followed by dropwise addition of TESCl (2.7 mL, 16.1 mmol). After 1.75 h, the reaction mixture was diluted with 150 mL of hexane, then poured into 100 mL of a saturated aqueous  $\text{NaHCO}_3$  solution and 150 mL of hexane. The organic phase was washed with two 100 mL portions of saturated aqueous  $\text{NaHCO}_3$  solution and with 100 mL of water, dried over anhydrous  $\text{Na}_2\text{SO}_4$ , and concentrated under reduced pressure to give 4.88 g of crude triethylsilyloxyalcohol 3. An analytical sample was obtained by plug filtration through a short pad of silica gel washing with hexane and then eluting the pure compound 3 ( $P_{10}$  = TES) (colorless oil) with 5% ethyl acetate in hexane.

3 ( $P_{10}$  = TES):  $^1\text{H}$  NMR (300 MHz,  $\text{CDCl}_3$ )  $\delta$  0.61 (q,  $J$  = 7.7 Hz, 6H, TES  $\text{CH}_2$ ), 0.89 (s, 3H,  $\text{CH}_3$  16), 0.96 (t,  $J$  = 7.7 Hz, 9H, TES  $\text{CH}_3$ ), 1.03 (d,  $J$  = 7.1 Hz, 3H,  $\text{CH}_3$  19), 1.07 (s, 3H,  $\text{CH}_3$  17), 1.23 (d,  $J$  = 14.3 Hz, 1H,  $\text{H}2\alpha$ ), 1.56 (dd,  $J$  = 6.0, 6.0 Hz, 1H,  $\text{H}7$ ), 1.76 (ddd,  $J$  = 5.0, 11.0, 13.7 Hz, 1H,  $\text{H}9$ ), 1.90 (ddd,  $J$  = 2.2, 8.8, 15.4 Hz, 1H,  $\text{H}9$ ), 1.96 (m, 1H,  $\text{H}14\alpha$ ), 2.37 (m, 2H,  $\text{H}2\beta$ ,  $\text{H}14\beta$ ), 2.51 (ddd,  $J$  = 7.7, 7.7, 10.4 Hz, 1H,  $\text{H}8\alpha$ ), 2.94 (s, 1H, OH-3), 4.21 (dd,  $J$  = 2.2, 5.0 Hz, 1H,  $\text{H}10$ ), 5.43 (dd,  $J$  = 2.8, 2.8 Hz, 1H,  $\text{H}13$ ).  $^{13}\text{C}$  NMR (75 MHz,  $\text{CDCl}_3$ )  $\delta$  (ppm) 4.8 (TES  $\text{CH}_2$ ), 6.7 (TES  $\text{CH}_3$ ), 15.02 ( $\text{CH}_3$  19), 23.0 ( $\text{CH}_3$  17), 26.2 ( $\text{CH}_3$  18), 28.0 ( $\text{CH}_3$  16), 33.6 (C14), 41.5 (C8), 44.2 (C2), 45.0 (C1), 45.2 (C15), 45.8 (C9), 69.6 (C11), 74.9 (C10), 96.0 (C3), 123.0 (C13), 143.7 (C12); IR ( $\text{CHCl}_3$ )  $\nu$  3530, 2970, 2930, 2900, 1460, 1340, 1140, 1100, 1080, 1045, 1010, 970, 915, 650  $\text{cm}^{-1}$ ; MS (CI) 351 (M+1, 58), 333 (100), 219 (34).

Hydroxy Ketone 4. To a vigorously stirred solution of the crude compound 3 ( $P_{10}$  = TES) in anhydrous  $\text{CH}_2\text{Cl}_2$  (30 mL) at 0 °C under nitrogen was added  $\text{Ti}(\text{O}^i\text{Pr})_4$  (13.5 mL, 43.1 mmol) followed by dropwise addition of anhydrous 2M  $t\text{-BuOOH}$  in hexane (18 mL, 36 mmol). After 45 min dimethylsulfide (15 mL) was added slowly over a period of 5 min. The solution was stirred for 10 min at 0 °C, then 15 min at room temperature and then moved to a 55 °C bath where it was

heated under reflux for 8h. The solvents were evaporated under reduced pressure, the resulting thick syrup was dissolved in ethyl acetate (850 mL) and 3.5 mL of H<sub>2</sub>O was added dropwise with vigorous stirring. The resulting mixture was stirred at room temperature for 1h and then filtered through a pad of Celite which was further washed with two portions of 100 mL of ethyl acetate. Evaporation of the solvent under reduced pressure afforded an oil that was filtered through a short pad of silica gel eluting with 10% ethyl acetate in hexane to give 4.78 g of pure hydroxyketone 4 (P<sub>10</sub> = TES) (colorless oil).

4 (P<sub>10</sub> = TES): <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 0.58 (q, J = 7.7 Hz, 6H, TES CH<sub>2</sub>), 0.94 (t, J = 7.7 Hz, 12H, CH<sub>3</sub> 19, TES CH<sub>3</sub>), 0.98 (s, 3H, CH<sub>3</sub> 17), 1.31 (s, 3H, CH<sub>3</sub> 16), 1.71 (dd, J = 5.0, 11.5 Hz, 1H, H2α), 1.85 (m, 3H, H1, H9β, H14β), 1.96 (s, 3H, CH<sub>3</sub> 18), 2.15 (d, J = 12.1, 1H, OH-13), 2.22 (ddd, J = 4.9, 13.2, 15.9 Hz, 1H, H9α), 2.56 (dddd, J = 3.8, 7.1, 13.7, 13.7 Hz, 1H, H8α), 2.75 (dd, J = 2.2, 11.0 Hz, 1H, H2β), 2.80 (ddd, J = 4.4, 7.7, 11.0 Hz, 1H, H14β), 4.10 (t, J = 11.0 Hz, 1H, H13β), 4.56 (d, J = 5.0 Hz, 1H, H10β); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) δ (ppm) 4.3 (TES CH<sub>2</sub>), 6.5 (TES CH<sub>3</sub>), 13.4 (CH<sub>3</sub> 18), 18.4 (CH<sub>3</sub> 19), 25.8 (CH<sub>3</sub> 17), 27.1 (CH<sub>3</sub> 16), 34.7 (C14), 38.2 (C15), 38.8 (C2), 44.0 (C8), 44.2 (C9), 47.8 (C1), 67.3 (C13), 69.7 (C10), 137.3 (C11), 138.8 (C12), 219.2 (C3); IR (CHCl<sub>3</sub>) ν 3550, 2960, 2880, 1660, 1460, 1410, 1240, 1200, 1160, 1140, 1080, 1050, 1000, 980, 900, 810 cm<sup>-1</sup>; MS (CI) 367 (M+1, 2), 349 (100), 331 (55).

Ketone 5. To a solution of hydroxyketone 4 (P<sub>10</sub> = TES) in anhydrous pyridine (25 mL) at -23 °C under nitrogen was added dropwise TBSOTf (3.2 mL, 13.9 mmol). After 5 min, the flask was moved to an ice bath and stirred for 1.75 h. The solution was diluted with 75 mL of hexane at 0 °C and then decanted from the insoluble oil into saturated aqueous NaHCO<sub>3</sub> solution (200 mL). The remaining oil was extracted with three 75 mL portions of hexane. The combined organic phases were washed with two 50 mL portions of saturated aqueous NaHCO<sub>3</sub> solution and then with 50 mL of water, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The yellowish oily residue was purified by filtration through a short pad of silica gel eluting with 10% ethyl acetate in hexane to give 4.78 g of pure ketone 5 (P<sub>10</sub> = TES, P<sub>13</sub> = TBS) (94% yield from 2).

**5** ( $P_{10}$  = TES,  $P_{13}$  = TBS):  $^1H$  NMR (300 MHz,  $CDCl_3$ )  $\delta$  0.03 (s, 3H, TBS  $CH_3$ ), 0.05 (s, 3H, TBS  $CH_3$ ), 0.57 (q,  $J$  = 8.2 Hz, 6H, TES  $CH_2$ ), 0.93 (t,  $J$  = 8.2 Hz, 9H, TES  $CH_3$ ), 0.93 (s, 9H, TBS t-Bu), 0.96 (d,  $J$  = 1.8 Hz, 3H,  $CH_3$  19), 1.06 (s, 3H,  $CH_3$  17), 1.33 (s, 3H,  $CH_3$  16), 1.68 (dd,  $J$  = 5.5, 11.5 Hz, 1H,  $H2\alpha$ ), 1.84 (m, 2H,  $H1$ ,  $H9\beta$ ), 1.89 (s, 3H,  $CH_3$  18), 1.92 (dd,  $J$  = 6.0, 14.3 Hz, 1H,  $H14\alpha$ ), 2.21 (ddd,  $J$  = 5.5, 13.2, 15.4 Hz, 1H,  $H9\alpha$ ), 2.39 (ddd,  $J$  = 8.2, 10.4, 14.3 Hz, 1H,  $H14\beta$ ), 2.52 (ddd,  $J$  = 3.9, 7.1, 13.6 Hz, 1H,  $H8\alpha$ ), 2.66 (dd,  $J$  = 2.8, 11.5 Hz, 1H,  $H2\beta$ ), 4.45 (dd,  $J$  = 5.5, 10.4 Hz, 1H,  $H13\beta$ ), 4.61 (d,  $J$  = 5.0 Hz, 1H,  $H10\beta$ );  $^{13}C$  NMR  $\delta$  (ppm) -5.4 (TBS  $CH_3$ ), -4.6 (TBS  $CH_3$ ), 4.3 (TES  $CH_2$ ), 6.5 (TES  $CH_3$ ), 14.1 ( $CH_3$  18), 17.9 (TBS  $C(CH_3)_3$ ), 19.1 ( $CH_3$  19), 25.4 ( $CH_3$  17), 25.8 (TBS  $C(CH_3)_3$ ), 26.8 ( $CH_3$  16), 33.5 (C14), 38.6 (C15), 39.4 (C2), 43.7 (C8), 44.4 (C9), 47.5 (C1), 67.5 (C13), 69.5 (C10), 136.8 (C11), 138.8 (C12), 213.5 (C3); IR ( $CHCl_3$ )  $\nu$  2950, 2900, 1680, 1460, 1420, 1395, 1365, 1250, 1200, 1110, 1080, 1000, 900, 860, 840  $cm^{-1}$ ; MS (CI) 481 (M+1, 3), 463 (16), 349 (100), 331 (50); Anal. Calcd. for  $C_{27}H_{52}O_3Si_2$ : C, 67.44; H, 10.90. Found: C, 67.31; H, 10.78.

**Ketocarbonate 6.** To a stirred solution of diisopropylamine (0.60 mL, 4.28 mmol) in THF (11 mL) under nitrogen at room temperature was added 1.26 mL of a 3.1 M solution (3.89 mmol) of  $MeMgBr$  in ether. After 3 h, a solution of ketone 5 ( $P_{10}$  = TES,  $P_{13}$  = TBS) (750 mg, 1.56 mmol) in THF (3.5 mL) was added dropwise at room temperature. After 1.5 h, the reaction mixture was cooled to -23 °C and a solution of 4-pentenal (327 mg, 3.89 mmol) in THF (4 mL) was added dropwise down the side of the flask. After 1 h, 10 mL of a saturated aqueous  $NH_4Cl$  solution was added. After 2 min, the reaction mixture was diluted with 100 mL of hexane, then poured into 100 mL of  $H_2O$ . The organic phase was washed with 100 mL of  $H_2O$  and 100 mL of brine, and dried over anhydrous  $Na_2SO_4$  and concentrated under reduced pressure to give 0.92 g of a yellow oil. To a solution of the crude mixture in  $CH_2Cl_2$  (10 mL) and pyridine (10 mL) under nitrogen at -23 °C was added 2.3 mL of 4 M solution (9.36 mmol) of phosgene in toluene dropwise and the reaction mixture was warmed to -10 °C. After 30 min, ethanol (3.7 mL) was added and the resulting mixture was stirred for 30 min. The reaction mixture was then diluted with 300 mL of hexane, washed with 200 mL of a saturated aqueous  $NaHCO_3$  solution, 200 mL of a

10 % aqueous  $\text{CuSO}_4$  solution, 200 mL of  $\text{H}_2\text{O}$ , 200 mL of a saturated aqueous  $\text{NaHCO}_3$  solution and 200 mL of brine, dried over anhydrous  $\text{Na}_2\text{SO}_4$  and concentrated under reduced pressure to give 1.05 g of a yellow solid. The crude mixture was filtered through silica gel with 10% ethyl acetate in hexanes to give 965 mg of a white solid which was further purified by silica gel chromatography eluting with 2% ethyl acetate in hexanes to yield 745 mg (75 %) of ketocarbonate **6** ( $\text{P}_{10}$  = TES,  $\text{P}_{13}$  = TBS, R = Et) as a white solid. The product was isolated as a 6:1 ratio of conformational isomers. The following NMR data is for the predominant conformer.

**6** ( $\text{P}_{10}$  = TES,  $\text{P}_{13}$  = TBS, R = Et): mp 103-104 °C;  $^1\text{H}$  NMR (500 MHz,  $\text{CDCl}_3$ )  $\delta$  0.08 (s, 3H, TBS  $\text{CH}_3$ ), 0.08 (s, 3H, TBS  $\text{CH}_3$ ), 0.56 (q,  $J$  = 7.8 Hz, 6H, TES  $\text{CH}_2$ ), 0.94 (t,  $J$  = 7.8 Hz, 9H, TES  $\text{CH}_3$ ), 0.96 (s, 9H, TBS t-Bu), 1.08 (s, 3H,  $\text{CH}_3$  17), 1.29 (m, 1H, H6), 1.38 (s, 3H,  $\text{CH}_3$  19), 1.42 (s, 3H,  $\text{CH}_3$  16), 1.66 (dd,  $J$  = 4.6, 12.5 Hz, 1H, H9 $\alpha$ ), 1.83 (s, 3H,  $\text{CH}_3$  18), 1.85 (dd,  $J$  = 4.5, 4.5 Hz, 1H, H14 $\alpha$ ), 2.05 (m, 1H, H5), 2.06 (dd,  $J$  = 6.4, 14.2 Hz, 1H, H5), 2.47 (m, 2H, H9 $\alpha$ , H6), 3.01 (dd,  $J$  = 3.7, 12.3 Hz, 1H, H14 $\beta$ ), 4.20 (m, 2H, H2 $\alpha$ , H2 $\beta$ ), 4.47 (d,  $J$  = 7.3 Hz, 1H, H13 $\beta$ ), 4.50 (dd,  $J$  = 4.6, 11.4 Hz, 1H, H10 $\beta$ ), 4.91 (dd,  $J$  = 1.83, 10.1 Hz, 1H, H20), 4.97 (dd,  $J$  = 1.8, 16.9 Hz, 1H, H20), 5.29 (dd,  $J$  = 0.9, 10.1 Hz, 1H, H7), 5.73 (dd,  $J$  = 6.9, 6.9, 10.5, 16.9 Hz, 1H, H4);  $^{13}\text{C}$  NMR  $\delta$  (ppm) -5.3 (TBS  $\text{CH}_3$ ), -4.5 (TBS  $\text{CH}_3$ ), 4.8 (TES  $\text{CH}_2$ ), 6.5 (TES  $\text{CH}_3$ ), 14.0 (OEt  $\text{CH}_3$ ), 15.5 ( $\text{CH}_3$  19), 15.9 ( $\text{CH}_3$  18), 18.1 (TBS  $\text{C}(\text{CH}_3)_3$ ), 25.8 (TBS  $\text{C}(\text{CH}_3)_3$ ), 27.6 ( $\text{CH}_3$  17), 28.2 ( $\text{CH}_3$  16), 30.4, 30.5 (C5, C6), 34.1 (C14), 39.0 (C15), 41.1 (C2), 47.1 (C1), 47.5 (C9), 55.1 (C8), 63.8 (OEt  $\text{CH}_2$ ), 66.3 (C13), 68.3 (C10), 84.0 (C7), 114.8 (C20), 134.8 (C11), 138.1 (C4'), 144.9 (C12), 155.7 (Ethylcarbonate C=O), 214.8 (C3); IR ( $\text{CCl}_4$ )  $\nu$  3000, 2950, 2900, 1770, 1700, 1490, 1390, 1280, 1140, 1100, 1030, 910, 880, 860  $\text{cm}^{-1}$ ; MS (EI) 636 (M, 100), 593 (20), 538 (34), 409 (33); Anal. Calcd. for  $\text{C}_{35}\text{H}_{64}\text{O}_6\text{Si}_2$ : C, 65.99; H, 10.13. Found: C, 65.88, H, 10.17.

**Hydroxyketone 7.** To a stirred solution of ketocarbonate **6** ( $\text{P}_{10}$  = TES,  $\text{P}_{13}$  = TBS, R = Et) (4.00 g, 6.28 mmol) in THF (65 mL) under nitrogen at -35 °C was added 50 mL of a 0.2 M solution (10 mmol) of LDA in THF down the side of the flask over a 10 min period. After 30 min, the reaction mixture was cooled to -78 °C and 2.29 g of (R)-camphorylsulfonyl oxaziridine (10 mmol) in THF (18 mL) was added dropwise down the side of the flask. After 30 min, the reaction mixture was

quenched with 300 mL of a saturated aqueous  $\text{NaHCO}_3$  solution and extracted with 500 mL and then 150 mL of 25% ethyl acetate in hexanes. The combined organic phases were washed with brine, dried over anhydrous  $\text{Na}_2\text{SO}_4$  and concentrated under reduced pressure to yield 7 g of a waxy solid. This material was purified by flash chromatography, eluting with 3% ethyl acetate in hexanes to yield 3.50 g of hydroxyketone 7 ( $P_{10}$  = TES,  $P_{13}$  = TBS, R = Et) (85%).

7 ( $P_{10}$  = TES,  $P_{13}$  = TBS, R = Et):  $^1\text{H}$  NMR (500 MHz,  $\text{CDCl}_3$ )  $\delta$  0.01 (s, 3H, TBS  $\text{CH}_3$ ), 0.03 (s, 3H, TBS  $\text{CH}_3$ ), 0.50 (q,  $J$  = 7.8 Hz, 6H, TES  $\text{CH}_2$ ), 0.87 (t,  $J$  = 7.8 Hz, 9H, TES  $\text{CH}_3$ ), 0.90 (s, 9H, TBS t-Bu), 1.03 (s, 3H,  $\text{CH}_3$  17), 1.25 (t,  $J$  = 7.0 Hz, 3H, OEt  $\text{CH}_3$ ), 1.35 (s, 3H,  $\text{CH}_3$  19), 1.40 (m, 1H, H6), 1.41 (s, 3H,  $\text{CH}_3$  16), 1.66 (dd,  $J$  = 4.6, 12.8 Hz, 1H, H9 $\beta$ ), 1.77 (d,  $J$  = 1.4 Hz, 3H,  $\text{CH}_3$  18), 1.83 (dd,  $J$  = 6.0, 14.7 Hz, 1H, H14 $\alpha$ ), 1.97 (dd,  $J$  = 4.1, 8.5 Hz, 1H, H1), 2.02 (m, 2H, H5, H5), 2.44 (dd,  $J$  = 11.9, 11.9 Hz, 1H, H9 $\alpha$ ), 2.75 (d,  $J$  = 10.5 Hz, 1H, OH-2), 4.14 (q,  $J$  = 14.2 Hz, 2H, OEt  $\text{CH}_2$ ), 4.35 (dd,  $J$  = 6.0, 8.7 Hz, 1H, H13), 4.42 (dd,  $J$  = 4.6, 11.0 Hz, 1H, H10), 4.49 (dd,  $J$  = 4.1, 10.1 Hz, 1H, H2), 4.86 (dd,  $J$  = 1.8, 10.3 Hz, 1H, H20), 4.92 (dd,  $J$  = 1.8, 16.9 Hz, 1H, H20), 5.23 (dd,  $J$  = 1.4, 10.1 Hz, 1H, H7), 5.67 (dd,  $J$  = 6.9, 6.9, 10.5, 16.9 Hz, 1H, H4);  $^{13}\text{C}$  NMR  $\delta$  (ppm) -5.3 (TBS  $\text{CH}_3$ ), -4.5 (TBS  $\text{CH}_3$ ), 4.7 (TES  $\text{CH}_2$ ), 6.5 (TES  $\text{CH}_3$ ), 14.0 (OEt  $\text{CH}_3$ ), 15.0 ( $\text{CH}_3$  19), 16.0 ( $\text{CH}_3$  18), 18.0 (TBS  $\text{C}(\text{CH}_3)_3$ ), 25.8 (TBS  $\text{C}(\text{CH}_3)_3$ ), 27.5, 27.8 ( $\text{CH}_3$  17), 28.1 ( $\text{CH}_3$  16), 30.4, 30.5 (C5, C6), 36.9 (C15), 47.3 (C9), 54.5 (C1), 54.7 (C8), 63.9 (OEt  $\text{CH}_2$ ), 66.2 (C13), 67.8 (C10), 70.3 (C2), 83.6 (C7), 114.9 (C20), 135.4(C11), 137.9 (C4'), 144.5 (C12), 155.6 (Ethylcarbonate C=O), 217.8 (C3); IR ( $\text{CCl}_4$ )  $\nu$  3600, 2950, 2900, 1750, 1700, 1660, 1470, 1400, 1370, 1240, 1080, 1050, 1000, 840, 680  $\text{cm}^{-1}$ ; MS (CI) 653 (M+1, 8), 564 (100), 431 (69), 389 (67).

**Hydroxycarbonate 8.** To a vigorously stirred solution of hydroxyketone 7 ( $P_{10}$  = TES,  $P_{13}$  = TBS, R = Et) (2.69 g, 4.12 mmol) in toluene (117 mL) under nitrogen at -78 °C was added dropwise down the side of the flask 85 mL of a 0.97 M solution (82.4 mmol) of RedAl in toluene. After 6 h at -78 °C, the solution was allowed to gradually warm to room temperature over a period of 6 h. The mixture was recooled to -10 °C and 125 mL of a 2 M solution (250 mmol) of acetic acid in THF was added dropwise down the side of the flask. The cloudy mixture was stirred 10

min then poured into 1200 mL of 50% ethyl acetate in hexanes and washed with 1 L of a saturated aqueous NaHCO<sub>3</sub> solution. The aqueous phase was extracted with four 500 mL portions of ethyl acetate and the combined organic phases were washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure to yield 2.29 g of 2,3,7-triol as a white solid. This material was used without further purification.

To a vigorously stirred solution of triol (2.29 g, 3.93 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (157 mL) and pyridine (15.7 mL) under nitrogen at -78 °C was quickly added 7.6 mL of a 3.0 M solution (23 mmol) of phosgene in toluene. The solution was allowed to warm to room temperature over a period of 1 h then poured into 250 mL of ethyl acetate, washed with two 125 mL portions of a saturated aqueous NaHCO<sub>3</sub> solution and 100 mL brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure to yield 2.52 g yellow oil. This material was filtered through a 2 inch pad of silica gel with 50% ethyl acetate in hexanes and concentration under reduced pressure yielded 2.39 g (95% from 7) of hydroxy carbonate 8 (P<sub>10</sub> = TES, P<sub>13</sub> = TBS) as a white solid.

8 (P<sub>10</sub> = TES, P<sub>13</sub> = TBS): mp 155 - 157 °C; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 0.09 (s, 3H, TBS -CH<sub>3</sub>), 0.10 (s, 3H, TBS CH<sub>3</sub>), 0.59 (q, J = 8.2 Hz, 6H, TES CH<sub>2</sub>), 0.96 (t, J = 8.2 Hz, 9H, TES CH<sub>3</sub>), 0.97 (s, 9H, TBS t-Bu), 1.11 (s, 3H, CH<sub>3</sub> 19), 1.14 (s, 3H, CH<sub>3</sub> 17), 1.30 (s, 3H, CH<sub>3</sub> 16), 1.39 (dd, J = 4.1, 13.3 Hz, 1H, H9β), 1.65 (m, 2H, H6, H6), 1.99 (dd, J = 6.4, 15.1 Hz, 1H, H14α), 2.01 (d, J = .9 Hz, 3H, CH<sub>3</sub> 18), 2.04 (d, J = 3.7 Hz, 1H, H1), 2.11 (ddd, J = 7.8, 15.6, 15.6 Hz, 1H, H5), 2.28 (ddd, J = 9.6, 9.6, 14.2 Hz, 1H, H14β), 2.34 (dd, J = 12.4, 13.3 Hz, 1H, H9β), 2.41 (m, 1H, H5), 3.87 (dd, J = 0.9, 10.5 Hz, 1H, H7), 3.95 (d, J = 3.7 Hz, 1H, H2), 4.59 (dd, J = 3.7, 11.4 Hz, 1H, H10β), 4.40 (s, 1H, H3), 4.55 (dd, J = 6.4, 8.7 Hz, 1H, H13), 5.03 (d, J = 10.5 Hz, 1H, H20), 5.07 (dd, J = 1.5, 17.0 Hz, 1H, H20), 5.77 (m, 1H, H4); <sup>13</sup>C NMR δ (ppm) -5.4 (TBS CH<sub>3</sub>), -4.4 (TBS CH<sub>3</sub>), 4.8 (TES CH<sub>2</sub>), 6.5 (TES CH<sub>3</sub>), 15.5 (CH<sub>3</sub> 18), 17.9 (TBS C(CH<sub>3</sub>)<sub>3</sub>), 18.2 (CH<sub>3</sub> 19), 25.6 (TBS C(CH<sub>3</sub>)<sub>3</sub>), 25.9 (CH<sub>3</sub> 16), 27.5 (CH<sub>3</sub> 17), 28.3 (C6), 28.4 (C5), 29.8 (C14), 30.8 (C15), 36.5 (C8), 36.8 (C9), 37.3, 50.8 (C1), 66.6 (C10), 67.8 (C13), 70.5 (C2), 91.9 (C3), 91.9 (C7), 116.3 (C20), 133.7 (C11), 137.9 (C4'), 142.6 (C12), 148.0 (cyclic carbonate C=O); IR (CCl<sub>4</sub>) ν 3450, 2950, 2870, 1750, 1460, 1380, 1350, 1220, 1120, 1080, 1040, 980, 900, 820, 710 cm<sup>-1</sup>; MS (CI) 625 (M+1-H<sub>2</sub>O, 6), 551 (11), 477 (100), 459 (12), 433 (8), 344 (90); Anal.

Calcd. for  $C_{33}H_{60}O_6Si_2$ : C, 64.92; H, 9.90; Found: C, 65.13; H, 9.88.

**Ketocarbonate 9.** To a vigorously stirred solution of dimethylsulfoxide (2.41 mL, 34 mmol) in  $CH_2Cl_2$  (57 mL) under nitrogen at -78 °C was added 8.5 mL of a 2.0 M solution (17.0 mmol) of oxalyl chloride in  $CH_2Cl_2$ . After 10 min, a solution of hydroxycarbonate 8 ( $P_{10}$  = TES,  $P_{13}$  = TBS) (3.45 g, 5.67 mmol) in 16 mL  $CH_2Cl_2$  was added dropwise down the side of the flask. After 30 min at -78 °C, triethylamine (6.8 mL, 49 mmol) was added and the mixture was warmed to room temperature. The mixture was diluted with 200 mL hexanes, washed with two 75 mL portions of a saturated aqueous  $NaHCO_3$  solution and brine, dried over anhydrous  $Na_2SO_4$  and concentrated under reduced pressure to yield 3.45 g of a yellow solid. This material was filtered through a 1 inch pad of silica gel with 10% ethyl acetate in hexanes and then recrystallized from hexanes to yield 2.62 g of ketocarbonate 9 as white crystals. The mother liquor was purified by silica gel chromatography, eluting with 10% ethyl acetate in hexanes and then recrystallization from hexanes to yield an additional 0.58 g of ketocarbonate 9 ( $P_{10}$  = TES,  $P_{13}$  = TBS) (total yield: 3.20 g, 93%).

**9** ( $P_{10}$  = TES,  $P_{13}$  = TBS): mp 140.0 - 141.5 °C;  $^1H$  NMR (500 MHz,  $CDCl_3$ )  $\delta$  0.11 (s, 3H, TBS  $CH_3$ ), 0.12 (s, 3H, TBS  $CH_3$ ), 0.60 (q,  $J$  = 7.8 Hz, 6H, TES  $CH_2$ ), 0.96 (t,  $J$  = 7.8 Hz, 9H, TES  $CH_3$ ), 0.98 (s, 9H, TBS t-Bu), 1.06 (s, 3H,  $CH_3$  19), 1.17 (s, 6H,  $CH_3$  16,  $CH_3$  19), 1.42 (dd,  $J$  = 3.7, 14.2 Hz, 1H,  $H9\beta$ ), 1.63 (m, 2H, H6, H6), 2.12 (m, 1H, H5), 2.38 (d,  $J$  = 0.9 Hz, 3H,  $CH_3$  18), 2.47 (dd,  $J$  = 11.4, 13.3 Hz, 1H,  $H9\alpha$ ), 2.65 (d,  $J$  = 8.2, 1H, H1), 3.94 (dd,  $J$  = 1.4, 10.4 Hz, 1H, H7), 4.44 (dd,  $J$  = 3.7, 11.4 Hz, 1H, H10), 4.49 (s, 1H, H3), 4.64 (dd,  $J$  = 6.9, 7.8 Hz, 1H, H13), 5.04 (dd,  $J$  = 1.4, 11.9 Hz, 1H, H20), 5.07 (dd,  $J$  = 1.8, 17.4 Hz, 1H, H20), 5.76 (m, 1H, H4);  $^{13}C$  NMR  $\delta$  (ppm) -5.4 (TBS  $CH_3$ ), -4.5 (TBS  $CH_3$ ), 4.8 (TES  $CH_2$ ), 6.5 (TES  $CH_3$ ), 15.7 ( $CH_3$  18), 17.8 ( $CH_3$  19), 17.9 (TBS  $C(CH_3)_3$ ), 25.5 (TBS  $C(CH_3)_3$ ), 28.2 ( $CH_3$  16), 28.3 ( $CH_3$  17), 28.3 (C6), 29.6 (C5), 30.4 (C14), 37.7 (C15), 38.0 (C8, C9), 62.1 (C1), 66.5 (C10), 67.5 (C13), 91.3 (C3), 91.5 (C7), 116.4 (C20), 132.8 (C11), 137.0 (C4'), 145.4 (C12), 146.6 (cyclic carbonate C=O), 206.8 (C2); IR ( $CCl_4$ )  $\nu$  2930, 2860, 1760, 1670, 1450, 1380, 1340, 1240, 1180, 1170, 1120, 1090, 1060, 1040, 980, 890, 860, 820, 700, 650  $cm^{-1}$ ; MS (CI) 607 (M+1, 6), 549 (11), 475 (100), 431 (4), 347 (45);

Anal. Calcd. for  $C_{33}H_{58}O_6Si_2$ : C, 65.30; H, 9.63; Found: C, 65.23; H, 9.66.

**2-Keto-3-Hydroxy-Lactone 10.** To a stirred solution of 3,7-cyclic carbonate **9** ( $P_{10}$  = TES,  $P_{13}$  = TBS) (2.246 g, 3.70 mmol) in THF (9 mL) was added 19.4 mL of 0.2 M LTMP (3.88 mmol) in THF dropwise down the sides of the flask at -25 °C. The reaction mixture was allowed to warm to -10 °C over the course of 30 min. The cold reaction mixture was poured into 100 mL of 10% aqueous acetic acid and extracted with 100 mL of 10% ethyl acetate in hexanes. The organic phase was washed with 50 mL of a saturated aqueous  $NaHCO_3$  solution and 50 mL of brine. The combined aqueous phases were extracted with two 20 mL portions of 10% ethyl acetate in hexanes. The organic phases were combined, dried over anhydrous  $Na_2SO_4$  and concentrated under reduced pressure to give 2.4 g of a yellow oil. This material was purified by silica gel chromatography, eluting with 5% then 10% ethyl acetate in hexanes to yield 2.033 g (90%) of the hydroxy lactone **10** ( $P_{10}$  = TES,  $P_{13}$  = TBS) as a foamy solid and 0.207 g (7.2%) of the 3-carbamate.

**10** ( $P_{10}$  = TES,  $P_{13}$  = TBS):  $^1H$  NMR (500 MHz,  $CDCl_3$ )  $\delta$  0.12 (s, 3H, TBS  $CH_3$ ), 0.14 (s, 3H, TBS  $CH_3$ ), 0.61 (q,  $J$  = 7.8 Hz, 6H, TES  $CH_2$ ), 0.92 (s, 9H, TBS t-Bu), 0.97 (t,  $J$  = 7.8 Hz, 9H, TES  $CH_3$ ), 1.11 (s, 3H,  $CH_3$  17), 1.22 (s, 3H,  $CH_3$  19), 1.27 (s, 3H,  $CH_3$  16), 1.32 (dd,  $J$  = 3.2, 13.3 Hz, 1H,  $H9\beta$ ), 1.64 (ddd,  $J$  = 2.3, 6.9, 9.2 Hz, 1H, H6), 2.07 (m, 2H, H6, H5), 2.17 (m, 1H, H14 $\alpha$ ), 2.33 (m, 1H, H5), 2.65 (m, 2H, H14 $\beta$ , H1), 2.74 (dd,  $J$  = 12.4, 12.4 Hz, 1H,  $H9\alpha$ ), 3.92 (dd,  $J$  = 2.8, 11.5 Hz, 1H, H7), 4.47 (dd,  $J$  = 3.2, 11.0 Hz, 1H, H10), 4.55 (dd,  $J$  = 2.8, 9.6 Hz, 1H, H13), 5.02 (d,  $J$  = 10.1 Hz, 1H, H20), 5.07 (dd,  $J$  = 1.4, 16.9 Hz, 1H, H20), 5.81 (dd,  $J$  = 6.9, 6.9, 10.5, 16.9 Hz, 1H, H4);  $^{13}C$  NMR  $\delta$  (ppm) -5.2 (TBS  $CH_3$ ), -4.5 (TBS  $CH_3$ ), 4.8 (TES  $CH_2$ ), 6.6 (TES  $CH_3$ ), 16.4 ( $CH_3$  18), 17.9 (TBS  $C(CH_3)_3$ ), 24.2 ( $CH_3$  19), 25.7 (TBS  $C(CH_3)_3$ ), 26.9 ( $CH_3$  16), 30.1 ( $CH_3$  17), 30.4 (C5), 32.7 (C6), 32.9 (C14), 39.1 (C15), 40.6 (C9), 48.1 (C8), 62.0 (C1), 67.3 (C10), 67.6 (C13), 87.9 (C3), 91.1 (C7), 115.8 (C20), 137.7 (C11), 138.5 (C4'), 143.0 (C12), 173.5 (C4), 207.6 (C2); IR ( $CCl_4$ )  $\nu$  3500, 2970, 2900, 1780, 1700, 1480, 1360, 1260, 1210, 1160, 1070, 1010, 910, 890, 840  $cm^{-1}$ ; MS (EI) 606 (M, 100), 549 (69), 474 (27), 431 (65), 417(40); Anal. Calcd. for  $C_{33}H_{58}O_6Si_2$ : C, 65.30; H, 9.63; Found: C, 65.38; H, 9.64.

**Keto Lactone 11.** To the 2-keto-3-hydroxylactone **10** ( $P_{10}$  = TES,  $P_{13}$  = TBS) (1.10 g, 1.83 mmol) was added a 0.1 M solution of  $\text{SmI}_2$  in THF (82 mL, 8.2 mmol). The resulting dark blue solution was stirred at room temperature under  $\text{N}_2$  for 4h. After cooling to 0 °C an ethereal solution of HCl (0.66M; 4.2 mL, 2.77 mmol) was added; after 5 min the flask was opened to the air and the reaction mixture was diluted with 200 mL of cold ethyl acetate, then poured into 50 mL of ice cold 0.2N aqueous HCl. The organic phase was separated and washed with 50 mL of a 5% aqueous citric acid solution, two 50 mL portions of a saturated aqueous  $\text{NaHCO}_3$  solution and 50 mL of brine, dried over anhydrous  $\text{Na}_2\text{SO}_4$  and concentrated under reduced pressure. The resulting material was dissolved in 100 mL of hexanes, then silica gel (230-400 mesh; 4.3 g) was added and the mixture was vigorously stirred at room temperature for 65 min before filtering through a 1 inch pad of silica gel eluting with 300 mL of 20% ethyl acetate in hexanes. The solvent was evaporated under reduced pressure and the residue was purified by silica gel chromatography, eluting with 10% ethyl acetate in hexanes to yield 822 mg (77%) of the *cis*-ketolactone **11** and 164 mg (15%) of the corresponding *trans* isomer.

To a solution of the *trans*-2-ketolactone (611 mg, 1.03 mmol) stirred in 10 mL of THF under nitrogen at 0 °C was added down the side of the flask 6.8 mL of a 0.6 M solution (4.1 mmol) of *t*-BuOK in THF. The resulting solution was stirred for 1.5 h then 10 mL of a 10% acetic acid solution in THF was added down the side of the flask. After stirring for 5 min the mixture was diluted with 200 mL of hexanes and poured into 100 mL of a saturated aqueous  $\text{NaHCO}_3$  solution. The organic layer was washed with water and brine then dried over anhydrous  $\text{Na}_2\text{SO}_4$  and concentrated under reduced pressure to yield 615 mg of pale brown oil. The oil was dissolved in 10 mL of hexanes and silica gel (3.0 g) was added. The mixture was stirred vigorously for 15 min then filtered through a 1/2 in plug of silica gel with 20% ethyl acetate in hexanes. Concentration of the filtrate under reduced pressure yielded 576 mg of pale yellow oil. This material was purified by silica gel chromatography, eluting with 10% then 20% ethyl acetate in hexanes to yield 472 mg (77%) of pure *cis*-2-ketolactone **11** ( $P_{10}$  = TES,  $P_{13}$  = TBS), 84 mg (13%) of pure *trans* isomer and 24 mg of a 6:1 mixture of *cis:trans* isomers.

**11** ( $P_{10}$  = TES,  $P_{13}$  = TBS): mp = 86.5 - 88.0 °C;  $^1\text{H}$  NMR (500 MHz,  $\text{CDCl}_3$ )  $\delta$  0.05 (s, 3H,

TBS CH<sub>3</sub>), 0.07 (s, 3H, TBS CH<sub>3</sub>), 0.54 (q, *J* = 7.8 Hz, 6H, TES CH<sub>2</sub>), 0.84 (s, 9H, TBS t-Bu), 0.90 (t, *J* = 7.8 Hz, 9H, TES CH<sub>3</sub>), 1.03 (s, 3H, CH<sub>3</sub> 17), 1.11 (s, 3H, CH<sub>3</sub> 16), 1.15 (s, 3H, CH<sub>3</sub> 19), 1.35 (dddd, *J* = 4.6, 4.6, 7.3, 14.2 Hz, 1H, H6), 1.43 (dd, *J* = 3.7, 12.8 Hz, 1H, H9 $\beta$ ), 1.67 (dddd, *J* = 3.2, 7.3, 10.1, 13.7 Hz, 1H, H6), 1.83 (dd, *J* = 4.6, 16.0 Hz, 1H, H14 $\alpha$ ), 2.03 (m, 1H, H5), 2.07 (d, *J* = 1.4 Hz, 3H, CH<sub>3</sub> 18), 2.25 (m, 1H, H5), 2.30 (dd, *J* = 11.9, 12.3 Hz, 1H, H9 $\alpha$ ), 2.45 (d, *J* = 8.2 Hz, 1H, H1), 2.58 (ddd, *J* = 8.7, 9.2, 16.0 Hz, 1H, H14 $\beta$ ), 3.93 (dd, *J* = 2.8, 11.4 Hz, 1H H7 $\beta$ ), 4.03 (s, 1H, H3 $\alpha$ ), 4.37 (dd, *J* = 3.7, 11.0 Hz, 1H, H10 $\beta$ ), 4.46 (ddd, *J* = 1.4, 4.6, 9.2 Hz, 1H, H13 $\beta$ ), 4.96 (dd, *J* = 1.4, 10.1 Hz, 1H, H20), 5.01 (dd, *J* = 1.4, 17.4 Hz, 1H, H20), 5.73 (dddd, *J* = 6.4, 7.3, 10.5, 16.9 Hz, 1H, H4); <sup>13</sup>C NMR  $\delta$  (ppm) -5.3 (TBS CH<sub>3</sub>), -4.6 (TBS CH<sub>3</sub>), 4.5 (TES CH<sub>2</sub>), 6.5 (TES CH<sub>3</sub>), 15.0 (CH<sub>3</sub> 18), 18.0 (TBS C(CH<sub>3</sub>)<sub>3</sub>), 25.7 (TBS C(CH<sub>3</sub>)<sub>3</sub>), 28.9 (CH<sub>3</sub> 19), 29.2 (CH<sub>3</sub> 16), 29.8 (C5), 29.9 (CH<sub>3</sub> 17), 30.3 (C6), 32.8 (C14), 38.5 (C15), 44.2 (C8), 44.9 (C9), 60.6 (C3), 61.2 (C1), 66.9 (C10), 67.8 (C13), 91.9 (C7), 115.7 (C20), 137.7 (C11), 138.5 (C4'), 142.4 (C12), 174.7 (C4), 204.8 (C2); IR (CCl<sub>4</sub>)  $\nu$  2975, 2899, 1780, 1705, 1460, 1355, 1260, 1180, 1070, 1060, 1000, 830 cm<sup>-1</sup>; MS (CI) 591 (M+1, 5), 523 (6), 459(100), 441 (5); Anal. Calcd. for C<sub>33</sub>H<sub>58</sub>O<sub>5</sub>Si<sub>2</sub>: C, 66.07; H, 9.89; Found: C, 66.97; H, 9.91.

1-Hydroxy-2-Keto-Lactone 12. To 34.2 mL of a stirred 0.2 M solution (6.84 mmol) of LTMP in THF under nitrogen at -10 °C was added a solution of ketolactone 11 (P<sub>10</sub> = TES, P<sub>13</sub> = TBS) (1.008 g, 1.71 mmol) in 10 mL of THF dropwise down the side of the flask. After 0.5 h, the reaction mixture was cooled to -40 °C and a solution of (+)-camphorsulfonyl oxaziridine (1.96 g, 8.55 mmol) in THF (10 mL) was added dropwise down the side of the flask. After 20 min, the reaction mixture was cooled to -78 °C, diluted with 200 mL of hexanes and rapidly poured into 250 mL of a vigorously stirred saturated aqueous NH<sub>4</sub>Cl solution. The aqueous phase was extracted with two 50 mL portions of hexane and the combined organic phase were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure to give 1.4 g of a waxy solid. This material was chromatographed (CH<sub>2</sub>Cl<sub>2</sub> followed by hexanes increasing to 10% ethyl acetate in hexanes) to give 0.882 g of hydroxyketolactone 12 (P<sub>10</sub> = TES, P<sub>13</sub> = TBS) (85%) as a white solid, 0.083 g of the corresponding *trans*-hydroxyketolactone (8 %) as a solid, and 31 mg of

returned ketolactone **11** (3 %).

**12** ( $P_{10}$  = TES,  $P_{13}$  = TBS): mp 124-126 °C;  $^1\text{H}$  NMR ( $\text{C}_6\text{D}_6$ )  $\delta$  (ppm) 0.09 (s, 3H,  $\text{CH}_3$  in TBDMS), 0.17 (s, 3H,  $\text{CH}_3$  in TBDMS), 0.62 (q,  $J$  = 7.78 Hz, 6H  $\text{CH}_2$ 's in TES), 1.03 (t,  $J$  = 7.78, 9H  $\text{CH}_3$ 's in TES), 1.05 (s, 3H,  $\text{CH}_3$  19), 1.13 (s, 9H, t-Bu in TBS), 1.20 (s, 3H,  $\text{CH}_3$  17), 1.39 (m, 1H, H6), 1.42 (s, 3H,  $\text{CH}_3$  16), 1.44 (dd,  $J$  = 0.92, 13.28 Hz, 1H, H9 $\beta$ ), 1.98 (dd,  $J$  = 9.61, 12.82 Hz, 1H, H14 $\beta$ ), 2.05 (m, 1H, H15), 2.06 (broad, 1H, OH1,  $\text{D}_2\text{O}$  exchangeable), 2.25 (m, 1H, H6), 2.27 (d,  $J$  = 0.91 Hz, 3H,  $\text{CH}_3$  18), 2.29 (m, 1H, H5), 2.41 (dd,  $J$  = 10.98, 13.28 Hz, 1H, H9 $\alpha$ ), 2.56 (dd,  $J$  = 3.21, 12.82 Hz, 1H, H14 $\alpha$ ), 3.83 (dd,  $J$  = 2.75, 11.90 Hz, 1H, H7), 4.04 (s, 1H, H3), 4.47 (dd,  $J$  = 0.92, 10.98 Hz, 1H, H10), 4.60 (ddq,  $J$  = 0.91, 3.21, 9.61 Hz, 1H, H13), 5.11 (br d,  $J$  = 10.53 Hz, 1H, H20), 5.18 (br d,  $J$  = 17.40 Hz, 1H, H20), 5.77 (m, 1H, H4);  $^{13}\text{C}$  NMR ( $\text{CDCl}_3$ )  $\delta$  (ppm) -5.4 (TBS  $\text{CH}_3$ ), -4.7 (TBS  $\text{CH}_3$ ), 4.5 (TES  $\text{CH}_2$ ), 6.5 (TES  $\text{CH}_3$ ), 15.5 ( $\text{CH}_3$  18), 17.9 (TBS  $\text{C}(\text{CH}_3)_3$ ), 22.5 ( $\text{CH}_3$  19), 25.7 (TBS  $\text{C}(\text{CH}_3)_3$ ), 26.3 ( $\text{CH}_3$  16), 29.8 ( $\text{CH}_3$  17), 29.8 (C5), 30.4 (C6), 39.6 (C14), 41.3 (C15), 44.5 (C9), 45.0 (C8), 58.1 (C3), 66.5 (C10), 68.2 (C13), 83.0 (C1), 91.7 (C7), 115.7 (C20), 137.0 (C11), 137.6 (C4'), 145.5 (C12), 175.0 (C4), 202.4 (C2); IR ( $\text{CCl}_4$ )  $\nu$  3500, 3000, 1780, 1720, 1100  $\text{cm}^{-1}$ ; MS (CI) 607 ( $M+1$ , 10), 589 (56), 475 (100), 457 (61); Anal. Calcd for  $\text{C}_{33}\text{H}_{58}\text{O}_6\text{Si}_2$ : C, 65.30; H, 9.63. Found: C, 65.19; H, 9.60.

**1,2-Dihydroxy-trans-lactone 13.** To a stirred 1.23 M solution of Red-Al (4.6 mmol, 5.6 mmol) in THF under nitrogen at -78 °C was quickly added a solution of *cis*-hydroxyketone **12** ( $P_{10}$  = TES,  $P_{13}$  = TBS) (342 mg, 0.563 mmol) in THF (25 mL). After 1.5 h, 25 mL of a 15 % aqueous NaOH solution was added dropwise directly to the reaction mixture. The reaction mixture was vigorously stirred at room temperature for 3 h and was then poured into 100 mL of  $\text{H}_2\text{O}$  and extracted with two 100 mL portions of ether. The organic phases were combined and washed with 100 mL of  $\text{H}_2\text{O}$  and 100 mL of brine, dried over anhydrous  $\text{Na}_2\text{SO}_4$  and concentrated under reduced pressure to give 0.35 g of a pale yellow solid. This material was purified by silica gel chromatography eluting with 10% ether in hexanes followed by 25% ethyl acetate in hexanes to yield 290 mg *trans*-diol **13** as colorless needles, 14.5 mg (4.2 %) of *trans*-hydroxyketone, and 20 mg of a mixture of *cis*-diol and unknown byproducts. To a solution of the mixture containing *cis*-

diol in THF (1 mL) under nitrogen at room temperature was added 0.5 mL a 30% aqueous solution of NaOH. After 2.5 h, the reaction mixture was poured into 30 mL of H<sub>2</sub>O and extracted with 30 mL of ether. The organic phase was washed with 30 mL of H<sub>2</sub>O and 30 mL of brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure to give 0.02 g of a yellow solid, which was purified by silica gel chromatography eluting with 5% ethyl acetate in hexanes to yield an additional 12 mg (total yield: 302 mg, 88%) of *trans*-diol 13 (P<sub>10</sub> = TES, P<sub>13</sub> = TBS).

13 (P<sub>10</sub> = TES, P<sub>13</sub> = TBS): mp 127-128°C, <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 0.09 (s, 3H, TBS CH<sub>3</sub>), 0.11 (s, 3H, TBS CH<sub>3</sub>), 0.60 (q, J = 8.1 Hz, 6H, TES CH<sub>2</sub>), 0.87 (s, 9H, TBS t-Bu), 0.96 (t, J = 8.1 Hz, 9H, TES CH<sub>3</sub>) 1.13 (s, 3H, CH<sub>3</sub> 17), 1.23 (s, 3H, CH<sub>3</sub> 16), 1.31 (s, 3H, CH<sub>3</sub> 19), 1.42 (dd, J = 3.7, 12.8 Hz, 1H, H9β), 1.46 (ddd, J = 4.8, 8.8, 11.4 Hz, 1H, H6), 1.74 (dddd, J = 3.3, 7.3, 9.9, 12.4 Hz, 1H, H6), 1.99 (d, J = 1.5 Hz, 3H, CH<sub>3</sub> 18), 2.10 (m, 1H, H5), 2.21 (dd, J = 3.7, 5.4 Hz, 1H, H14α), 2.26 (m, 3H, H5, H9α, H14β), 2.92 (d, J = 7.7 Hz, 1H, H3), 3.84 (dd, J = 2.2, 7.7 Hz, 1H, H2), 3.85 (s, 1H, OH1), 3.97 (dd, J = 2.9, 11.4 Hz, 1H, H7), 4.47 (dd, J = 3.7, 11.4 Hz, 2H, H13, H10), 5.01 (dd, J = 1.8, 12.2 Hz, 1H, H20), 5.07 (dd, J = 1.7, 17.0 Hz, 1H, H20), 5.78 (dddd, J = 7.3, 7.3, 10.1, 16.5 Hz, 1H, H4), 6.87 (d, J = 2.9 Hz, 1H, OH2), <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ (ppm) -5.31, -4.59, 4.79, 6.55, 16.60, 17.68, 21.24, 24.70, 25.62, 28.50, 29.52, 30.05, 40.20, 40.41, 44.18, 45.18, 45.60, 66.62, 69.25, 71.32, 88.91, 116.09, 136.96, 138.63, 139.93, 180.10, IR (CHCl<sub>3</sub>) ν 3050, 1730, 1460, 1350 cm<sup>-1</sup>, MS (EI) 608 (M, 13), 590 (26), 267 (100), Anal. Calcd. for C<sub>33</sub>H<sub>60</sub>O<sub>6</sub>Si<sub>2</sub>: C, 65.08; H, 9.92. Found C, 65.06; H, 9.98.

**Carbonate 14.** To a stirred solution of diol 13 (P<sub>10</sub> = TES, P<sub>13</sub> = TBS) (1.00 g, 1.64 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (58 mL) and pyridine (5.8 mL) under nitrogen at -78 °C was added dropwise 8.2 mL of 2 M solution (16.4 mmol) of phosgene in toluene. Then the reaction mixture was warmed to -23 °C and stirred for 30 min. To the resulting mixture, 50 mL of a saturated aqueous NaHCO<sub>3</sub> solution was added. After warming to room temperature for 10 min, the reaction mixture was extracted with 200 mL of 10% ethyl acetate in hexanes. The organic phase was washed with 100 mL of a 10 % aqueous CuSO<sub>4</sub> solution, two 200 mL portions of a saturated aqueous NaHCO<sub>3</sub> solution and brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure to give 1.1 g of a

pale yellow solid. This material was filtered through a 3 inch pad of silica gel with 15% ethyl acetate in hexanes to yield 1.045 g (100%) of carbonate **14** ( $P_{10}$  = TES,  $P_{13}$  = TBS) as a white solid.

**14** ( $P_{10}$  = TES,  $P_{13}$  = TBS): mp 146-147 °C,  $^1\text{H}$  NMR (500 MHz,  $\text{CDCl}_3$ )  $\delta$  0.11 (s, 3H, TBS  $\text{CH}_3$ ), 0.12 (s, 3H, TBS  $\text{CH}_3$ ), 0.61 (q,  $J$  = 7.8 Hz, 6H, TES  $\text{CH}_2$ ), 0.88 (s, 9H, TBS t-Bu), 0.96 (t,  $J$  = 7.8 Hz, 9H TES  $\text{CH}_3$ ), 1.20 (s, 3H,  $\text{CH}_3$  17), 1.30 (s, 3H,  $\text{CH}_3$  16), 1.32 (s, 3H,  $\text{CH}_3$  19), 1.40 (ddd,  $J$  = 2.7, 4.5, 9.2 Hz, 1H, H6), 1.44 (d,  $J$  = 3.7, 13.3 Hz, 1H,  $\text{H}9\beta$ ), 1.71 (dddd,  $J$  = 2.7, 6.9, 9.6, 12.8 Hz, 1H, H6), 2.11 (ddd,  $J$  = 7.8, 15.3, 15.3 Hz, 1H, H5), 2.29 (dd,  $J$  = 3.2, 15.6 Hz, 1H,  $\text{H}14\alpha$ ), 2.31 (m, 2H, H5,  $\text{H}9\alpha$ ), 2.59 (dd,  $J$  = 9.2, 15.6 Hz, 1H,  $\text{H}14\beta$ ), 2.99 (d,  $J$  = 7.3 Hz, 1H,  $\text{H}3\alpha$ ), 4.02 (dd,  $J$  = 2.7, 11.4 Hz, 1H,  $\text{H}7\beta$ ), 4.38 (dd,  $J$  = 3.7, 11.0 Hz, 1H,  $\text{H}10\beta$ ), 4.47 (d,  $J$  = 7.3 Hz, 1H,  $\text{H}2\beta$ ), 4.57 (dd,  $J$  = 2.1, 9.2 Hz, 1H,  $\text{H}13\beta$ ), 5.02 (dd,  $J$  = 1.4, 10.1 Hz, 1H, H20), 5.06 (dd,  $J$  = 1.4, 16.9 Hz, 1H, H20), 5.77 (dddd,  $J$  = 6.9, 6.9, 10.1, 17.0 Hz, 1H, H4),  $^{13}\text{C}$  NMR ( $\text{CDCl}_3$ )  $\delta$  (ppm) -5.37, -4.60, 4.75, 6.51, 17.02, 17.60, 21.24, 24.64, 25.55, 27.36, 29.50, 30.11, 37.56, 39.96, 42.89, 43.75, 45.39, 66.54, 68.29, 87.37, 90.05, 116.15, 136.54, 136.94, 144.93, 153.32, 169.89, IR ( $\text{CHCl}_3$ )  $\nu$  3070, 1800  $\text{cm}^{-1}$ . MS (EI) 634 (M, 12), 577 (100), Anal. Calcd. for  $\text{C}_{34}\text{H}_{58}\text{O}_7\text{Si}_2$ : C, 64.31; H, 9.21. Found C, 64.41; H, 9.22.

**Ketoester 15.** To a stirred solution of lactone **14** ( $P_{10}$  = TES,  $P_{13}$  = TBS) (1.05g, 1.65 mmol) in methanol (70 mL) under nitrogen at -78 °C was added a saturated solution of ozone in methylene chloride (50 mL, 40 mL then 8 mL) until no more starting material remained by TLC analysis. Triethylamine (4.8 mL) and trimethylphosphite (3.1 mL) were added sequentially to the resulting mixture at -78 °C. After stirring 5 min, the solution was warmed to 0 °C and stirred for 2 h. The resulting solution was poured into 250 mL of a saturated aqueous  $\text{NaHCO}_3$  solution and extracted with three 200 mL portions of  $\text{CH}_2\text{Cl}_2$ . The combined organic layers were washed with 150 mL of a saturated  $\text{NaHCO}_3$  solution, dried over anhydrous  $\text{Na}_2\text{SO}_4$  and concentrated under reduced pressure to give 1.10 g of the aldehyde as a colorless oil. This material was used further purification.

To a stirred solution of the aldehyde (1.10 g) in t-butanol (30.8 mL), acetone (10.3 mL) and 8 mL

of a 1.25 M (10 mmol) aqueous  $\text{KH}_2\text{PO}_4$  solution at 0 °C was added 11.3 mL of a 1 M (11.3 mmol) aqueous  $\text{KMnO}_4$  solution over the course of 2 min. The reaction mixture was stirred at 0 °C for 30 min, poured into 200 mL of a 10% aqueous  $\text{Na}_2\text{S}_2\text{O}_3$  solution and extracted with three 200 mL portions of ethyl acetate. The combined organic layers were washed with 50 mL of water, dried over anhydrous  $\text{Na}_2\text{SO}_4$  and concentrated under reduced pressure. To a stirred solution of the oily residue in ether (30 mL) at room temperature was added an ethereal solution of  $\text{CH}_2\text{N}_2$  (20 mL). The solution was concentrated under reduced pressure to give 1.15 g of a colorless oil. This material was filtered through a 2 inch pad of silica gel with 40% ethyl acetate in hexanes and concentration under reduced pressure yielded 1.01 g (91%) of lactone ester 15 ( $P_{10}$  = TES,  $P_{13}$  = TBS, R = Me).

15 ( $P_{10}$  = TES,  $P_{13}$  = TBS, R = Me):  $^1\text{H}$  NMR (500 MHz,  $\text{CDCl}_3$ )  $\delta$  0.12 (s, 3H, TBS  $\text{CH}_3$ ), 0.12 (s, 3H, TBS  $\text{CH}_3$ ), 0.60 (q,  $J$  = 8.1 Hz, 6H, TES  $\text{CH}_2$ ), 0.88 (s, 9H, TBS t-Bu), 0.96 (t,  $J$  = 8.1 Hz, 9H, TES  $\text{CH}_3$ ), 1.21 (s, 3H,  $\text{CH}_3$ ), 1.30 (s, 3H,  $\text{CH}_3$ ), 1.33 (s, 3H,  $\text{CH}_3$ ), 1.51 (dd,  $J$  = 3.7, 13.2 Hz, 1H,  $\text{H}9\beta$ ), 1.53 (m, 1H, H6), 2.06 (d,  $J$  = 1.1 Hz, 3H,  $\text{CH}_3$  18), 2.07 (ddd,  $J$  = 2.9, 7.7, 21.6 Hz, 1H, H6), 2.29 (dd,  $J$  = 3.7, 15.8 Hz, 1H,  $\text{H}14\alpha$ ), 2.31 (dd,  $J$  = 13.2, 13.2 Hz, 1H,  $\text{H}9\alpha$ ), 2.46 (ddd,  $J$  = 7.7, 16.8, 24.5 Hz, 1H, H5), 2.53 (ddd,  $J$  = 5.5, 7.7, 16.8 Hz, 1H, H5), 2.60 (dd,  $J$  = 9.2, 15.8 Hz, 1H,  $\text{H}14\beta$ ), 2.99 (d,  $J$  = 7.3 Hz, 1H,  $\text{H}3\alpha$ ), 3.68 (s, 3H,  $\text{CO}_2\text{Me}$ ), 4.09 (dd,  $J$  = 2.6, 12.1 Hz, 1H,  $\text{H}7\beta$ ), 4.39 (dd,  $J$  = 3.7, 11.0 Hz, 1H,  $\text{H}10\beta$ ), 4.47 (d,  $J$  = 7.3 Hz, 1H,  $\text{H}2\beta$ ), 4.59 (dd,  $J$  = 1.8, 9.2 Hz, 1H,  $\text{H}13\beta$ ); Anal. Calcd. for  $\text{C}_{34}\text{H}_{58}\text{O}_9\text{Si}_2$ : C, 61.22; H, 8.77. Found C, 61.30; H, 8.79.

Enol ester 16. To a stirred solution of lactone ester 15 ( $P_{10}$  = TES,  $P_{13}$  = TBS, R = Me) (1.01 g, 1.51 mmol) in THF (24.5 mL) at -78 °C was added slowly a 19.4 mL of a 0.2 M solution (3.88 mmol) of LDA in THF down the side of the flask over the course of 3 min. After stirring 35 min, 10 mL of a 33% solution of acetic acid in THF was quickly added. After 5 min, the mixture was poured into 150 mL of a saturated aqueous  $\text{NaHCO}_3$  solution and extracted with three 200 mL portions of  $\text{CHCl}_3$ . The combined organic phases were dried over anhydrous  $\text{Na}_2\text{SO}_4$  and concentrated under reduced pressure to give 1.02 g of crude enol ester 16 ( $P_{10}$  = TES,  $P_{13}$  = TBS, R = Me) as a colorless oil. Approximately 3% of unreacted ester lactone 15 was still present.

but this material was used without further purification.

**16** ( $P_{10}$  = TES,  $P_{13}$  = TBS, R = Me):  $^1\text{H}$  NMR (300 MHz,  $\text{CDCl}_3$ )  $\delta$  0.09 (s, 3H, TBS  $\text{CH}_3$ ), 0.10 (s, 3H, TBS  $\text{CH}_3$ ), 0.61 (q, 6H, TES  $\text{CH}_2$ ), 0.87 (s, 9H, TBS t-Bu), 0.96 (t,  $J$  = 8.0 Hz, TES  $\text{CH}_3$ ), 1.08 (s, 3H,  $\text{CH}_3$ ), 1.21 (s, 3H,  $\text{CH}_3$ ), 1.33 (s, 3H,  $\text{CH}_3$ ), 1.61 (d,  $J$  = 4.3 Hz, 1H, OH-7), 1.89 (dd,  $J$  = 4.3, 13.9 Hz, 1H, H9 $\alpha$ ), 1.95 (dd,  $J$  = 11.2, 11.2 Hz, 1H, H9 $\beta$ ), 2.01 (d,  $J$  = 1.1 Hz, 3H,  $\text{CH}_3$  18), 2.22 (ddd,  $J$  = 2.7, 10.7, 15.5 Hz, 1H, H6 $\beta$ ), 2.45 (dd,  $J$  = 4.8, 15.5 Hz, 1H, H6 $\alpha$ ), 2.54 (dd,  $J$  = 9.1, 15.0 Hz, 1H, H14 $\beta$ ), 2.86 (dd,  $J$  = 3.7, 15.0 Hz, 1H, H14 $\alpha$ ), 3.07 (s, 1H, H3 $\alpha$ ), 3.40 (ddd,  $J$  = 4.8, 4.8, 9.6 Hz, 1H, H7 $\alpha$ ), 3.75 (s, 3H,  $\text{CO}_2\text{Me}$ ), 4.39 (dd,  $J$  = 4.3, 11.2 Hz, 1H, H10 $\beta$ ), 4.60 (d,  $J$  = 4.3, 11.2 Hz, 1H, H2 $\beta$ ), 4.67 (dd,  $J$  = 2.1, 9.1 Hz, 1H, H13 $\beta$ ), 12.24 (s, 1H, OH4).

**Enol ester 17.** To a stirred solution of crude enol ester **16** ( $P_{10}$  = TES,  $P_{13}$  = TBS, R = Me) (1.02 g) in THF (13 mL) and 2-methoxypropene (13 mL) under nitrogen at 0 °C was added 0.48 mL of a 0.1 M solution (0.048 mmol) of p-toluenesulfonic acid in THF. The mixture was stirred at 0 °C for 10 min and then triethylamine (0.66 mL) was added. The mixture was concentrated under reduced pressure and purified by silica gel chromatography, eluting with 7.5% ethyl acetate in hexanes increasing to 30% ethyl acetate in hexanes to yield 938 mg enol ester **17** ( $P_7$  = MOP,  $P_{10}$  = TES,  $P_{13}$  = TBS, R = Me) (84% from **15**) and 30 mg (3%) of recovered lactone ester **15**.

**17** ( $P_7$  = MOP,  $P_{10}$  = TES,  $P_{13}$  = TBS, R = Me): mp 95-97 °C,  $^1\text{H}$  NMR (300 MHz,  $\text{CDCl}_3$ )  $\delta$  0.08 (s, 3H, TBS  $\text{CH}_3$ ), 0.10 (s, 3H, TBS  $\text{CH}_3$ ), 0.59 (q,  $J$  = 7.7 Hz, 6H, TES  $\text{CH}_3$ ), 0.87 (s, 9H, TBS t-Bu), 0.95 (t,  $J$  = 7.7 Hz, 9H, TES  $\text{CH}_3$ ), 1.10 (s, 3H,  $\text{CH}_3$ ), 1.19 (s, 3H,  $\text{CH}_3$ ), 1.30 (s, 3H,  $\text{CH}_3$ ), 1.34 (s, 3H, MOP  $\text{CH}_3$ ), 1.37 (s, 3H, MOP  $\text{CH}_3$ ), 1.84 (m, 2H, H9 $\alpha$ , H9 $\beta$ ), 1.98 (s, 3H,  $\text{CH}_3$  18), 2.17 (ddd,  $J$  = 2.8, 10.4, 15.9 Hz, 1H, H6 $\beta$ ), 2.52, (dd,  $J$  = 9.3, 15.4 Hz, 1H, H14 $\beta$ ), 2.63 (dd,  $J$  = 4.4, 15.9 Hz, 1H, H6 $\alpha$ ), 2.88 (dd,  $J$  = 3.8, 15.4 Hz, 1H, H14 $\alpha$ ), 3.06 (s, 1H, H3 $\alpha$ ), 3.26 (s, 3H, MOP OMe), 3.37 (dd,  $J$  = 4.4, 10.4 Hz, 1H, H7 $\alpha$ ), 3.72 (s, 3H,  $\text{CO}_2\text{Me}$ ), 4.36 (dd,  $J$  = 6.0, 9.3 Hz, 1H, H10 $\beta$ ), 4.57 (d,  $J$  = 2.2 Hz, 1H, H2 $\beta$ ), 4.67 (dd,  $J$  = 2.8, 9.3 Hz, 1H, H13 $\beta$ ), 12.24 (s, 1H, OH4).

**Enol ester 17** ( $P_7$  = TES). To a solution of the enol ester **16** ( $P_{10}$  = TES,  $P_{13}$  = TBS, R = Me) (9

mg, 0.0137 mmole) and DMAP (3.5 mg, 0.0286 mmole) in pyridine (0.6 mL) at 0 °C was added triethylsilyl chloride (0.025 mL, 0.14 mmole). The solution was stirred at room temperature for 16 h, diluted with ethyl acetate (10 mL), poured into a saturated aqueous sodium bicarbonate solution (20 mL) and extracted with 20% ethyl acetate/hexane (20 mL x 3). The combined organic layer was dried over anhydrous NaSO<sub>4</sub>, filtered and concentrated to yield 25 mg of crude 17. Column chromatography (10% ethyl acetate/ hexane) provided 10 mg (95%) of pure enol ester 17 (P<sub>7</sub> = P<sub>10</sub> = TES, P<sub>13</sub> = TBS, R = Me).

17 (P<sub>7</sub> = P<sub>10</sub> = TES, P<sub>13</sub> = TBS, R = Me): <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 0.08 (s, 3H, TBS CH<sub>3</sub>), 0.10 (s, 3H, TBS CH<sub>3</sub>), 0.59 (q, J = 8.1 Hz, 12H, TES CH<sub>2</sub>), 0.87 (s, 9H; TBS t-Bu), 0.95 (t, J = 7.7 Hz, 18H, TES CH<sub>3</sub>), 1.05 (s, 3H, CH<sub>3</sub>), 1.19 (s, 3H, CH<sub>3</sub>), 1.30 (s, 3H, CH<sub>3</sub>), 1.84 (m, 2H, H9α, H9β), 1.98 (s, 3H, CH<sub>3</sub> 18), 2.17 (ddd, J = 2.8, 10.4, 15.9 Hz, 1H, H6β), 2.31 (dd, J = 4.4, 15.9 Hz, 1H, H6α), 2.52, (dd, J = 9.3, 15.4 Hz, 1H, H14β), 2.85 (dd, J = 3.8, 15.4 Hz, 1H, H14α), 3.03 (br s, 1H, H3α), 3.34 (dd, J = 5.0, 10.4 Hz, 1H, H7α), 3.75 (s, 3H, CO<sub>2</sub>Me OMe), 4.36 (dd, J = 5.0, 10.4 Hz, 1H, H10β), 4.58 (d, J = 2.7 Hz, 1H, H2β), 4.66 (br d, J = 11.0 Hz, 1H, H13β), 12.22 (s, 1H, OH4).

**Ketone 18.** To a stirred solution of enol ester 17 (P<sub>7</sub> = MOP, P<sub>10</sub> = TES, P<sub>13</sub> = TBS, R = Me) (963 mg, 1.3 mmol) in DMF (30 mL) under nitrogen at room temperature was added solid potassium thiophenoxyde (250 mg, 1.69 mmol) followed by thiophenol (0.4 mL, 3.9 mmol). The solution was warmed to 86 °C for 3.5 hours. The solution was allowed to cool to room temperature then was poured directly into 250 mL of a saturated aqueous NaHCO<sub>3</sub> solution and extracted with three 150 mL portions of 30% ethyl acetate in hexanes. The combined organic phases were then filtered through a 2 inch silica gel pad and subsequently concentrated under reduced pressure to yield 1.29 g of crude product. This material was purified by radial chromatography, eluting with 15% then 20% and finally 25% ethyl acetate in hexanes to yield 763 mg (86%) of ketone 18 (P<sub>7</sub> = MOP, P<sub>10</sub> = TES, P<sub>13</sub> = TBS).

18 (P<sub>7</sub> = MOP, P<sub>10</sub> = TES, P<sub>13</sub> = TBS): <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 0.10 (s, 3H, TBS CH<sub>3</sub>), 0.14 (s, 3H, TBS CH<sub>3</sub>), 0.58 (q, J = 8.2 Hz, 6H, TES CH<sub>2</sub>), 0.94 (s, 9H, TBS t-Bu), 0.95 (t, J = 8.2 Hz, 9H, TES CH<sub>3</sub>), 1.22 (s, 3H, CH<sub>3</sub> 19), 1.30 (s, 3H, CH<sub>3</sub> 17), 1.32 (s, 6H,

MOP CH<sub>3</sub>), 1.33 (s, 3H, CH<sub>3</sub> 16), 1.80 (m, 1H, H5), 1.81 (dd, *J* = 3.8, 3.8 Hz, 1H, H9 $\beta$ ), 1.98 (m, 1H, H5), 1.99 (d, *J* = 1.1 Hz, 3H, CH<sub>3</sub> 18), 2.21 (m, 1H, H6 $\beta$ ), 2.29 (dd, *J* = 10.4, 12.1 Hz, 1H, H9 $\alpha$ ), 2.43 (dd, *J* = 9.3, 15.4 Hz, 1H, H14 $\alpha$ ), 2.53 (m, 1H, H6 $\alpha$ ), 2.63 (dd, *J* = 5.0, 15.4 Hz, 1H, H14 $\beta$ ), 2.70 (d, *J* = 5.0 Hz, 1H, H3), 3.20 (s, 3H, MOP OMe), 3.39 (dd, *J* = 6.1, 10.4 Hz, 1H, H7), 4.34 (dd, *J* = 3.9, 10.4 Hz, 1H, H10), 4.55 (d, *J* = 5.5 Hz, 1H, H2), 4.73 (dd, *J* = 5.3, 7.7 Hz, 1H, H13). Anal. Calcd. for C<sub>36</sub>H<sub>64</sub>O<sub>8</sub>Si<sub>2</sub>: C, 63.49; H, 9.47. Found C, 63.56; H, 9.55.

**18** (P<sub>7</sub>=P<sub>10</sub>=TES, P<sub>13</sub>=TBS): <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  0.10 (s, 3H, TBS CH<sub>3</sub>), 0.14 (s, 3H, TBS CH<sub>3</sub>), 0.47-0.63 (m, 12H, TES CH<sub>2</sub>), 0.90-0.99 (m, 27H, TBS t-Bu, TES CH<sub>3</sub>), 1.22 (s, 3H, CH<sub>3</sub>), 1.25 (s, 3H, CH<sub>3</sub>), 1.33 (s, 3H, CH<sub>3</sub>), 1.75 (dt, *J* = 11.6, 1.6 Hz, 1H), 1.85 (d, *J* = 3.3 Hz, 1H), 1.90 (t, *J* = 3.9 Hz, 1H), 1.97 (t, *J* = 8.1 Hz, 1H), 2.00 (s, 3H, CH<sub>3</sub>), 2.30 (m, 1H), 2.39-2.60 (m, 3H), 2.65 (m, 1H), 3.35 (dd, *J* = 9.6, 7.8 Hz, 1H, H7 $\alpha$ ), 4.35 (dd, *J* = 10.8, 3.3 Hz, 1H, H10 $\beta$ ), 4.57 (d, *J* = 5.1 Hz, 1H, H2 $\beta$ ), 4.72 (m, 1H, H13 $\beta$ ).

**Ketone 18 (P<sub>7</sub>=BOM).** To a stirred solution of ketone **18** (P<sub>7</sub> = MOP, P<sub>10</sub> = TES, P<sub>13</sub> = TBS) (293 mg, 0.43 mmol) in THF (28.6 mL) and methanol (9.5 mL) under nitrogen at room temperature was added dropwise 0.20 mL of a 0.1 M solution of PPTS in CH<sub>2</sub>Cl<sub>2</sub> (0.02 mmol). The reaction mixture was stirred for 3 h, poured into 100 mL of a saturated aqueous NaHCO<sub>3</sub> solution and extracted with two 100 mL portions of ethyl acetate. The combined organic phases were washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure to yield 274 mg of the hydroxy ketone **18** (P<sub>7</sub>=H) as a colorless oil. This material was used without further purification.

**18** (P<sub>7</sub>=H, P<sub>10</sub> = TES, P<sub>13</sub> = TBS): mp 75-77 °C, <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>)  $\delta$  0.10 (s, 3H, TBS CH<sub>3</sub>), 0.13 (s, 3H, TBS CH<sub>3</sub>), 0.61 (q, *J* = 8.2 Hz, 6H, TES CH<sub>2</sub>), 0.93 (s, 9H, TBS t-Bu), 0.95 (t, *J* = 7.7 Hz, 9H, TES CH<sub>3</sub>), 1.19 (s, 3H, CH<sub>3</sub> 19), 1.22 (s, 3H, CH<sub>3</sub> 17), 1.35 (s, 3H, CH<sub>3</sub> 16), 1.84 (dd, *J* = 13.7, 4.1 Hz, 1H, H9 $\alpha$ ), 1.88 (m, 2H, H9 $\beta$ , OH7), 1.92 (m, 1H, H6 $\beta$ ), 2.05 (d, *J* = 1.4 Hz, 3H, CH<sub>3</sub> 18), 2.10 (m, 1H, H6 $\alpha$ ), 2.36 (dd, *J* = 1.4, 4.1, 9.9, 14.4 Hz, 1H, H5 $\alpha$ ), 2.47 (dd, *J* = 8.9, 15.4 Hz, 1H, H14 $\beta$ ), 2.51 (m, 1H, H5 $\beta$ ), 2.54 (dd, *J* = 4.8, 15.4 Hz, 1H, H14 $\beta$ ), 2.86 (d, *J* = 5.5 Hz, 1H, H3), 3.59 (ddd, *J* = 4.5, 6.2, 11.3 Hz,

1H, H7), 4.38 (dd,  $J$  = 4.1, 9.1 Hz, 1H, H10), 4.56 (d,  $J$  = 5.5 Hz, 1H, H2), 4.69 (ddd,  $J$  = 1.4, 4.8, 9.3 Hz 1H, H13). Anal. Calcd. for  $C_{32}H_{56}O_7Si_2x.5H_2O$ : C, 62.19; H, 9.30. Found C, 62.16; H, 9.22.

To a stirred solution of hydroxy ketone **18** ( $P_7$ =H) (179 mg, 0.29 mmol) in  $CH_2Cl_2$  (9.5 mL), diisopropylethylamine (1.49 mL, 8.6 mmol) and tetrabutylammonium iodide (253 mg, 0.69 mmol) under nitrogen was added dropwise benzylloxymethylchloride (0.42 mL, 2.86 mmol). The reaction mixture was brought to reflux for 32 h, cooled to room temperature, poured into 100 mL of a saturated aqueous  $NaHCO_3$  solution and extracted with two 100 mL portions of 50% ethyl acetate in hexanes. The combined organic phases were washed with brine, dried over anhydrous  $Na_2SO_4$  and concentrated under reduced pressure to yield 249 mg of the hydroxy ketone as a yellowish oil. This material was purified by silica gel chromatography to yield 196 mg (92%) of ketone **18** ( $P_7$ =BOM,  $P_{10}$  = TES,  $P_{13}$  = TBS) as a colorless oil.

**18** ( $P_7$ =BOM,  $P_{10}$  = TES,  $P_{13}$  = TBS):  $^1H$  NMR (500 MHz,  $CDCl_3$ )  $\delta$  0.10 (s, 3H, TBS  $CH_3$ ), 0.13 (s, 3H, TBS  $CH_3$ ), 0.59 (q,  $J$  = 7.7 Hz, 6H, TES  $CH_2$ ), 0.94 (s, 9H, TBS t-Bu), 0.94 (t,  $J$  = 7.7 Hz, 9H, TES  $CH_3$ ), 1.22 (s, 3H,  $CH_3$  17), 1.31 (s, 3H,  $CH_3$  19), 1.33 (s, 3H,  $CH_3$  16), 1.87 (dd,  $J$  = 12.1, 3.8 Hz, 1H, H9 $\alpha$ ), 1.98 (d,  $J$  = 1.4 Hz, 3H,  $CH_3$  18), 1.99 (m, 2H, H6 $\beta$ , H9 $\beta$ ), 2.21 (m, 1H, H6 $\alpha$ ), 2.34 (dd,  $J$  = 10.4, 12.1 Hz, 1H, H5 $\alpha$ ), 2.43 (dd,  $J$  = 9.3, 15.4 Hz, 1H, H14 $\alpha$ ), 2.55 (ddd,  $J$  = 5.5, 11.0, 13.7 Hz, 1H, H5 $\beta$ ), 2.62 (dd,  $J$  = 5.0, 15.4 Hz, 1H, H14 $\beta$ ), 2.74 (d,  $J$  = 5.0 Hz, 1H, H3), 3.38 (dd,  $J$  = 6.6, 11 Hz, 1H, H7), 4.38 (dd,  $J$  = 3.8, 10.4 Hz, 1H, H10), 4.56 (d,  $J$  = 5.0 Hz, 1H, H2), 4.58 (d,  $J$  = 11.5 Hz 1H,  $CH_2Ph$ ), 4.64 (d,  $J$  = 11.5 Hz 1H,  $CH_2Ph$ ), 4.68 (m, 2H, H13,  $OCH_2O$ ), 4.82 (d,  $J$  = 7.2 Hz 1H,  $OCH_2O$ ), 7.31 (m, 5H, Ph).

**Ketone 22a** ( $P_5$ =TMS). To a vigorously stirred solution of ketone **18** ( $P_7$ =BOM,  $P_{10}$  = TES,  $P_{13}$  = TBS) (315 mg, 0.42 mmol) in THF (10.5 mL), triethylamine (0.88 mL, 6.3 mmol) and trimethylsilyl chloride (0.53 mL, 4.2 mmol) under nitrogen at -78 °C was added dropwise down the side of the flask 1.35 mL of a 0.5 M solution (0.68 mmol) of LDA in THF. After 25 min, 2 mL of a saturated aqueous  $NaHCO_3$  solution was added. The reaction mixture was diluted with 150 mL of hexanes and washed with 20 mL of a saturated aqueous  $NaHCO_3$  solution and brine,

dried over anhydrous  $\text{Na}_2\text{SO}_4$  and concentrated under reduced pressure. The resulting oil was filtered through celite with hexanes and the filtrate was concentrated under reduced pressure to give 338 mg (99%) of the TMS enol ether **21a** ( $P_7=\text{BOM}$ ,  $P_{10}=\text{TES}$ ,  $P_{13}=\text{TBS}$ ,  $P_4=\text{TMS}$ ) as a colorless oil. To a vigorously stirred solution of TMS enol ether **21a** ( $P_7=\text{BOM}$ ,  $P_{10}=\text{TES}$ ,  $P_{13}=\text{TBS}$ ,  $P_4=\text{TMS}$ ) (224 mg, 0.274 mmol) in hexanes (2.8 mL) under nitrogen at room temperature was added dropwise 14.9 mL of a 0.02 M solution (0.30 mmol) of MCPBA in hexanes. After 5 h, 2 mL of a saturated aqueous  $\text{NaHCO}_3$  solution and 2 mL of a 10% aqueous  $\text{Na}_2\text{S}_2\text{O}_3$  solution were added. The reaction mixture was diluted with 150 mL of ethyl acetate and washed with 20 mL of a saturated aqueous  $\text{NaHCO}_3$  solution, 20 mL of a 10% aqueous  $\text{Na}_2\text{S}_2\text{O}_3$  solution, 20 mL of a saturated aqueous  $\text{NaHCO}_3$  solution and brine, dried over anhydrous  $\text{Na}_2\text{SO}_4$  and concentrated under reduced pressure to give 231 mg of the crude material as a colorless oil. This material was used without further purification, or, alternatively, was purified by flash chromatography on silica gel to give 168 mg (74%) of **22a** ( $P_7=\text{BOM}$ ,  $P_{10}=\text{TES}$ ,  $P_{13}=\text{TBS}$ ,  $P_5=\text{TMS}$ ) along with a mixture (15%) of **21a** and **18** which could be recycled.

**22a** ( $P_7=\text{BOM}$ ,  $P_{10}=\text{TES}$ ,  $P_{13}=\text{TBS}$ ,  $P_5=\text{TMS}$ ): mp 50.5-52 °C,  $^1\text{H}$  NMR (500 MHz,  $\text{CDCl}_3$ )  $\delta$  0.10 (s, 3H, TBS  $\text{CH}_3$ ), 0.13 (s, 9H, TMS  $\text{CH}_3$ ), 0.14 (s, 3H, TBS  $\text{CH}_3$ ), 0.59 (q,  $J=8.2$  Hz, 6H, TES  $\text{CH}_2$ ), 0.94 (s, 9H, TBS t-Bu), 0.94 (t,  $J=8.2$  Hz, 9H, TES  $\text{CH}_3$ ), 1.24 (s, 3H,  $\text{CH}_3$  17), 1.32 (s, 3H,  $\text{CH}_3$  19), 1.33 (s, 3H,  $\text{CH}_3$  16), 1.82 (dd,  $J=11.3$ , 13.7 Hz, 1H, H9 $\alpha$ ), 1.95 (d,  $J=1.4$  Hz, 3H,  $\text{CH}_3$  18), 1.98 (dd,  $J=3.4$ , 13.7 Hz, 1H, H9 $\beta$ ), 2.16 (ddd,  $J=6.2$ , 7.2, 13.3 Hz, 1H, H6 $\alpha$ ), 2.40 (dt,  $J=11.4$ , 13.3 Hz, 6 $\beta$ ), 2.43 (dd,  $J=9.2$ , 15.2 Hz, 1H, H14 $\beta$ ), 2.63 (dd,  $J=5.5$ , 15.2 Hz, 1H, H14 $\alpha$ ), 2.74 (d,  $J=5.5$  Hz, 1H, H3 $\alpha$ ), 3.40 (dd,  $J=7.2$ , 10.6 Hz, 1H, H7 $\alpha$ ), 4.36 (dd,  $J=3.4$ , 11.3 Hz, 1H, H10 $\beta$ ), 4.40 (dd,  $J=6.2$ , 12.0 Hz, 1H, H5 $\alpha$ ), 4.54 (d,  $J=5.5$  Hz, 1H, H2 $\beta$ ), 4.57 (d,  $J=11.7$  Hz 1H,  $\text{CH}_2\text{Ph}$ ), 4.64 (d,  $J=11.7$  Hz 1H,  $\text{CH}_2\text{Ph}$ ), 4.68 (d,  $J=7.0$  Hz 1H,  $\text{OCH}_2\text{O}$ ), 4.74 (m, 1H, H13), 4.78 (d,  $J=7.0$  Hz, 1H,  $\text{OCH}_2\text{O}$ ), 7.31 (m, 5H, Ph). Anal. Calcd. for  $\text{C}_{43}\text{H}_{72}\text{O}_9\text{Si}_3$ : C, 63.19; H, 8.88. Found C, 63.19; H, 8.92.

**Ketone 22a** ( $P_5=\text{H}$ ). To a vigorously stirred solution of crude **22a** ( $P_7=\text{BOM}$ ,  $P_{10}=\text{TES}$ ,  $P_{13}=\text{TBS}$ ,  $P_5=\text{TMS}$ ) (231 mg, 0.274 mmol) in acetonitrile (7 mL) at 0°C was added dropwise 7 mL

of a 1:10:10 (by volume) mixture of 48% aqueous HF:pyridine:acetonitrile. After stirring for 20 min, 2 mL of a saturated aqueous NaHCO<sub>3</sub> solution was added. The reaction mixture was diluted with 150 mL of ethyl acetate and washed with 30 mL of a saturated aqueous NaHCO<sub>3</sub> solution and brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure to give 223 mg of the crude alcohol as a colorless oil. This material was purified by silica gel chromatography to yield 155 mg (74%) of ketone 22a (P<sub>7</sub> = BOM, P<sub>10</sub> = TES, P<sub>13</sub> = TBS, P<sub>5</sub> = H), 15 mg (7%) of the 5 $\beta$ -hydroxy ketone and 33 mg (14% recoverable material) of a 1:1 mixture of TMS enol ether 21a and ketone 18.

**22a** (P<sub>7</sub> = BOM, P<sub>10</sub> = TES, P<sub>13</sub> = TBS, P<sub>5</sub> = H): <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>)  $\delta$  0.10 (s, 3H, TBS CH<sub>3</sub>), 0.14 (s, 3H, TBS CH<sub>3</sub>), 0.59 (q, J = 8.2 Hz, 6H, TES CH<sub>2</sub>), 0.94 (s, 9H, TBS t-Bu), 0.94 (t, J = 8.2 Hz, 9H, TES CH<sub>3</sub>), 1.23 (s, 3H, CH<sub>3</sub> 19), 1.32 (s, 3H, CH<sub>3</sub> 17), 1.33 (s, 3H, CH<sub>3</sub> 16), 1.83 (dd, J = 11.0, 13.7 Hz, 1H, H6 $\beta$ ), 1.97 (d, J = 1.4 Hz, 3H, H18), 2.01 (dd, J = 3.2, 13.7 Hz, 1H, H9 $\beta$ ), 2.11 (ddd, J = 5.5, 7.7, 13.7 Hz, 1H, H6 $\alpha$ ), 2.47 (dd, J = 8.7, 15.4 Hz, 1H, H14 $\beta$ ), 2.57 (m, 2H, H14 $\alpha$ , H9 $\alpha$ ), 2.88 (d, J = 5.5 Hz, 1H, H3 $\alpha$ ), 3.39 (dd, J = 7.7, 11.0 Hz, 1H, H7 $\alpha$ ), 3.41 (d, J = 3.3 Hz, 1H, OH-5), 4.38 (m, 2H, H5 $\beta$ , H10), 4.55 (d, J = 5.5 Hz, 1H, H2 $\beta$ ), 4.57 (d, J = 11.5 Hz 1H, CH<sub>2</sub>Ph), 4.62 (d, J = 11.5 Hz 1H, CH<sub>2</sub>Ph), 4.72 (m, 2H, H13 $\beta$ , OCH<sub>2</sub>O), 4.80 (d, J = 7.1 Hz 1H, OCH<sub>2</sub>O), 7.31 (m, 5H, Ph).

**Ketone 22a (P<sub>5</sub>=TMS)** from ketone 22a (P<sub>5</sub>=H). To a vigorously stirred solution of 5-hydroxy-4-ketone 22a (P<sub>7</sub> = BOM, P<sub>10</sub> = TES, P<sub>13</sub> = TBS, P<sub>5</sub> = H) (51 mg, 0.067 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (2.2 mL) and triethylamine (0.14 mL, 1.0 mmol) under nitrogen at 0 °C was added trimethylsilylchloride (0.041 mL, 0.34 mmol). After 0.5 h, the reaction mixture was quenched with 5 mL of a saturated aqueous NaHCO<sub>3</sub> solution and extracted with 150 mL hexanes. The organic phase was washed with 50 mL of a saturated aqueous NaHCO<sub>3</sub> solution and brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure to give 56 mg a colorless oil. This material was filtered through silica gel and the filtrate was concentrated under reduced pressure to yield 54 mg (96 %) of ketone 22a (P<sub>7</sub> = BOM, P<sub>10</sub> = TES, P<sub>13</sub> = TBS, P<sub>5</sub> = TMS).

**Alcohol 23a.** To a stirred solution of ketone 22a (P<sub>7</sub> = BOM, P<sub>10</sub> = TES, P<sub>13</sub> = TBS, P<sub>5</sub> = TMS)

(18.9 mg, 0.023 mmol) in  $\text{CH}_2\text{Cl}_2$  (4 mL) under nitrogen at -65 °C was added dropwise a 0.073 mL of a 3.1 M solution of  $\text{MeMgBr}$  in ether (0.23 mmol). The reaction mixture was allowed to warm to -48 °C, stirred for 16.5 h and then quenched with 0.13 mL of a 2.0M solution of  $\text{AcOH}$  in THF (0.25 mmol) and then poured into a stirring mixture of 50 mL of a saturated aqueous  $\text{NaHCO}_3$  solution and 50 mL of ethyl acetate. The aqueous phase was extracted with 50 mL ethyl acetate. The combined organic phases were washed with brine, dried over anhydrous  $\text{Na}_2\text{SO}_4$  and concentrated under reduced pressure to yield 20.5 mg of a colorless oil. This material was purified by silica gel chromatography to yield 18.4 mg (95%) of alcohol **23a** ( $P_7 = \text{BOM}$ ,  $P_{10} = \text{TES}$ ,  $P_{13} = \text{TBS}$ ,  $P_5 = \text{TMS}$ ) as a colorless oil.

**23a** ( $P_7 = \text{BOM}$ ,  $P_{10} = \text{TES}$ ,  $P_{13} = \text{TBS}$ ,  $P_5 = \text{TMS}$ ):  $^1\text{H}$  NMR (500 MHz,  $\text{CDCl}_3$ )  $\delta$  0.09 (s, 9H, TMS), 0.11 (s, 3H, TBS  $\text{CH}_3$ ), 0.12 (s, 3H, TBS  $\text{CH}_3$ ), 0.56 (q,  $J = 7.9$  Hz, 6H, TES  $\text{CH}_2$ ), 0.92 (t,  $J = 7.9$  Hz, 9H, TES  $\text{CH}_3$ ), 0.93 (s, 9H, TBS t-Bu), 1.25 (s, 3H,  $\text{CH}_3$  17), 1.28 (s, 3H,  $\text{CH}_3$  19), 1.33 (s, 3H,  $\text{CH}_3$  20), 1.34 (s, 3H,  $\text{CH}_3$  16), 1.74 (ddd,  $J = 3.8, 4.1, 13.0$  Hz, 1H, H6 $\alpha$ ), 1.99 (d,  $J = 1.4$  Hz, 3H, H18), 2.01 (dd,  $J = 11.3, 13.0$  Hz, 1H, H9 $\alpha$ ), 2.06 (m, 2H, H3, H9 $\beta$ ), 2.13 (ddd,  $J = 1.7, 12.3, 13.0$  Hz, 1H, H6 $\beta$ ), 2.37 (dd,  $J = 5.5, 15.0$  Hz, 1H, H14 $\alpha$ ), 2.54 (dd,  $J = 9.2, 15.0$  Hz, 1H, H14 $\beta$ ), 2.96 (s, 1H, OH-4), 3.51 (dd,  $J = 1.7, 4.1$  Hz, 1H, H5), 3.73 (dd,  $J = 3.8, 12.3$  Hz, 1H, H7 $\alpha$ ), 4.32 (dd,  $J = 4.1, 11.3$  Hz, 1H, H10 $\beta$ ), 4.64 (s, 2H,  $\text{CH}_2\text{Ph}$ ), 4.72 (d,  $J = 6.8$  Hz, 1H,  $\text{OCH}_2\text{O}$ ), 4.80 (m, 3H, H2, H13,  $\text{OCH}_2\text{O}$ ), 7.31 (m, 5H, Ph). Anal. Calcd. for  $\text{C}_{44}\text{H}_{76}\text{O}_9\text{Si}_3$ : C, 63.42; H, 9.19. Found C, 63.40; H, 9.15.

**Hydroxy olefin 24a.** To a refluxing solution of alcohol **23a** ( $P_7 = \text{BOM}$ ,  $P_{10} = \text{TES}$ ,  $P_{13} = \text{TBS}$ ,  $P_5 = \text{TMS}$ ) (46.7 mg, 0.055 mmol) in toluene (1.1 mL) was added 1.1 mL of a 0.1M solution of Burgess reagent in toluene (0.11 mmol). The mixture was refluxed for 20 min then cooled to room temperature, diluted with ethyl acetate, washed with a saturated solution of  $\text{NaHCO}_3$  and brine, dried over anhydrous  $\text{Na}_2\text{SO}_4$  and filtered. Concentration of the filtrate under vacuum yielded 46 mg of crude olefin. This material was used without further purification.

To a stirred solution of this crude olefin (46 mg, 0.055 mmol) in acetonitrile (2.5 mL) at 0 °C was added 2.5 mL of a 1:10:10 (by volume) mixture of 48% aqueous HF : pyridine : acetonitrile. The

mixture was stirred at 0 °C for 20 min, quenched with a saturated solution of NaHCO<sub>3</sub> and extracted twice with ethyl acetate. The combined organic phases were washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and filtered. Concentration of the filtrate under vacuum yielded 48 mg of a colorless oil which was purified by silica gel chromatography to yield 25.9 mg (62%) of hydroxy olefin 24a (P<sub>7</sub> = BOM, P<sub>10</sub> = TES, P<sub>13</sub> = TBS, R = H) as well as 2.1 mg of unreacted alcohol 23a (4%).

**24a** (P<sub>7</sub> = BOM, P<sub>10</sub> = TES, P<sub>13</sub> = TBS, R = H): mp 66-68 °C <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 0.12 (s, 3H, TBS CH<sub>3</sub>), 0.13 (s, 3H, TBS CH<sub>3</sub>), 0.59 (q, J = 7.9 Hz, 6H, TES CH<sub>2</sub>), 0.94 (t, J = 7.9 Hz, 9H, TES CH<sub>3</sub>), 0.95 (s, 9H, TBS t-Bu), 1.18 (s, 3H, CH<sub>3</sub> 19), 1.23 (s, 3H, CH<sub>3</sub> 17), 1.35 (s, 3H, CH<sub>3</sub> 16), 1.73 (d, 1H, J = 3.4 Hz, OH5), 1.83 (dd, J = 9.9, 10.5 Hz, 1H, H9α), 1.91 (ddd, J = 7.2, 7.5, 13.4 Hz, 1H, H6α), 1.97 (dd, J = 3.8, 9.9 Hz, 1H, H9β), 2.03 (d, J = 1.4 Hz, 3H, 18), 2.14 (ddd, J = 9.6, 9.6, 13.4 Hz, 1H, H6β) 2.35 (dd, J = 5.1, 15.4 Hz, 1H, H14α), 2.50 (dd, J = 9.6, 15.4 Hz, 1H, H14β), 3.03 (d, J = 5.8 Hz, 1H, H3α), 3.44 (dd, J = 7.5, 9.6, Hz, 1H, H7α), 4.38 (m, 2H, H10, H5), 4.54 (d, J = 5.8 Hz, 1H, H2), 4.58 (d, J = 11.6 Hz, 1H, CH<sub>2</sub>Ph), 4.62 (d, J = 11.6 Hz, 1H, CH<sub>2</sub>Ph), 4.73 (d, J = 7.0 Hz, 1H, OCH<sub>2</sub>O), 4.75 (m, 1H, H13), 4.79 (d, J = 7.0 Hz, 1H, OCH<sub>2</sub>O), 5.00 (s, 1H, H20E), 5.18 (s, 1H, H20Z), 7.31 (m, 5H, Ph). Anal. Calcd. for C<sub>41</sub>H<sub>66</sub>O<sub>8</sub>Si<sub>2</sub> × 0.5H<sub>2</sub>O: C, 65.47; H, 8.98. Found C, 65.63; H, 8.97.

**Allyl mesylate 24aa.** To a stirred solution of allyl alcohol 24a (P<sub>7</sub> = BOM, P<sub>10</sub> = TES, P<sub>13</sub> = TBS, R = H) (11.5 mg, 0.0154 mmol) in pyridine (0.6 mL) under nitrogen at 0 °C was added dropwise methanesulfonyl chloride (0.02 mL, 0.258 mmol). After 45 min, a saturated aqueous NaHCO<sub>3</sub> solution (0.05 mL) was added. The mixture was stirred for 10 min, poured into 20 mL of a saturated aqueous NaHCO<sub>3</sub> solution and extracted with 40% ethyl acetate/hexane (20 mL x 3). The combined organic phase was dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure to give 13 mg of 24aa (P<sub>7</sub> = BOM, P<sub>10</sub> = TES, P<sub>13</sub> = TBS, R = Ms) as a colorless oil. This material was used without further purification.

**24aa** (P<sub>7</sub> = BOM, P<sub>10</sub> = TES, P<sub>13</sub> = TBS, R = Ms): <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>); δ 0.12 (s, 3H, TBS CH<sub>3</sub>), δ 0.13 (s, 3H, TBS CH<sub>3</sub>), 0.58 (q, J = 7.9 Hz, 6H, TES CH<sub>2</sub>), 0.93 (s, 9H,

TBS t-Bu), 0.94 (t,  $J$  = 7.9 Hz, 9H, TES CH<sub>3</sub>), 1.23 (s, 3H, CH<sub>3</sub> 17), 1.22 (s, 3H, CH<sub>3</sub> 19), 1.34 (s, 3H, CH<sub>3</sub> 16), 1.80 (br t,  $J$  = 13 Hz, 1H, H9 $\alpha$ ), 1.98 (m, 1H, H6), 1.79 (ddd,  $J$  = 2.2, 5.5, 15.1 Hz, 1H, H14 $\alpha$ ), 2.01 (d,  $J$  = 1.1 Hz, 1H, CH<sub>3</sub> 18), 2.06 (dd,  $J$  = 3.3, 13.7 Hz, 1H, H9 $\beta$ ), 2.01 (br s, 3H, CH<sub>3</sub> 18), 2.22-2.32 (m, 3H, H14 $\alpha$ , H6 $\alpha$ , H6 $\beta$ ), 2.54 (dd,  $J$  = 9.9, 15.4 Hz, 1H, H14 $\beta$ ), 3.02 (s, 3H, OSO<sub>2</sub>CH<sub>3</sub>), 3.05 (d,  $J$  = 6.0 Hz, 1H, H3 $\alpha$ ), 3.45 (t,  $J$  = 8.5 Hz, 1H, H7 $\alpha$ ), 4.37 (dd,  $J$  = 3.6, 11.0 Hz, 1H, H10 $\beta$ ), 4.57 (d,  $J$  = 6.0 Hz, 1H, H2 $\beta$ ), 4.59 (q, 2H, PhCH<sub>2</sub>O), 4.69 (d,  $J$  = 7.1 Hz, 1H, OCH<sub>2</sub>O), 4.74 (m, 1H, H13 $\beta$ ), 4.76 (d,  $J$  = 7.1 Hz, 1H, OCH<sub>2</sub>O), 5.03 (br t,  $J$  = 8.5 Hz, 1H, H5 $\beta$ ), 5.09 (br s, 1H, H20), 5.24 (br s, 1H, H20), 7.35 (m, 5H, Ph).

**Triol 25a.** To a stirred solution of allyl alcohol 24a ( $P_7$  = BOM,  $P_{10}$  = TES,  $P_{13}$  = TBS, R = H) (45 mg, 0.0606 mmol) in a mixture of pyridine (0.32 mL) and ether (3.2 mL) under nitrogen at 0 °C was added a 0.157 M solution of OsO<sub>4</sub> in THF (0.42 mL, 0.066 mmole). After 12 h at 0 °C, NaHSO<sub>3</sub> (530 mg), pyridine (0.3 mL), THF (2 mL) and water (3 mL) were added. The mixture was vigorously stirred at room temperature for 14 h, poured into 50 mL of a saturated aqueous NaHCO<sub>3</sub> solution and extracted with ethyl acetate (40 mL x 3). The combined organic phase was dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure to give 60 mg of a pale yellow oil, which was column chromatographed (30% ethyl acetate/hexane) to yield 34.3 mg (73 %) of triol 25a ( $P_7$  = BOM,  $P_{10}$  = TES,  $P_{13}$  = TBS).

**25a** ( $P_7$  = BOM,  $P_{10}$  = TES,  $P_{13}$  = TBS): <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>);  $\delta$  0.11 (s, 6H, TBS CH<sub>3</sub>), 0.60 (ddd,  $J$  = 9.0 Hz, 6H, TES CH<sub>2</sub>), 0.79 (s, 3H, CH<sub>3</sub> 19), 0.93 (s, 9H, TBS t-Bu), 0.94 (dd,  $J$  = 9.0 Hz, 9H, TES CH<sub>3</sub>), 1.22 (s, 3H, CH<sub>3</sub> 17), 1.35 (s, 3H, CH<sub>3</sub> 16), 1.64 (dd,  $J$  = 5.6, 16.4 Hz, 1H, H9 $\beta$ ), 1.70 (m, 1H, H6 $\beta$ ), 2.22 (dd,  $J$  = 2.7, 16.8 Hz, 1H, H9 $\alpha$ ), 2.23 (d,  $J$  = 0.7 Hz, 3H, CH<sub>3</sub> 18), 2.36 (dd,  $J$  = 9.2, 15.0 Hz, 1H, H14 $\beta$ ), 2.45 (m, 1H, H6 $\alpha$ ), 2.96 (s, 1H, OH5), 3.21 (dd, 6.9, 15.0 Hz, 1H, H14 $\alpha$ ), 3.42 (d,  $J$  = 5.0 Hz, 1H, H3 $\alpha$ ), 3.53 (m, 1H, H20), 3.38 (s, 1H, OH4), 3.70 (t,  $J$  = 3.0 Hz, 1H, H5 $\beta$ ), 4.04 (br d,  $J$  = 11 Hz, 1H, H20), 4.06 (dd,  $J$  = 11.5, 5.0 Hz, 1H, H7 $\alpha$ ), 4.48 (d,  $J$  = 5.0 Hz, 1H, H2 $\beta$ ), 4.49 (d,  $J$  = 12.0 Hz, 1H, PhCH<sub>2</sub>O), 4.53 (br s, 1H, H10 $\beta$ ), 4.71 (m, 1H, H13 $\beta$ ), 4.72 (d,  $J$  = 12.0 Hz, 1H, PhCH<sub>2</sub>O), 4.85 (d,  $J$  = 6.8 Hz, 1H, OCH<sub>2</sub>O), 4.98 (d,  $J$  = 6.8 Hz, 1H, OCH<sub>2</sub>O), 7.34 (m, 5H,

Ph). Anal. Calcd. for  $C_{41}H_{68}O_{10}Si_2$ : C, 63.36; H, 8.82. Found C, 63.19; H, 8.75.

**Diol mesylate 26a.** To a stirred solution of allyl mesylate 24aa ( $P_7$  = BOM,  $P_{10}$  = TES,  $P_{13}$  = TBS, R = Ms) (5 mg, 0.0064 mmol) in a mixture of pyridine (0.4 mL) and THF (0.4 mL) under nitrogen at room temperature was added a 0.157 M solution of  $OsO_4$  in THF (0.06 mL). After 7 h,  $NaHSO_3$  (150 mg) and water (0.2 mL) were added. The mixture was vigorously stirred for 14 h, poured into 20 mL of a saturated aqueous  $NaHCO_3$  solution and extracted with ethyl acetate (20 mL x 3). The combined organic phase was dried over anhydrous  $Na_2SO_4$  and concentrated under reduced pressure to give 6 mg of a pale yellow oil. The oil was column chromatographed (40% ethyl acetate/hexane) to yield 2.7 mg (50%) of diol mesylate 26a ( $P_7$  = BOM,  $P_{10}$  = TES,  $P_{13}$  = TBS, R = Ms).

**26a** ( $P_7$  = BOM,  $P_{10}$  = TES,  $P_{13}$  = TBS, R = Ms):  $^1H$  NMR (500 MHz,  $CDCl_3$ ):  $\delta$  0.14 (s, 6H, TBS  $CH_3$ ), 0.58 (ddd,  $J$  = 8.0 Hz, 6H, TES  $CH_2$ ), 0.89 (s, 3H,  $CH_3$  19), 0.93 (s, 9H, TBS t-Bu), 0.94 (dd,  $J$  = 8.0 Hz, 9H, TES  $CH_3$ ), 1.31 (s, 3H,  $CH_3$  17), 1.37 (s, 3H,  $CH_3$  16), 1.76 (dd,  $J$  = 5.5, 15.1, 1Hz,  $H9\beta$ ), 1.95 (m, 1H,  $H6\beta$ ), 2.23 (d,  $J$  = 0.7 Hz, 3H,  $CH_3$  18), 2.25 (dd,  $J$  = 4.8, 15.1 Hz, 1H,  $H9\alpha$ ), 2.39 (dd,  $J$  = 9.2, 15.1 Hz, 1H,  $H14\beta$ ), 2.45 (m, 1H,  $H6\alpha$ ), 2.89 (dd, 6.8, 15.1 Hz, 1H,  $H14\alpha$ ), 3.05 (d,  $J$  = 3.4 Hz, 1H,  $H3\alpha$ ), 3.06 (s, 3H,  $OSO_2CH_3$ ), 3.35 (s, 1H,  $OH4$ ), 3.52 (m, 1H,  $H20$ ), 3.92 (dd,  $J$  = 4.5, 11.6 Hz, 1H,  $H7\alpha$ ), 4.13 (dd,  $J$  = 1.0, 11.3 Hz, 1H,  $H20$ ), 4.46 (br d,  $J$  = 4.5 Hz, 1H,  $H10$ ), 4.52 (d,  $J$  = 3.4 Hz, 1H,  $H2$ ), 4.54 (d,  $J$  = 12.0 Hz, 1H,  $PhCH_2O$ ), 4.70 (d,  $J$  = 12.0 Hz, 1H,  $PhCH_2O$ ), 4.83 (d,  $J$  = 6.9 Hz, 1H,  $OCH_2O$ ), 4.84 (m, 1H,  $H5\beta$ ), 4.92 (m, 1H,  $H13\beta$ ), 4.93 (d,  $J$  = 6.9 Hz, 1H,  $OCH_2O$ ), 7.34 (m, 5H, Ph).

**Diol tosylate 26aa.** To a stirred solution of triol 25a ( $P_7$  = BOM,  $P_{10}$  = TES,  $P_{13}$  = TBS) (37 mg, 0.0476 mmole) in  $CH_2Cl_2$  (0.4 mL) under nitrogen at -78 °C was added triethylamine (0.25 mL) followed by trimethylchlorosilane (0.075 mL). The solution was stirred at -78 °C for 1 h, poured into 20 mL of a saturated aqueous  $NaHCO_3$  solution and extracted with chloroform (30 mL x 3). The combined organic phase was dried over anhydrous  $Na_2SO_4$ , and concentrated under reduced pressure to give 38.2 mg of a colorless oil. This oil was dissolved in THF (0.5 mL) and

cooled to -78 °C. To this solution was added a 0.2 M solution of LDA in THF (0.9 mL, 0.18 mmole). After 20 min at -78°C, p-toluenesulfonyl chloride (35 mg, 0.183 mmole) was added. After stirring at -35 °C for 3 h, MeOH (0.2 mL) and diethylamine (0.3 mL) were added. The solution was stirred at -35 °C for 30 min and poured into 30 mL of a saturated aqueous NaHCO<sub>3</sub> solution and extracted with chloroform (40 mL x 3). The combined organic phases were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and concentrated under reduced pressure to give 58 mg of a colorless oil. The oil was dissolved in acetonitrile (3.6 mL) and pyridine (3.6 mL). To this solution at 0 °C was added 48 % aqueous solution of HF (0.36 mL). The solution was stirred at 0 °C for 15 min, poured into 30 mL of a saturated aqueous NaHCO<sub>3</sub> solution and extracted with chloroform (40 mL x 3). The combined organic phase was dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and concentrated under reduced pressure to give 56 mg of crude diol tosylate 26aa. Column chromatography (40% ethylacetate/hexane) yielded 34 mg (80 %) diol tosylate 26aa (P<sub>7</sub> = BOM, P<sub>10</sub> = TES, P<sub>13</sub> = TBS, R = Ts).

**26aa** (P<sub>7</sub> = BOM, P<sub>10</sub> = TES, P<sub>13</sub> = TBS, R = Ts). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>); δ 0.18 (s, 6H, TBS CH<sub>3</sub>), 0.58 (d, J = 12.5 Hz, 6H, TES CH<sub>2</sub>), 0.82 (s, 3H, CH<sub>3</sub> 19), 0.94 (dd, J = 13.0 Hz, 9H, TES CH<sub>3</sub>), 0.97 (s, 9H, TBS t-Bu), 1.28 (s, 3H, CH<sub>3</sub> 17), 1.34 (s, 3H, CH<sub>3</sub> 16), 1.67 (dd, J = 16.5, 4.4 Hz, 1H, H9β), 1.80 (m, 1H, H6β), 2.13 (dd, J = 16.5, 4.4 Hz, 1H, H9α), 2.18 (m, 1H, H6α), 2.24 (s, 3H, CH<sub>3</sub> 18), 2.33 (s, 3H, CH<sub>3</sub>Ph), 2.42 (dd, J = 14.8, 9.3 Hz, 1H, H14β), 2.90 (m, 1H, H14α), 2.93 (br s, 1H, OH4), 3.08 (br d, J = 3.3 Hz, 1H, H3α), 3.38 (br t, J = 11.0 Hz, 1H, H7α), 3.87 (m, 1H, H20), 4.09 (br d, J = 9.9 Hz, 1H, H20), 4.52 (d, J = 3.3 Hz, 1H, H2β), 4.45 (br d, J = 4.4 Hz, 1H, H10β), 4.46 (d, J = 12.1 Hz, 1H, PhCH<sub>2</sub>O), 4.59 (d, J = 12.1 Hz, 1H, PhCH<sub>2</sub>O), 4.66 (br t, J = 3.8 Hz, 1H, H5β), 4.75 (d, J = 7.1 Hz, 1H, OCH<sub>2</sub>O), 4.83 (d, J = 7.1 Hz, 1H, OCH<sub>2</sub>O), 4.89 (br dd, J = 7.7, 6.6 Hz, 1H, H13β), 7.14 (d, J = 8.2 Hz, 2H, SO<sub>2</sub>Ph), 7.34 (m, 5H, OCH<sub>2</sub>Ph), 7.75 (d, J = 8.2 Hz, 2H, SO<sub>2</sub>Ph).

Oxetane 27a from diol mesylate 26a. To a stirred solution of diol mesylate 26a (P<sub>7</sub> = BOM, P<sub>10</sub> = TES, P<sub>13</sub> = TBS, R = Ms) (2.7 mg) in toluene (0.4 mL) under nitrogen at room temperature was added diisopropyl ethylamine (0.008 mL). The solution was refluxed for 3.5 h, cooled to room

temperature, poured into 20 mL of a saturated aqueous  $\text{NaHCO}_3$  solution and extracted with ethyl acetate (20 mL  $\times$  3). The combined organic phase was dried over anhydrous  $\text{Na}_2\text{SO}_4$ , and concentrated under reduced pressure to give 3 mg of a pale yellow oil. The oil was column chromatographed (30% ethyl acetate/hexane) to yield 1 mg (42%) of oxetane 27a.

**27a** ( $P_7 = \text{BOM}$ ,  $P_{10} = \text{TES}$ ,  $P_{13} = \text{TBS}$ ):  $^1\text{H}$  NMR (500 MHz,  $\text{CDCl}_3$ ):  $\delta$  0.10 (s, 6H, TBS  $\text{CH}_3$ ), 0.59 (dd,  $J = 8.0$  Hz, 6H, TES  $\text{CH}_2$ ), 0.92 (s, 9H, TBS t-Bu), 0.94 (dd,  $J = 8.0$  Hz, 9H, TES  $\text{CH}_3$ ), 1.20 (s, 3H,  $\text{CH}_3$  17), 1.26 (s, 3H,  $\text{CH}_3$  19), 1.32 (s, 3H,  $\text{CH}_3$  16), 1.93 (dd,  $J = 11.3$ , 13.4 Hz, 1H, H9 $\alpha$ ), 1.98 (d,  $J = 1.4$  Hz, 3H,  $\text{CH}_3$  18), 2.06 (dd,  $J = 6.0$ , 18.6 Hz, 1H, H6 $\beta$ ), 2.11 (dd,  $J = 4.5$ , 13.4 Hz, 1H, H9 $\beta$ ), 2.14 (d,  $J = 5.5$  Hz, 1H, H3 $\alpha$ ), 2.41 (dd,  $J = 9.2$ , 15.1 Hz, 1H, H14 $\beta$ ), 2.43 (m, 1H, H6 $\alpha$ ), 2.54 (s, 1H, OH4), 2.76 (dd,  $J = 5.2$ , 15.1 Hz, H14 $\alpha$ ), 3.21 (dd,  $J = 3.4$ , 13.0 Hz, 1H, H7 $\alpha$ ), 4.36 (d,  $J = 8.6$  Hz, 1H, H20 $\alpha$ ), 4.37 (dd,  $J = 4.1$ , 11.3 Hz, 1H, H10 $\beta$ ), 4.40 (br d,  $J = 8.2$  Hz, 1H, H5 $\alpha$ ), 4.60 (d,  $J = 5.5$  Hz, 1H, H2 $\beta$ ), 4.61 (d,  $J = 12.6$  Hz, 1H,  $\text{PhCH}_2\text{O}$ ), 4.67 (m, 1H, H13 $\beta$ ), 4.69 (d,  $J = 12.6$  Hz, 1H,  $\text{PhCH}_2\text{O}$ ), 4.75 (d,  $J = 7.5$  Hz, 1H,  $\text{OCH}_2\text{O}$ ), 4.86 (d,  $J = 7.5$  Hz, 1H,  $\text{OCH}_2\text{O}$ ), 4.91 (dd,  $J = 0.7$ , 8.6 Hz, 1H, H20 $\beta$ ), 7.34 (m, 5H, Ph). Anal. Calcd. for  $\text{C}_{41}\text{H}_{66}\text{O}_9\text{Si}_2$ : C, 64.87; H, 8.76. Found C, 64.61; H, 8.78.

**Oxetane 27a from diol tosylate 26aa.** To a stirred solution of diol tosylate 26aa ( $P_7 = \text{BOM}$ ,  $P_{10} = \text{TES}$ ,  $P_{13} = \text{TBS}$ , R = Ts) (33 mg, 0.0354 mmole) in toluene (3.3 mL) under nitrogen at room temperature was added DBU (0.11 mL, 0.73 mmole). The solution was heated at 80 °C for 10 min, then the temperature was increased up to 110 °C during a 40 min period, maintained at 110 °C for 30 more min and cooled to room temperature. The solution was filtered through a short pad of silica gel using 30% ethyl acetate/hexane as eluent. The filtrate was concentrated to give 25 mg of crude 27a, which was column chromatographed (30% ethyl acetate/hexane) to yield 21 mg (78 %) of oxetane 27a ( $P_7 = \text{BOM}$ ,  $P_{10} = \text{TES}$ ,  $P_{13} = \text{TBS}$ ).

**Oxetane 29.** To a stirred solution of oxetane 27a ( $P_7 = \text{BOM}$ ,  $P_{10} = \text{TES}$ ,  $P_{13} = \text{TBS}$ ) (21 mg, 0.0276 mmole) and dimethylaminopyridine (3.4 mg, 0.0278 mmole) in pyridine (110  $\mu\text{L}$ , 1.37 mmole) under nitrogen at room temperature was added acetic anhydride (26  $\mu\text{L}$ , 0.276 mmole).

The solution was stirred for 25h, diluted with ethyl acetate, poured into 20 mL of saturated aqueous  $\text{NaHCO}_3$  solution and extracted with ethyl acetate (20 mL x 3). The combined organic phases were dried over anhydrous  $\text{Na}_2\text{SO}_4$  and concentrated under reduced pressure to give 26 mg of a pale yellow oil, which was column chromatographed (25% ethyl acetate/hexane) to yield 16 mg (72%) of oxetane 29 ( $P_7 = \text{BOM}$ ,  $P_{10} = \text{TES}$ ,  $P_{13} = \text{TBS}$ ).

29 ( $P_7 = \text{BOM}$ ,  $P_{10} = \text{TES}$ ,  $P_{13} = \text{TBS}$ ):  $^1\text{H}$  NMR (500 MHz,  $\text{CDCl}_3$ );  $\delta$  0.10 (s, 3H, TBS  $\text{CH}_3$ ), 0.12 (s, 3H, TBS  $\text{CH}_3$ ), 0.56 (q, 6H, TES  $\text{CH}_2$ ), 0.92 (t, 9H, TES  $\text{CH}_3$ ), 0.94 (s, 9H, TBS t-Bu), 1.35 (s, 3H,  $\text{CH}_3$  16), 1.30 (s, 3H,  $\text{CH}_3$  17), 1.29 (s, 3H,  $\text{CH}_3$  19), 1.96 (br t,  $J = 13.0$  Hz, 1H, H9 $\alpha$ ), 1.98 (d,  $J = 1.4$  Hz, 3H,  $\text{CH}_3$  18), 2.02 (dd,  $J = 7.5$ , 13.0, 1H, H9 $\beta$ ), 2.07 (dt,  $J = 8.0$ , 13.0 Hz, 1H, H6 $\beta$ ), 2.13 (s, 3H, OAc), 2.24 (dd,  $J = 3.4$ , 15.0 Hz, 1H, H14 $\alpha$ ), 2.40 (dd,  $J = 8.6$ , 15.0 Hz, 1H, H14 $\beta$ ), 2.51 (ddd,  $J = 4.1$ , 9.2, 15.0 Hz, 1H, H6 $\alpha$ ), 2.63 (d,  $J = 6.5$  Hz, 1H, H3 $\alpha$ ), 3.69 (dd,  $J = 4.1$ , 13.0 Hz, H7 $\alpha$ ), 4.35 (dd,  $J = 3.4$ , 11.3 Hz, 1H, H10 $\beta$ ), 4.64 (m, 4H,  $\text{PhCH}_2\text{O}$ , H2 $\beta$ , H5 $\alpha$ ), 4.75 (d,  $J = 7.2$  Hz, 1H,  $\text{OCH}_2\text{O}$ ), 4.76 (br d,  $J = 9.2$  Hz, 1H, H20), 4.83 (d,  $J = 7.2$  Hz, 1H,  $\text{OCH}_2\text{O}$ ), 4.85 (br d,  $J = 9.2$  Hz, 1H, H20), 4.88 (br t,  $J = 8.2$  Hz, 1H, H13 $\beta$ ), 7.35 (m, 5H, Ph).

**Benzoate 30.** To a stirred solution of oxetane 29 ( $P_7 = \text{BOM}$ ,  $P_{10} = \text{TES}$ ,  $P_{13} = \text{TBS}$ ) (6 mg, 0.0075 mmol) in THF (0.5 mL) under nitrogen at -78 °C was added a 0.3M solution of phenyllithium in ether (44  $\mu\text{L}$ , 0.013 mmol). The solution was stirred at -78 °C for 15 min and quenched with a 10% solution of acetic acid in THF. The solution was diluted with ethyl acetate, poured into 20 mL of a saturated aqueous  $\text{NaHCO}_3$  solution and extracted with ethyl acetate (20 mL x 3). The combined organic phases were dried over anhydrous  $\text{Na}_2\text{SO}_4$  and concentrated under reduced pressure to give 8 mg of a pale yellow oil. The oil was column chromatographed (25% ethyl acetate/hexane) to yield 6.2 mg (94%) of benzoate 30 ( $P_7 = \text{BOM}$ ,  $P_{13} = \text{TBS}$ ,  $R = \text{TES}$ ).

30 ( $P_7 = \text{BOM}$ ,  $P_{13} = \text{TBS}$ ,  $R = \text{TES}$ ):  $^1\text{H}$  NMR (500 MHz,  $\text{CDCl}_3$ );  $\delta$  0.09 (s, 3H, TBS  $\text{CH}_3$ ), 0.14 (s, 3H, TBS  $\text{CH}_3$ ), 0.60 (ddd, 6H, TES  $\text{CH}_2$ ), 0.94 (s, 9H, TBS t-Bu), 0.96 (t, 6H, TES  $\text{CH}_3$ ), 1.23 (s, 3H,  $\text{CH}_3$  17), 1.38 (s, 3H,  $\text{CH}_3$  19), 1.46 (s, 3H,  $\text{CH}_3$  16), 1.69 (s, 1H, OH1), 1.97 (ddd,  $J = 14.5$ , 10.0, 3.1 Hz, 1H, H6 $\beta$ ), 2.05 (dd,  $J = 16.1$ , 5.1 Hz, 1H, H9 $\beta$ ), 2.09 (dd,

*J* = 15.1, 6.2 Hz, 1H, H14 $\beta$ ), 2.13 (s, 3H, CH<sub>3</sub> 18), 2.22 (dd, *J* = 15.1, 8.2 Hz, 1H, H14 $\alpha$ ), 2.23 (dd, *J* = 15.0, 8.5 Hz, 1H, H9 $\beta$ ), 2.24 (s, 1H, OAc 4), 2.38 (dd, *J* = 16.1, 4.1 Hz, 1H, H9 $\alpha$ ), 2.67 (m, 1H, H6 $\alpha$ ), 3.40 (d, *J* = 6.2 Hz, 1H, H3 $\alpha$ ), 3.99 (dd, *J* = 10.1, 6.8 Hz, 1H, H7 $\alpha$ ), 4.20 (d, *J* = 8.2 Hz, 1H, H20 $\beta$ ), 4.29 (d, *J* = 8.2 Hz, 1H, H20 $\alpha$ ), 4.49 (d, *J* = 12.0 Hz, 1H, PhCH<sub>2</sub>O), 4.63 (br t, 1H, H10 $\beta$ ), 4.74 (d, *J* = 12.0 Hz, 1H, PhCH<sub>2</sub>O), 4.92 (d, *J* = 6.9 Hz, 1H, OCH<sub>2</sub>O), 4.91-4.95 (m, 2H, H13 $\beta$  & H5 $\alpha$ ), 5.01 (d, *J* = 6.9 Hz, 1H, OCH<sub>2</sub>O), 5.66 (d, *J* = 6.2 Hz, 1H, H2 $\beta$ ), 7.28 (m, 1H, PhCH<sub>2</sub>), 7.35 (m, 4H, PhCH<sub>2</sub>), 7.48 (m, 2H, PhCOO-*m*), 7.59 (m, 1H, PhCOO-*p*), 8.11 (m, 2H, PhCOO-*o*).

**Alcohol 31.** To a solution of benzoate 30 (P<sub>7</sub> = BOM, P<sub>13</sub> = TBS, R = TES) (6.2 mg, 0.007 mmol) in 2 mL of THF was added 0.1 mL of a 0.1 M solution of TBAF in THF. The mixture was stirred for 2 h at 25 °C under nitrogen. The reaction mixture was diluted with 10 mL of ethyl acetate, then poured into 10 mL of a saturated aqueous NaHCO<sub>3</sub> solution. The organic phase was washed with 10 mL of a saturated aqueous NaHCO<sub>3</sub> solution, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure to give 4.5 mg (93%) of alcohol 31 (P<sub>7</sub> = BOM, P<sub>13</sub> = TBS, R = H).

**31** (P<sub>7</sub> = BOM, P<sub>13</sub> = TBS, R = H): mp 213-216 °C <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>);  $\delta$  0.10 (s, 3H, TBS CH<sub>3</sub>), 0.15 (s, 3H, TBS CH<sub>3</sub>), 0.94 (s, 9H, TBS t-Bu), 1.26 (s, 3H, CH<sub>3</sub> 17), 1.39 (s, 3H, CH<sub>3</sub> 19), 1.45 (s, 3H, CH<sub>3</sub> 16), 1.68 (s, 1H, OH1), 1.89 (ddd, *J* = 14.5, 10.0, 2.5 Hz, 1H, H6 $\beta$ ), 2.10 (dd, *J* = 15.0, 9.0 Hz, 1H, H14 $\beta$ ), 2.15 (dd, *J* = 15.0, 8.0 Hz, 1H, H14 $\alpha$ ), 2.18 (s, 3H, CH<sub>3</sub> 18), 2.23 (dd, *J* = 15.0, 8.5 Hz, 1H, H9 $\beta$ ), 2.26 (s, 1H, OAc 4), 2.40 (dd, *J* = 15.0, 3.5 Hz, 1H, H9 $\alpha$ ), 2.68 (m, 1H, H6 $\alpha$ ), 2.90 (br s, 1H, OH10), 3.54 (d, *J* = 6.0 Hz, 1H, H3 $\alpha$ ), 4.16 (d, *J* = 8.0 Hz, 1H, H20 $\beta$ ), 4.23 (dd, *J* = 10.0, 7.0 Hz, 1H, H7 $\alpha$ ), 4.30 (d, *J* = 8.0 Hz, 1H, H20 $\alpha$ ), 4.68 (dd, *J* = 15 Hz, 2H, PhCH<sub>2</sub>O), 4.78 (m, 1H, H10 $\beta$ ), 4.87 (d, *J* = 6.5 Hz, 1H, OCH<sub>2</sub>O), 4.95 (t, *J* = 2.0 Hz, 1H, H20 $\alpha$ ), 4.92 (d, *J* = 7.0 Hz, 1H, OCH<sub>2</sub>O), 4.93 (br d, *J* = 2.0 Hz, 1H, H13 $\beta$ ), 4.96 (br d, *J* = 6.5 Hz, 1H, H5 $\alpha$ ), 4.97 (d, *J* = 6.5 Hz, 1H, OCH<sub>2</sub>O), 5.68 (d, *J* = 6.0 Hz, 1H, H2 $\beta$ ), 7.28 (m, 1H, PhCH<sub>2</sub>O), 7.35 (m, 4H, PhCH<sub>2</sub>O), 7.40 (m, 2H, PhCOO-*m*), 7.59 (m, 1H, PhCOO-*p*), 8.13 (m, 2H, PhCOO-*o*). Anal. Calcd. for C<sub>43</sub>H<sub>60</sub>O<sub>10</sub>Si<sub>6</sub>0.5H<sub>2</sub>O: C, 66.72; H, 7.94. Found C, 66.75; H, 7.96.

Alcohol 31 through Alcohol 30a. To a stirred solution of oxetane 29 ( $P_7$  = BOM,  $P_{10}$  = TES,  $P_{13}$  = TBS) (16 mg, 0.02 mmole) in acetonitrile (0.33 mL) at 0 °C was added a 4% solution of HF-pyridine complex in acetonitrile (0.8 mL). The solution was stirred at 0 °C for 11 h, diluted with ethyl acetate, poured into 20 mL of a saturated aqueous  $\text{NaHCO}_3$  solution and extracted with  $\text{CHCl}_3$  (30 mL x 3). The combined organic phases were dried over anhydrous  $\text{Na}_2\text{SO}_4$  and concentrated under reduced pressure to give 13.5 mg (0.0196 mmole) of 30a as an oil. This oil was dissolved in THF (1 mL) and cooled to -78 °C. To this solution at -78 °C was added a 0.285 M solution of phenyllithium in THF (0.144 mL, 2.1 eq.). After 10 min, the solution was poured into 20 mL of saturated aqueous  $\text{NaHCO}_3$  solution and  $\text{CHCl}_3$  (30 mL x 3). The combined organic phase was dried over anhydrous  $\text{Na}_2\text{SO}_4$  and concentrated under reduced pressure to give 16 mg of a pale yellow oil, which was crystallized to yield 12.7 mg (85%) of benzoate 31 ( $P_7$  = BOM,  $P_{13}$  = TBS, R = H).

Ketone 32. To a solution of benzoate 31 ( $P_7$  = BOM,  $P_{13}$  = TBS, R = H) (18 mg, 0.235 mmole) and 4-methylmorpholine N-oxide (18 mg, 0.154 mmole) in  $\text{CH}_2\text{Cl}_2$  (2.6 mL) at room temperature was added tetrapropylammonium perruthenate (6 mg, 0.017 mmole). The solution was stirred at room temperature for 15 min and filtered through silica gel with 30 % ethyl acetate/hexane. The filtrate was concentrated under reduced pressure to yield ketobenzoate 32 ( $P_7$  = BOM,  $P_{13}$  = TBS) (18 mg, 100%).

**32** ( $P_7$  = MOP,  $P_{13}$  = TBS):  $^1\text{H}$  NMR (300 MHz,  $\text{CDCl}_3$ )  $\delta$  0.12 (s, 3H, TBS  $\text{CH}_3$ ), 0.16 (s, 3H, TBS  $\text{CH}_3$ ), 0.94 (s, 9H, TBS t-Bu), 1.25 (s, 3H,  $\text{CH}_3$ ), 1.42 (s, 3H,  $\text{CH}_3$ ), 1.44 (s, 6H, MOP  $\text{CH}_3$ ), 1.49 (s, 3H,  $\text{CH}_3$ ), 1.75 (s, 1H, OH1), 1.76 (m, 1H, H6), 1.83 (s, 3H,  $\text{CH}_3$  18), 2.21 (dd,  $J$  = 7, 15 Hz, 1H, H14), 2.25 (s, 3H, OAc), 2.29 (dd,  $J$  = 8, 15 Hz, 1H, H14), 2.61 (d,  $J$  = 16 Hz, 1H, H9), 2.74 (ddd,  $J$  = 8, 9, 17 Hz, 1H, H6), 3.19 (s, 3H, MOP  $\text{OCH}_3$ ), 3.20 (d,  $J$  = 6 Hz, 1H, H3 $\alpha$ ), 3.32 (d,  $J$  = 16 Hz, 1H, H9), 3.78 (dd,  $J$  = 8, 10 Hz, 1H, H7), 4.15 (d,  $J$  = 8 Hz, 1H, H20), 4.34 (d,  $J$  = 8 Hz, 1H, H20), 4.89 (d,  $J$  = 9 Hz, 1H, H5), 5.04 (m, 1H, H13), 5.90 (d,  $J$  = 6 Hz, 1H, H2), 7.50 (m, 2H, PhCOO -*m*), 7.62 (m, 1H, PhCOO -*p*), 8.24 (m, 2H, PhCOO -*o*).

**32** ( $P_7$  = TES,  $P_{13}$  = TBS):  $^1\text{H}$  NMR (300 MHz,  $\text{CDCl}_3$ )  $\delta$  0.12 (s, 3H, TBS  $\text{CH}_3$ ), 0.16 (s,

3H, TBS CH<sub>3</sub>), 0.65 (q, *J* = 8 Hz, 3H, TES CH<sub>3</sub>), 0.66 (q, *J* = 8 Hz, 3H, TES CH<sub>3</sub>), 0.94 (s, 9H, TBS t-Bu), 1.00 (t, *J* = 8 Hz, 3H, TES CH<sub>2</sub>), 1.24 (s, 3H, CH<sub>3</sub>), 1.38 (s, 3H, CH<sub>3</sub>), 1.49 (s, 3H, CH<sub>3</sub>), 1.75 (s, 1H, OH1), 1.80 (m, 1H, H6), 1.81 (s, 3H, CH<sub>3</sub> 18), 2.20 (dd, *J* = 9, 15 Hz, 1H, H14), 2.26 (s, 3H, OAc CH<sub>3</sub>), 2.29 (dd, *J* = 8, 15 Hz, 1H, H14), 2.48 (ddd, *J* = 8, 9, 17 Hz, 1H, H6), 2.58 (d, *J* = 17 Hz, 1H, H9), 3.15 (d, *J* = 6 Hz, 1H, H3 $\alpha$ ), 3.36 (d, *J* = 17 Hz, 1H, H9), 3.79 (dd, *J* = 7, 9 Hz, 1H, H7), 4.14 (d, *J* = 8 Hz, 1H, H20), 4.33 (d, *J* = 8 Hz, 1H, H20), 4.90 (d, *J* = 9 Hz, 1H, H5), 5.04 (m, 1H, H13), 5.90 (d, *J* = 6 Hz, 1H, H2), 7.49 (m, 2H, PhCOO -*m*), 7.61 (m, 1H, PhCOO -*p*), 8.13 (m, 2H, PhCOO -*o*).

32 (P<sub>7</sub> = BOM, P<sub>13</sub> = TBS): <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>);  $\delta$  0.16 (s, 3H, TBS CH<sub>3</sub>), 0.18 (s, 3H, TBS CH<sub>3</sub>), 0.94 (s, 9H, TBS t-Bu), 1.26 (s, 3H, CH<sub>3</sub> 17), 1.47 (s, 3H, CH<sub>3</sub> 19), 1.52 (s, 3H, CH<sub>3</sub> 16), 1.76 (s, 1H, OH1), 1.83 (d, 3H, *J* = 0.5 Hz, CH<sub>3</sub> 18), 1.89 (ddd, *J* = 15.0, 9.5, 1.5 Hz, 1H, H6 $\beta$ ), 2.21 (dd, *J* = 15.0, 9.0 Hz, 1H, H14 $\beta$ ), 2.26 (s, 1H, OAc 4), 2.29 (dd, *J* = 15.0, 8.0 Hz, 1H, H14 $\alpha$ ), 2.72 (m, 1H, H6 $\alpha$ ), 2.75 (d, *J* = 16 Hz, 1H, H9 $\alpha$ ), 3.18 (d, *J* = 6.5 Hz, 1H, H3 $\alpha$ ), 3.26 (d, *J* = 16.5 Hz, H9 $\alpha$ ), 3.65 (dd, *J* = 9.0, 7.5 Hz, 1H, H7 $\alpha$ ), 4.15 (d, *J* = 7.5 Hz, 1H, H20 $\beta$ ), 4.34 (d, *J* = 7.5 Hz, 1H, H20 $\alpha$ ), 4.61 (d, *J* = 12.0 Hz, 1H, PhCH<sub>2</sub>O), 4.72 (d, *J* = 12.0 Hz, 1H, PhCH<sub>2</sub>O), 4.81 (d, *J* = 7.0 Hz, 1H, OCH<sub>2</sub>O), 4.92 (d, *J* = 7.0 Hz, 1H, OCH<sub>2</sub>O), 4.93 (br d, *J* = 6.5 Hz, 1H, H5 $\alpha$ ), 5.05 (br t, *J* = 6.5 Hz, 1H, H13 $\beta$ ), 5.91 (d, *J* = 6.0 Hz, 1H, H2 $\beta$ ), 7.28 (m, 1H, PhCH<sub>2</sub>O), 7.35 (m, 4H, PhCH<sub>2</sub>O), 7.50 (m, 2H, PhCOO -*m*), 7.62 (m, 1H, PhCOO -*p*), 8.13 (m, 2H, PhCOO -*o*)

**Hydroxyketone 33.** To a THF (1.3 mL) solution of 32 (P<sub>7</sub> = BOM, P<sub>13</sub> = TBS) (16.2 mg, 0.02 mmol) at -78 °C was added 4 equivalents of a 0.24M *t*-BuOK solution in THF (0.33 mL, 0.08 mmol.). The solution was warmed to -20 °C for 40 min and then briefly warmed to 0 °C before being cannulated into a 0 °C THF (1.3 mL) suspension of benzeneseleninic anhydride (57 mg, 0.16 mmol.). The reaction was stirred for 40 min. at 0 °C before being diluted with 20 mL of ethyl acetate and poured into 50 mL of aqueous saturated NaHCO<sub>3</sub>. The organic layer was then washed with 50 mL of aqueous saturated Na<sub>2</sub>S<sub>2</sub>O<sub>3</sub> followed by 50 mL of aqueous saturated NaHCO<sub>3</sub>. The organic layer was then dried with Na<sub>2</sub>SO<sub>4</sub>, filtered and evaporated to give 18.8 mg of the hydroxyketone as an oil. To a THF (1.3 mL) solution of the crude hydroxyketone (18.8 mg) was

added 0.33 mL of a 0.24M solution of *t*-BuOK (0.08 mmol) at -78 °C. The reaction was stirred 20 min. and then 0.25 mL of a 0.8M AcOH/THF solution was added at -78 °C and stirred 5 min. The mixture was diluted with 20 mL of ethyl acetate and was poured into 50 mL of aqueous saturated NaHCO<sub>3</sub>. The organic layer was then dried with Na<sub>2</sub>SO<sub>4</sub>, filtered and evaporated to give 18.6 mg of a yellow solid which was then plug filtered through silica gel with 2% ethyl acetate/hexanes followed by 30% ethyl acetate/hexanes to give 15.9 mg of 33 (P<sub>7</sub> = BOM, P<sub>13</sub> = TBS) (96% yield).

**33 (P<sub>7</sub> = BOM, P<sub>13</sub> = TBS):** m.p.: 234-236°C, <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 0.13 (s, 3H, TBS CH<sub>3</sub>), 0.15 (s, 3H, TBS CH<sub>3</sub>), 0.95 (s, 9H, TBS *t*-Bu), 1.11 (s, 3H, CH<sub>3</sub> 16), 1.18 (s, 3H, CH<sub>3</sub> 17), 1.59 (s, 1H, OH1), 1.82 (s, 3H, CH<sub>3</sub> 18), 1.89 (ddd, *J* = 2.1, 12.4, 14.4 Hz, 1H, H6β), 1.97 (d, *J* = 2.0 Hz, 3H, CH<sub>3</sub> 18), 2.14 (dd, *J* = 8.6, 15.4 Hz, 1H, H14β), 2.21 (dd, *J* = 8.9, 15.4 Hz, 1H, H14α), 2.29 (s, 3H, Ac), 2.70 (ddd, *J* = 6.5, 9.6, 14.4 Hz, 1H, H6α), 3.93 (d, *J* = 6.9 Hz, 1H, H3α), 4.17 (d, *J* = 8.6 Hz, 1H, H20β), 4.28 (d, *J* = 2.4 Hz, 1H, OH10β), 4.31 (dd, *J* = 6.5, 12.4 Hz, 1H, H7α), 4.32 (d, *J* = 8.6 Hz, 1H, H20α), 4.45 (d, *J* = 12.2 Hz, 1H, PhCH<sub>2</sub>O), 4.60 (d, *J* = 12.2 Hz, 1H, PhCH<sub>2</sub>O), 4.60 (d, *J* = 7.3 Hz, 1H, OCH<sub>2</sub>O), 4.73 (d, *J* = 7.3 Hz, 1H, OCH<sub>2</sub>O), 4.97 (dd, *J* = 2.1, 9.6 Hz, 1H, H5α), 5.01 (ddd, *J* = 2.0, 8.6, 8.9 Hz, 1H, H13β), 5.35 (d, *J* = 2.4 Hz, 1H, H10α), 5.64 (d, *J* = 6.9 Hz, 1H, H2β), 7.3 (m, 5H, PhCH<sub>2</sub>), 7.49 (tt, *J* = 1.7, 7.9 Hz, 2H, PhCOO-*m*), 7.61 (tt, *J* = 1.7, 7.6 Hz, 1H, PhCOO-*p*), 8.10 (dd, *J* = 1.2, 7.9 Hz, PhCOO-*o*).

**33 (P<sub>7</sub> = MOP, P<sub>13</sub> = TBS):** <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 0.13 (s, 3H, TBS CH<sub>3</sub>), 0.15 (s, 3H, TBS CH<sub>3</sub>), 0.95 (s, 9H, TBS *t*-Bu), 1.00 (s, 3H, CH<sub>3</sub> 16), 1.09 (s, 3H, CH<sub>3</sub> 17), 1.23 (s, 3H, MOP CH<sub>3</sub>), 1.37 (s, 3H, MOP CH<sub>3</sub>), 1.58 (s, 1H, OH1), 1.79 (s, 3H, CH<sub>3</sub> 19), 1.90 (ddd, *J* = 2.6, 8.8, 13.7 Hz, 1H, H6β), 2.04 (s, 3H, CH<sub>3</sub> 18), 2.13 (dd, *J* = 8.8, 15.5 Hz, 1H, H14β), 2.22 (dd, *J* = 8.8, 15.5 Hz, 1H, H14α), 2.29 (s, 3H, OAc), 2.79 (ddd, 6.3, 9.9, 14.8 Hz, 1H, H6α), 3.17 (s, 3H, MOP OCH<sub>3</sub>), 3.90 (d, *J* = 7.1 Hz, 1H, H3α), 4.16 (d, *J* = 8.2 Hz, 1H, H20α), 4.25 (d, *J* = 2.2 Hz, 1H, OH4), 4.32 (d, *J* = 8.8 Hz, 1H, H20β), 4.41 (dd, *J* = 6.6, 11.0 Hz, 1H, H7α), 4.94 (dd, *J* = 2.2, 9.9 Hz, 1H, H5α), 5.03 (ddd, *J* = 1.1, 8.2, 8.8 Hz, 1H, H13β), 5.20 (d, *J* = 6.2 Hz, 1H, H10α), 5.60 (d, *J* = 7.2 Hz, 1H, H2β), 7.48 (t, *J* = 7.7 Hz, 2H, PhCOO-*m*), 7.61 (t, *J* = 7.7 Hz, 1H, PhCOO-*p*), 8.10 (d, *J* = 7.1 Hz, 2H,

PhCOO-*o*).

**Acetate 34.** To a pyridine (0.1 mL) solution of 33 ( $P_7$  = BOM,  $P_{13}$  = TBS) (15.9 mg, 0.02 mmol) and DMAP (1.2 mg, 0.01 mmol) at room temperature was added acetic anhydride (38  $\mu$ L, 0.4 mmol) and the reaction stirred 19 h. The mixture was then diluted with 20 mL of ethyl acetate and poured into 50 mL of aqueous saturated NaHCO<sub>3</sub>. The organic layer was dried with Na<sub>2</sub>SO<sub>4</sub>, filtered and evaporated to give 18.1 mg of crude product. The material was plug filtered through silica gel with 20% ethyl acetate/hexanes to give 16.8 mg of 34 ( $P_7$  = BOM,  $P_{13}$  = TBS) (100% yield).

**34** ( $P_7$  = BOM,  $P_{13}$  = TBS): <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>)  $\delta$  0.14 (s, 3H, TBS Me), 0.16 (s, 3H, TBS Me), 0.95 (s, 9H, TBS t-Bu), 1.17 (s, 3H, CH<sub>3</sub> 17), 1.18 (s, 3H, CH<sub>3</sub> 16), 1.63 (s, 1H, OH1), 1.76 (s, 3H, CH<sub>3</sub> 19), 1.99 (ddd,  $J$  = 2.1, 10.6, 14.7 Hz, 1H, H6 $\beta$ ), 2.04 (d,  $J$  = 1.0 Hz, 3H, CH<sub>3</sub> 18), 2.17 (dd,  $J$  = 8.6, 15.1 Hz, 1H, H14 $\beta$ ), 2.19 (s, 3H, AcO10), 2.24 (dd,  $J$  = 8.6, 15.1 Hz, 1H, H14 $\alpha$ ), 2.28 (s, 3H, AcO4), 2.88 (ddd,  $J$  = 6.5, 9.8, 14.7 Hz, 1H, H6 $\alpha$ ), 3.87 (d,  $J$  = 7.0 Hz, 1H, H3 $\alpha$ ), 4.15 (d,  $J$  = 8.2 Hz, 1H, H20 $\beta$ ), 4.24 (dd,  $J$  = 6.5, 10.6 Hz, 1H, H7 $\alpha$ ), 4.31 (d,  $J$  = 8.2 Hz, 1H, H20 $\alpha$ ), 4.44 (d,  $J$  = 12.0 Hz, 1H, PhCH<sub>2</sub>O), 4.68 (d,  $J$  = 12.0 Hz, 1H, PhCH<sub>2</sub>O), 4.85 (s, 2H, OCH<sub>2</sub>O), 4.95 (dd,  $J$  = 2.1, 9.8 Hz, 1H, H5 $\alpha$ ), 5.65 (d,  $J$  = 7.0 Hz, 1H, H2 $\beta$ ), 6.39 (s, 1H, H10 $\alpha$ ), 7.30 (m, 5H, PhCH<sub>2</sub>), 7.49 (tt,  $J$  = 1.4, 8.2 Hz, 2H, PhCOO-*m*), 7.61 (tt,  $J$  = 1.4, 7.2 Hz, 1H, PhCOO-*p*), 8.05 (dd,  $J$  = 1.2, 8.2 Hz, 1H, PhCOO-*o*), IR (CHCl<sub>3</sub>)  $\nu$  3600, 3050, 2975, 2880, 1750, 1730, 1460, 1379, 1250, 1100, 1020, 860  $\text{cm}^{-1}$ .

**34** ( $P_7$ = $P_{13}$ =TES): <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  0.57 (q,  $J$  = 7.7 Hz, 6H, TES CH<sub>2</sub>), 0.67 (q,  $J$  = 7.7 Hz, TES CH<sub>2</sub>), 0.92 (t,  $J$  = 7.7 Hz, 9H, TES CH<sub>3</sub>), 1.01 (t,  $J$  = 7.7 Hz, 9H, TES CH<sub>3</sub>), 1.11 (s, 3H, CH<sub>3</sub> 17), 1.19 (s, 3H, CH<sub>3</sub> 19), 1.61 (s, 1H, OH1), 1.67 (s, 3H, CH<sub>3</sub> 16), 1.86 (ddd,  $J$  = 2.2, 10.4, 14.3 Hz, 1H, H6 $\beta$ ), 2.11 (d,  $J$  = 1.1 Hz, 3H, CH<sub>3</sub> 18), 2.12 (m, 1H, H14 $\beta$ ), 2.17 (s, 3H, OAc10), 2.23 (dd,  $J$  = 7.6, 14.9 Hz, 1H, H14 $\alpha$ ), 2.28 (s, 3H, OAc4), 2.51 (ddd,  $J$  = 6.9, 9.6, 14.3 Hz, 1H, H6 $\alpha$ ), 3.82 (d,  $J$  = 7.2 Hz, 1H, H3 $\alpha$ ), 4.14 (d,  $J$  = 0.3 Hz, 1H, H20 $\beta$ ), 4.30 (d,  $J$  = 8.3 Hz, 1H, H20 $\alpha$ ), 4.48 (dd,  $J$  = 6.6, 10.4 Hz, 1H, H7 $\alpha$ ), 4.92 (dd,  $J$  = 7.7, 8.8 Hz, 1H, H5 $\alpha$ ), 4.96 (d,  $J$  = 8.2 Hz, 1H, H13 $\beta$ ), 5.63 (d,  $J$  = 6.6 Hz, 1H,

H2 $\alpha$ ), 6.47 (s, 1H, H10 $\alpha$ ), 7.47 (t,  $J$  = 7.1 Hz, 2H, PhCOO -*m*), 7.60 (t,  $J$  = 7.1 Hz, PhCOO -*p*), 8.10 (d,  $J$  = 7.1 Hz, PhCOO -*o*).

**Diol 35.** A solution of 34 ( $P_7$  = BOM,  $P_{13}$  = TBS) (16.3 mg, 0.0199 mmol) in THF (0.5 mL) was added to tris(diethylamino)sulfoniumdifluorotrimethylsilicate (TASF) (37 mg, 0.134 mmole) at room temperature under nitrogen atmosphere. The solution was stirred for 40 min, diluted with ethyl acetate, poured into 20 mL of a saturated aqueous NaHCO<sub>3</sub> solution and extracted with CHCl<sub>3</sub> (30 mL x 3). The combined organic phase was dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure to give 16 mg of a pale yellow oil, which was filtered through a pad of silica gel using 70 % ethyl acetate/hexane as eluent. The filtrate was concentrated to yield 13.5 mg (94 %) of 7-BOM BIII (35).

**35 (P<sub>7</sub>=BOM)** mp. 224-225 °C, <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>),  $\delta$  1.08 (s, 3H, CH<sub>3</sub> 17), 1.18 (s, 3H, CH<sub>3</sub> 16), 1.61 (s, 1H, OH1), 1.77 (s, 3H, CH<sub>3</sub> 19), 1.99 (ddd,  $J$  = 2, 10.5, 14.5 Hz, 1H, H6 $\beta$ ), 2.02 (d,  $J$  = 5 Hz, 1H, OH13), 2.10 (d,  $J$  = 1.5 Hz, 3H, CH<sub>3</sub> 18), 2.20 (s, 3H, AcO), 2.28 (s, 3H, AcO), 2.27-2.29 (m, 2H, H14), 2.89 (ddd,  $J$  = 7, 10, 16.5 Hz, 1H, H6 $\alpha$ ), 3.94 (d,  $J$  = 7 Hz, 1H, H3), 4.16 (dd,  $J$  = 1, 8.5 Hz, 1H, H20 $\beta$ ), 4.24 (dd,  $J$  = 6.5, 10.5 Hz, 1H, H7), 4.31 (d,  $J$  = 8 Hz, 1H, H20 $\alpha$ ), 4.45 (d,  $J$  = 12.0 Hz, 1H, OCH<sub>2</sub>Ph), 4.67 (d,  $J$  = 12.0 Hz, 1H, OCH<sub>2</sub>Ph), 4.84 (d,  $J$  = 5 Hz, 1H, OCH<sub>2</sub>O), 4.86 (d,  $J$  = 5 Hz, 1H, OCH<sub>2</sub>O), 4.87 (m, 1H, H13 $\beta$ ), 4.95 (dd,  $J$  = 2.0, 9.5 Hz, 1H, H5 $\alpha$ ), 5.63 (d,  $J$  = 7 Hz, 1H, H2 $\beta$ ), 6.40 (s, 1H, H10 $\alpha$ ), 7.30 (m, 5H, PhCH<sub>2</sub>), 7.48 (m, 2H, PhCOO -*m*), 7.61 (m, 1H, PhCOO -*p*), 8.10 (2H, m, PhCOO -*o*). <sup>13</sup>C NMR (CDCl<sub>3</sub>)  $\delta$  (ppm) 10.3, 14.9, 20.0, 20.7, 22.4, 26.6, 35.3, 38.4, 42.7, 47.2, 57.4, 67.8, 69.9, 74.6, 75.8, 76.4, 78.7, 80.3, 80.3, 80.9, 84.4, 96.7, 127.7, 127.9, 128.5, 128.8, 129.6, 130.3, 132.4, 133.8, 138.0, 144.4, 167.3, 169.8, 171.0, 203.0. IR (CHCl<sub>3</sub>)  $\nu$  1720, 1460 cm<sup>-1</sup>. Anal. Calcd. for C<sub>39</sub>H<sub>46</sub>O<sub>12</sub>: C, 66.28; H, 6.56. Found C, 66.09; H, 6.59.

**7-BOM-Taxol.** To a solution of 7-BOM baccatin III (35) (13.2 mg, 0.018 mmol) in 0.25 mL of THF at -45 °C was added dropwise 21  $\mu$ L of a 1.03 M solution of lithium bis(trimethylsilyl)amide in THF. After 1h at -45 °C, a solution of (S)-*cis*-1-benzoyl-3-triethylsilyloxy-4-azetidin-2-one (15

mg, 0.039 mmol) in 0.25 mL of THF was added dropwise to the mixture. The solution was warmed to 0 °C and kept at that temperature for 1 h before 0.2 mL of a 10% solution of AcOH in THF was added. The mixture was partitioned between saturated aqueous NaHCO<sub>3</sub> and 60% ethyl acetate / hexane. Evaporation of the organic layer gave a residue which was purified by filtration through silica gel to give 20.2 mg of crude (2'R,3'S)-2'-triethylsilyl-7-BOM taxol.

To a solution of 20.2 mg (0.018 mmol) of (2'R,3'S)-2'-triethylsilyl-7-BOM taxol in 0.8 mL of acetonitrile and 0.3 mL of pyridine at 0 °C was added 0.10 mL of 48% aqueous HF. The mixture was stirred at 0 °C for 1 h and then partitioned between saturated aqueous sodium bicarbonate and ethyl acetate. Evaporation of the ethyl acetate solution gave 17.7 mg of material which was purified by flash chromatography to give 15.4 mg (86%) of 7-BOM-taxol.

7-BOM-Taxol: m.p 169-172 °C, <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz) δ 8.11 (d, J = 7.1 Hz, 2H, benzoate *ortho*), 7.76 (d, J=7.1 Hz, 1H, benzamide *ortho*), 7.61-7.26 (m, 11 H, aromatic), 7.06(d, J = 8.8 Hz, 1H, NH), 6.33 (s, 1H, H10), 6.17 (dd, J = 8.8, 8.8 Hz, 1H, H13), 5.79 (dd, J = 8.8, 2.2 Hz, 1H, H3'), 5.67 (d, J = 6.6 Hz, 1H, H2b), 4.91 (d, J=8.8 Hz, 1H, H5), 4.87-4.77(m, 3H, H2', OCH<sub>2</sub>Ph), 4.67(d, J=12 Hz, OCH<sub>2</sub>O) 4.43(d, J=12 Hz, OCH<sub>2</sub>O), 4.30 (d, J = 8.2 Hz, 1H, H20a), 4.19 (d, J = 8.2 Hz, 1H, H20b), 4.15 (m, 1H, H7), 3.70 (d, J = 6.6 Hz, 1H, H3), 3.61 (d, J = 2.5 Hz, 1H, 2'OH), 2.85 (m, 1H, H6a), 2.35 (s, 3H, 4Ac), 2.30 (m, 2H, H14), 2.19 (s, 3H, 10Ac), 2.05 (m, 1H, H6b), 1.78 (br s, 6H, Me18,Me19), 1.72 (s, 1H, 1OH), 1.19 (br s, 6H, Me16, Me17). Anal. Calcd. for C<sub>55</sub>H<sub>59</sub>O<sub>15</sub>×0.5H<sub>2</sub>O: C, 67.20; H, 6.15. Found C, 67.08; H, 6.16.

Taxol. To a suspension of 10% Pd on carbon (50 mg) in ethanol (0.6 mL) saturated with hydrogen at room temperature was added a solution of 7-BOM-taxol (14.4 mg, 0.0148 mmol) in ethanol (0.2 mL x 4). The reaction mixture was refluxed for 45 min under hydrogen and then filtered through silica gel eluting with ethyl acetate. The solvent was evaporated under reduced pressure to give 11.9 mg of taxol (94%) as colorless needles, which exhibited spectra identical with an authentic sample of taxol.

Taxol: mp. 210-212 °C, <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 1.15 (s, 3H, CH<sub>3</sub> 16), 1.24 (s, 3H, CH<sub>3</sub> 17), 1.68 (s, 3H, CH<sub>3</sub> 19), 1.75 (s, 1H, OH1), 1.79 (s, 3H, CH<sub>3</sub> 18), 1.90 (ddd, J = 14.6,

11.0, 2.3 Hz, 1 H, H6 $\beta$ ), 2.26 (s, 3H, AcO10), 2.33 (dd,  $J$  = 15.4, 8.9 Hz, 1H, H14 $\beta$ ), 2.38 (dd,  $J$  = 15.4, 8.9 Hz, 1H, H14 $\alpha$ ), 2.41 (s, 3H, AcO4), 2.46 (d,  $J$  = 4.1 Hz, 1H, OH7), 2.57 (ddd,  $J$  = 10.0, 14.6, 6.5 Hz, 1H, H6 $\alpha$ ), 3.54 (d,  $J$  = 5.0 Hz, 1H, OH2'), 3.82 (d,  $J$  = 6.9 Hz, 1H, H3 $\alpha$ ), 4.22 (d,  $J$  = 8.5 Hz, 1 H, H20 $\alpha$ ), 4.32 (d,  $J$  = 8.5 Hz, 1 H, H20 $\beta$ ), 4.42 (ddd,  $J$  = 11.0, 6.5, 4.1 Hz, 1 H, H7 $\alpha$ ), 4.81 (dd,  $J$  = 5.0, 2.5 Hz, 1 H, H2'), 4.96 (dd,  $J$  = 10.0, 2.3 Hz, 1H, H5 $\alpha$ ), 5.69 (d,  $J$  = 6.9 Hz, 1 H, H2 $\beta$ ), 5.81 (dd,  $J$  = 8.7, 2.5 Hz, 1 H, H3'), 6.25 (dd,  $J$  = 8.9, 8.9 Hz, 1 H, H13 $\beta$ ), 6.29 (s, 1H, H 10 $\alpha$ ), 6.98 (d,  $J$  = 8.7 Hz, 1H, NH), 7.37 (m, 1H, PhCON-*p*), 7.46 (m, 9 H, Ph 3', PhCOO 2' -*m*, PhCON -*m*), 7.62 (m, 1H, PhCOO -*p*), 7.76 (br d,  $J$  = 8.7 Hz, 1H, PhCON -*o*), 8.16 (br d,  $J$  = 7.3 Hz, 1 H, PhCOO -*o*). IR (CHCl<sub>3</sub>)  $\nu$  1730, 1650 cm<sup>-1</sup>.

**10-Deacetyl baccatin III (3 6).** To a mixture of ketone 3 3 ( $P_7$  = MOP,  $P_{13}$  = TES) (2.2 mg, 0.003 mmol) in pyridine (30  $\mu$ L, 0.36 mmol) and acetonitrile (20  $\mu$ L) at 0 °C was added 48% aqueous HF (12  $\mu$ L, 0.32 mmol) and the solution was then warmed to room temperature and stirred for 36 hours. The mixture was then diluted with 2 mL of ethyl acetate and poured in to a separatory funnel containing 30 mL of aqueous saturated Na<sub>2</sub>CO<sub>3</sub> and 20 mL ethyl acetate. The aqueous layer was extracted twice with 20 mL of ethyl acetate and the organic layers were combined, dried with Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to give 2.7 mg of a yellow oil. The material was purified by plug silica gel column chromatography by eluting with a 50% ethyl acetate/hexanes mixture followed by ethyl acetate to give 1.5 mg of 3 6, which exhibited spectra identical with an authentic sample of 10-DAB.

**Baccatin III (3 7).** To a mixture of ketone 3 4 ( $P_7$  = MOP) (2.1 mg, 0.003 mmol) in pyridine (30  $\mu$ L, 0.36 mmol) and acetonitrile (20  $\mu$ L) at 0 °C was added 48% aqueous HF (12  $\mu$ L, 0.32 mmol) and the solution was then warmed to room temperature and stirred for 36 hours. The mixture was then diluted with 2 mL of ethyl acetate and poured in to a separatory funnel containing 30 mL of aqueous saturated Na<sub>2</sub>CO<sub>3</sub> and 20 mL ethyl acetate. The aqueous layer was extracted twice with 20 mL of ethyl acetate and the organic layers were combined, dried with Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to give 2.7 mg of a yellow oil. The material was purified by plug silica gel column

chromatography by eluting with an ethyl acetate/hexanes mixture to give 1.7 mg of **37**, which exhibited spectra identical with an authentic sample of baccatin III.

#### REACTION SCHEME A'

**Hydroxyketone 19.** To a vigorously stirred solution of ketone **18** ( $P_7$ =MOP) (181 mg, 0.265 mmol) in THF (2.2 mL) under nitrogen at -78 °C was added dropwise down the side of the flask 2.13 mL of a 0.2 M solution (0.426 mmol) of LDA in THF. After 10 min, a solution of 116 mg of (S)-camphorsulfonyloxaziridine (116 mg, 0.396 mmol) in 1.5 mL THF was added dropwise down the side of the flask. The reaction mixture was cooled to -40 °C and, after stirring 1 h, 2 mL of a saturated aqueous  $\text{NaHCO}_3$  solution was added. The reaction mixture was diluted with 50 mL of 30% ethyl acetate in hexanes and washed with 20 mL of a saturated aqueous  $\text{NaHCO}_3$  solution and brine, dried over anhydrous  $\text{Na}_2\text{SO}_4$  and concentrated under reduced pressure. The resulting oil was filtered through silica gel with 30% ethyl acetate in hexanes and concentrated to give 210 mg of a colorless oil. This material was purified by radial chromatography, eluting with 25% ethyl acetate in hexanes to yield 150 mg (81%)  $5\beta$ -hydroxyketone **19** as a white solid, 15 mg (8%) returned starting ketone **18** and 10 mg (5%) of the corresponding  $5\alpha$ -hydroxyketone.

**19** ( $P_7$ =MOP):  $^1\text{H}$  NMR (500 MHz,  $\text{CDCl}_3$ )  $\delta$  0.08 (s, 3H, TBS  $\text{CH}_3$ ), 0.12 (s, 3H, TBS  $\text{CH}_3$ ), 0.62 (q,  $J$  = 8.2 Hz, 6H, TES  $\text{CH}_2$ ), 0.90 (s, 9H, TBS t-Bu), 0.96 (t,  $J$  = 8.2 Hz, 9H, TES  $\text{CH}_3$ ), 1.05 (s, 3H,  $\text{CH}_3$  19), 1.19 (s, 3H,  $\text{CH}_3$  17), 1.33 (s, 3H,  $\text{CH}_3$  16), 1.35 (s, 3H, MOP  $\text{CH}_3$ ), 1.43 (s, 3H, MOP  $\text{CH}_3$ ), 1.67 (dd,  $J$  = 5.0, 14.7 Hz, 1H,  $\text{H}9\beta$ ), 1.87 (m, 1H,  $\text{H}6\beta$ ), 2.12 (dd,  $J$  = 4.1, 15.1 Hz, 1H,  $\text{H}14\alpha$ ), 2.14 (d,  $J$  = 1.4 Hz, 3H,  $\text{CH}_3$  18), 2.23 (dd,  $J$  = 7.3, 14.7 Hz, 1H,  $\text{H}9\alpha$ ), 2.55 (dd,  $J$  = 9.2, 15.1 Hz, 1H,  $\text{H}14\beta$ ), 2.76 (ddd,  $J$  = 3.7, 7.3, 13.7 Hz, 1H,  $\text{H}6\alpha$ ), 3.22 (s, 3H, MOP  $\text{OCH}_3$ ), 3.24 (d,  $J$  = 4.1 Hz, 1H, OH5), 3.28 (d,  $J$  = 6.0 Hz, 1H,  $\text{H}3\alpha$ ), 3.83 (dd,  $J$  = 3.7, 9.2 Hz, 1H,  $\text{H}7\alpha$ ), 4.06 (ddd,  $J$  = 4.1, 7.3, 7.3 Hz, 1H,  $\text{H}5\alpha$ ), 4.46 (dd,  $J$  = 5.0, 7.3 Hz, 1H,  $\text{H}10\beta$ ), 4.53 (d,  $J$  = 6.0 Hz, 1H,  $\text{H}2\beta$ ), 4.63 (dd,  $J$  = 2.8, 9.2 Hz, 1H,  $\text{H}13\beta$ ).

**Ketone 20.** To a vigorously stirred solution of 5-hydroxy-4-ketone **19** ( $P_7$ =MOP) (420 mg, 0.602 mmol) in  $\text{CH}_2\text{Cl}_2$  (20 mL) and triethylamine (1.18 mL, 8.5 mmol) under nitrogen at 0 °C

was added trimethylsilylchloride (0.40 mL, 3.3 mmol). After 0.5 h, the reaction mixture was quenched with 5 mL of a saturated aqueous NaHCO<sub>3</sub> solution and extracted with 50 mL CHCl<sub>3</sub>. The organic phase was washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure to give 453 mg (98%) of ketone 20 as a colorless oil. This material was used without further purification.

**20 (P<sub>7</sub>=MOP):** <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>)  $\delta$  0.11 (s, 6H, TBS CH<sub>3</sub>), 0.12 (s, 9H, TMS CH<sub>3</sub>), 0.59 (q, *J* = 7.8 Hz, 6H, TES CH<sub>2</sub>), 0.94 (s, 9H, TBS t-Bu), 0.96 (t, *J* = 7.8 Hz, 9H, TES CH<sub>3</sub>), 1.23 (s, 3H, CH<sub>3</sub> 17), 1.32 (s, 3H, CH<sub>3</sub> 19), 1.33 (s, 3H, MOP CH<sub>3</sub>), 1.35 (s, 3H, CH<sub>3</sub> 16), 1.37 (s, 3H, MOP CH<sub>3</sub>), 1.86 (m, 3H, H6 $\beta$ , H9 $\alpha$ , H9 $\beta$ ), 2.05 (d, *J* = 1.4 Hz, 3H, CH<sub>3</sub> 18), 2.43 (d, *J* = 3.7 Hz, 1H, H14 $\beta$ ), 2.45 (d, *J* = 4.6 Hz, 1H, H14 $\alpha$ ), 2.59 (ddd, *J* = 6.0, 8.2, 14.2 Hz, 1H, H6 $\alpha$ ), 2.84 (d, *J* = 6.0 Hz, 1H, H3 $\alpha$ ), 3.21 (s, 3H, MOP OMe), 3.51 (dd, *J* = 6.0, 11.0 Hz, 1H, H7 $\alpha$ ), 3.94 (dd, *J* = 4.1, 8.2 Hz, 1H, H5 $\alpha$ ), 4.38 (dd, *J* = 5.0, 8.7 Hz, 1H, H10 $\beta$ ), 4.54 (d, *J* = 6.0 Hz, 1H, H2 $\beta$ ), 4.74 (dd, *J* = 6.4, 6.4 Hz, 1H, H13 $\beta$ ).

**Diol 21.** To a stirred solution of ketone 20 (P<sub>7</sub>=MOP) (453 mg, 0.588 mmol) in THF (23 mL) under nitrogen at -78 °C was added dropwise 1.95 mL of a 3 M solution of MeMgBr in ether (5.85 mmol). The reaction mixture was stirred for 5.5 h, poured into 100 mL of a saturated aqueous NaHCO<sub>3</sub> solution and extracted with three 100 mL portions of CHCl<sub>3</sub>. The combined organic phases were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure to yield 453 mg of the hydroxy trimethylsilyl ether as a colorless oil. This material was used without further purification.

To a stirred solution of the trimethylsilyl ether (453 mg) in pyridine (8 mL) and acetonitrile (8 mL) at 0 °C was added 0.8 mL of a 48% aqueous HF solution. After stirring 20 min, the resulting mixture was poured into 100 mL of a saturated aqueous NaHCO<sub>3</sub> solution and extracted with three 150 mL portions of CHCl<sub>3</sub>. The combined organic layers were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure to yield 422 mg of diol 21. This material used without further purification.

**21 (P<sub>7</sub>=MOP):** <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  0.08 (s, 3H, TBS CH<sub>3</sub>), 0.10 (s, 3H, TBS CH<sub>3</sub>), 0.56 (q, *J* = 7.7 Hz, 6H, TES CH<sub>2</sub>), 0.90 (s, 9H, TBS t-Bu), 0.93 (t, *J* = 7.7 Hz, 9H, TES

CH<sub>3</sub>), 1.16 (s, 3H, CH<sub>3</sub> 17), 1.25 (s, 3H, CH<sub>3</sub> 16), 1.29 (s, 3H, CH<sub>3</sub> 19), 1.31 (s, 3H, CH<sub>3</sub> 20), 1.38 (s, 3H, MOP CH<sub>3</sub>), 1.46 (s, 3H, MOP CH<sub>3</sub>), 1.81 (d, *J* = 3.8 Hz, 1H, H3 $\alpha$ ), 1.86 (d, *J* = 9.9 Hz, 1H, H9 $\beta$ ), 1.90 (dd, *J* = 6.1, 8.3 Hz, 1H, H9 $\alpha$ ), 1.96 (s, 3H, CH<sub>3</sub> 18), 2.12 (ddd, *J* = 3.3, 3.3, 10.4 Hz, 1H, H6 $\alpha$ ), 2.30 (m, 1H, H6 $\beta$ ), 2.42 (dd, *J* = 3.9, 15.4 Hz, 1H, H14 $\alpha$ ), 2.61 (dd, *J* = 9.3, 15.4 Hz, 1H, H14 $\beta$ ), 2.81 (s, 1H, OH4), 3.04 (m, 1H, OH5), 3.40 (dd, *J* = 3.9, 15.8 Hz, 1H, H7 $\alpha$ ), 4.28 (dd, *J* = 6.6, 8.2 Hz, 1H, H10 $\beta$ ), 4.62 (dd, *J* = 1.6, 7.8 Hz, 1H, H13 $\beta$ ), 4.66 (d, *J* = 3.8, 1H, H2 $\beta$ ).

**Acetate 22.** To a stirred solution of diol 21 (P<sub>7</sub>=MOP) (470 mg, 0.66 mmol) in pyridine (12 mL) under nitrogen at room temperature was added acetic anhydride (4.5 mL). After 11 h, the reaction mixture was diluted with 50 mL of CHCl<sub>3</sub>, then poured into 50 mL of saturated aqueous sodium bicarbonate solution. The aqueous phase was extracted with CHCl<sub>3</sub> then the combined extracts were washed with brine, dried with Na<sub>2</sub>SO<sub>4</sub> and filtered. Concentration of the filtrate under vacuum yielded 470 mg (94% from 20) of crude material which was pure acetate 22 by <sup>1</sup>H NMR and TLC analysis.

**22 (P<sub>5</sub>=Ac, P<sub>7</sub>=MOP):** <sup>1</sup>H NMR (500MHz, CDCl<sub>3</sub>)  $\delta$  0.10 (s, 3H, TBS CH<sub>3</sub>), 0.13 (s, 3H, TBS CH<sub>3</sub>), 0.59 (q, *J* = 7.8 Hz, 6H, TES CH<sub>2</sub>), 0.94 (s, 9H, TBS t-Bu), 0.95 (t, *J* = 7.8 Hz, 9H, TES CH<sub>3</sub>), 1.18 (s, 3H, CH<sub>3</sub> 17), 1.30 (s, 3H, CH<sub>3</sub> 16), 1.32 (s, 3H, CH<sub>3</sub> 19), 1.33 (s, 6H, CH<sub>3</sub> 20, MOP CH<sub>3</sub>), 1.41 (s, 3H, MOP CH<sub>3</sub>), 1.91 (d, *J* = 3.4 Hz, 1H, H3 $\alpha$ ), 1.94 (m, 2H, H9, H9), 2.00 (d, *J* = 1.5 Hz, 3H, CH<sub>3</sub> 18), 2.06 (ddd, *J* = 3.9, 3.9, 11.7 Hz, 1H, H6 $\alpha$ ), 2.10 (s, 3H, OAc), 2.14 (dd, *J* = 11.7, 23.9 Hz, 1H, H6 $\beta$ ), 2.38 (dd, *J* = 3.9, 15.1 Hz, 1H, H14 $\alpha$ ), 2.63 (dd, *J* = 9.3, 15.1 Hz, 1H, H14 $\beta$ ), 2.78 (d, *J* = 1.5 Hz, 1H, OH4), 3.20 (s, 3H, OMe CH<sub>3</sub>), 3.38 (dd, *J* = 3.9, 11.7 Hz, 1H, H7 $\alpha$ ), 4.30 (dd, *J* = 4.9, 10.3 Hz, 1H, H10 $\beta$ ), 4.50 (ddd, *J* = 1.5, 3.9, 12.2 Hz, 1H, H5 $\alpha$ ), 4.64 (dd, *J* = 1.5, 1.5 Hz, 1H, H13 $\beta$ ), 4.66 (d, *J* = 3.4 Hz, 1H, H2 $\beta$ ).

**Olefin 23.** To a stirred solution of alcohol 22 (P<sub>5</sub>=Ac, P<sub>7</sub>=MOP) (26 mg, 0.034 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (1.48 mL) and pyridine (0.37 mL) under nitrogen at 10 °C was added SOCl<sub>2</sub> (0.037 mL, 5.1 mmol) over a period of three minutes. The mixture was warmed to room temperature and

stirred for 2.3 h then diluted with  $\text{CHCl}_3$  and poured into saturated aqueous sodium bicarbonate solution. The aqueous phase was extracted with  $\text{CHCl}_3$  and the combined extracts were washed with brine, dried over anhydrous  $\text{Na}_2\text{SO}_4$  and filtered. Concentration of the filtrate under vacuum yielded 24 mg of crude material which was purified by silica gel chromatography to give 13 mg (52%) of a 4:1 mixture of 7-MOP-*exo;endo* cyclic olefins and 6 mg (27%) of a 4:1 mixture of 7-hydroxy-*exo;endo* cyclic olefins.

**23** ( $P_5=\text{Ac}$ ,  $P_7=\text{MOP}$ ):  $^1\text{H}$  NMR (500 MHz,  $\text{CDCl}_3$ )  $\delta$  0.10 (s, 3H, TBS  $\text{CH}_3$ ), 0.12 (s, 3H, TBS  $\text{CH}_3$ ), 0.59 (q,  $J = 7.9$ , 6H, TES  $\text{CH}_2$ ), 0.93 (s, 9H, TBS t-Bu), 0.96 (t,  $J = 7.9$ , 9H, TES  $\text{CH}_3$ ), 1.21 (s, 3H,  $\text{CH}_3$  17), 1.30 (s, 3H,  $\text{CH}_3$  19), 1.32 (s, 3H, MOP  $\text{CH}_3$ ), 1.34 (s, 3H, MOP  $\text{CH}_3$ ), 1.37 (s, 3H,  $\text{CH}_3$  16), 1.72 (m, 2H,  $\text{H}6\beta$ ,  $\text{H}9\beta$ ), 1.89 (dd,  $J = 3.8$ , 13.4 Hz, 1H,  $\text{H}9\beta$ ), 2.03 (d,  $J = 1.37$  Hz, 3H,  $\text{CH}_3$  18), 2.05 (s, 3H, OAc  $\text{CH}_3$ ), 2.33 (dd,  $J = 5.1$ , 15.4 Hz, 1H,  $\text{H}14\alpha$ ), 2.47 (m, 2H,  $\text{H}6\alpha$ ,  $\text{H}14\beta$ ), 3.06 (d,  $J = 5.8$  Hz, 1H,  $\text{H}3\alpha$ ), 3.20 (s, 3H, MOP OMe), 3.38 (dd,  $J = 6.9$ , 11.0 Hz, 1H,  $\text{H}7\alpha$ ), 4.37 (dd,  $J = 3.8$ , 11.0 Hz, 1H,  $\text{H}10\beta$ ), 4.53 (d,  $J = 5.8$  Hz, 1H,  $\text{H}2\beta$ ), 4.74 (m, 1H,  $\text{H}13\beta$ ), 5.15 (s, 1H,  $\text{H}20\text{E}$ ), 5.21 (d,  $J = 1.37$  Hz, 1H,  $\text{H}20\text{Z}$ ), 5.36 (d,  $J = 9.3$  Hz, 1H,  $\text{H}5\alpha$ ).

**Diol 24.** To a stirred solution of a 4:1 mixture of the *exo, endocyclic* olefins **23** ( $P_5=\text{Ac}$ ,  $P_7=\text{MOP}$ ) (249 mg, 0.337 mmol) in pyridine (4.6 mL) under nitrogen at 0 °C was added 2.35 mL of a 0.157 M solution (0.368 mmol) of  $\text{OsO}_4$  in THF. After 1 h,  $\text{NaHSO}_3$  was added along with 6.2 mL of water and the mixture was stirred for 1 h at room temperature. The mixture was then diluted with ethyl acetate and poured into saturated aqueous sodium bicarbonate. The aqueous layer was extracted with ethyl acetate and the combined extracts were washed with brine, dried over anhydrous  $\text{Na}_2\text{SO}_4$  and concentrated under reduced pressure to yield 281 mg of crude material which was purified by silica gel chromatography, eluting with 50% ethyl acetate/hexane to yield 190 mg (73%) of pure diol **24** and 48 mg (19%) of the enol acetate.

**24** ( $P_5=\text{Ac}$ ,  $P_7=\text{MOP}$ ):  $^1\text{H}$  NMR (500 MHz,  $\text{CDCl}_3$ )  $\delta$  0.10 (s, 3H, TBS  $\text{CH}_3$ ), 0.11 (s, 3H, TBS  $\text{CH}_3$ ), 0.60 (dq,  $J = 1.5$ , 7.8 Hz, 6H, TES  $\text{CH}_2$ ), 0.87 (s, 3H,  $\text{CH}_3$  19), 0.93 (s, 9H, TBS t-Bu), 0.95 (t,  $J = 7.8$  Hz, 9H, TES  $\text{CH}_3$ ), 1.20 (s, 3H,  $\text{CH}_3$  17), 1.31 (s, 3H,  $\text{CH}_3$  16), 1.33 (s, 3H, MOP  $\text{CH}_3$ ), 1.47 (s, 3H, MOP  $\text{CH}_3$ ), 1.54 (dd,  $J = 12.3$ , 25.0 Hz, 1H,  $\text{H}6\beta$ ), 1.63 (dd,  $J =$

5.5, 15.1 Hz, 1H, H9 $\beta$ ), 2.05 (s, 3H, OAc), 2.15 (s, 3H, CH<sub>3</sub> 18), 2.26 (m, 2H, H9 $\alpha$ , OH20) 2.37 (dd, *J* = 9.2, 14.7 Hz, 1H, H14 $\beta$ ), 2.46 (ddd, *J* = 4.8, 4.8, 13.4 Hz, 1H, H6 $\alpha$ ), 2.69 (d, *J* = 4.5 Hz, 1H, H3 $\alpha$ ), 3.18 (s, 3H, MOP CH<sub>3</sub>), 3.28 (dd, *J* = 3.8, 14.7 Hz, 1H, H14 $\alpha$ ), 3.76 (dd, *J* = 4.0, 11.6 Hz, 1H, H7 $\alpha$ ), 3.84 (m, 2H, H20, H20), 3.95 (s, 1H, OH4), 4.42 (dd, *J* = 5.1, 5.8 Hz, 1H, H10 $\beta$ ), 4.44 (d, *J* = 4.1 Hz, 1H, H2 $\beta$ ), 4.63 (dd, *J* = 4.1, 12.3 Hz, 1H, H5 $\alpha$ ), 4.67 (dd, *J* = 4.1, 9.2 Hz, 1H, H13 $\beta$ ).

**24** (P<sub>7</sub>=BOM): <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  0.9 (s, 3H, TBS CH<sub>3</sub>), 0.10 (s, 3H, TBS CH<sub>3</sub>), 0.58 (q, *J* = 7.9 Hz, 2H, TES CH<sub>2</sub>), 0.83 (s, 3H, CH<sub>3</sub> 19), 0.92 (s, 9H, TBS t-Bu), 0.93 (t, *J* = 7.9 Hz, TES CH<sub>3</sub>), 1.20 (s, 3H, CH<sub>3</sub> 17), 1.33 (s, 3H, CH<sub>3</sub> 16), 1.58 (q, *J* = 13.2 Hz, 1H, H6 $\beta$ ), 1.71 (dd, *J* = 10.4, 5.5 Hz, H9 $\beta$ ), 2.04 (s, 3H, OAc), 2.17 (br s, 3H, CH<sub>3</sub> 18), 2.20 (dd, *J* = 10.4, 3.8 Hz, 1H, H9 $\alpha$ ), 2.35 (dd, *J* = 14.8, 9.1 Hz, 1H, H14 $\beta$ ), 2.43 (dt, *J* = 13.2, 5.0 Hz, 1H, H6 $\alpha$ ), 2.80 (d, *J* = 4.6 Hz, 1H, H3 $\alpha$ ), 3.31 (dd, *J* = 4.4, 14.8 Hz, 1H, H14 $\alpha$ ), 3.71 (dd, *J* = 4.9, 13.0 Hz, 1H, H7 $\alpha$ ), 3.83 (m, 2H, H20), 3.98 (s, 1H, OH1), 4.46 (d, *J* = 4.8 Hz, 1H, H2 $\beta$ ), 4.48 (m, 1H, H10 $\beta$ ), 4.51 (d, *J* = 12.1 Hz, 1H, PhCH<sub>2</sub>O), 4.64 (dd, *J* = 13.2, 5.0 Hz, 1H, H5 $\alpha$ ), 4.66 (m, 1H, H13 $\beta$ ), 4.70 (d, *J* = 12.1 Hz, 1H, PhCH<sub>2</sub>O), 4.83 (d, *J* = 7.1 Hz, 1H, OCH<sub>2</sub>O), 4.94 (d, *J* = 7.1 Hz, 1H, OCH<sub>2</sub>O), 7.33 (m, 5H, Ph).

**Triol 25.** To a stirred solution of acetoxydiol **24** (P<sub>5</sub>=Ac, P<sub>7</sub>=MOP) (26.5 mg, 0.035 mmol) in anhydrous methanol (0.9 mL) at -5 °C under nitrogen was added 0.060 mL of a 0.166 M (0.01 mmol) methanolic solution of sodium methoxide. After 2.5 h, the reaction mixture was diluted with 10 mL of ethyl acetate, then poured into 10 mL of a saturated aqueous NaHCO<sub>3</sub> solution. The organic phase was washed with 10 mL of a saturated aqueous NaHCO<sub>3</sub> solution, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure to give 25 mg of pure triol **25** (100%).

**25** (P<sub>7</sub>=MOP): <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>)  $\delta$  0.10 (s, 3H, TBS CH<sub>3</sub>), 0.11 (s, 3H, TBS CH<sub>3</sub>), 0.60 (q, *J* = 8.06 Hz, 6H, TES CH<sub>2</sub>), 0.87 (s, 3H, CH<sub>3</sub> 19), 0.94 (s, 9H, TBS t-Bu), 0.95 (t, *J* = 8.1 Hz, 9H, TES CH<sub>3</sub>), 1.19 (s, 3H, CH<sub>3</sub> 17), 1.31 (s, 3H, CH<sub>3</sub> 16), 1.33 (s, 3H, MOP CH<sub>3</sub>), 1.47 (s, 3H, MOP CH<sub>3</sub>), 1.59 (dd, *J* = 11.7, 11.7 Hz, 1H, H6 $\beta$ ), 1.62 (dd, *J* = 5.5, 16.1 Hz, 1H, H9 $\beta$ ), 2.11 (d, *J* = 0.7 Hz, 3H, CH<sub>3</sub> 18), 2.24 (dd, *J* = 5.5, 16.1 Hz, 1H, H9 $\alpha$ ), 2.38

(dd,  $J = 9.5, 15.0$  Hz, 1H, H14 $\beta$ ), 2.45 (ddd,  $J = 4.4, 4.4, 13.6$  Hz, 1H, H6 $\alpha$ ), 2.60 (d,  $J = 4.4$  Hz, 1H, H3 $\alpha$ ), 3.21 (s, 3H, MOP OMe), 3.25 (dd,  $J = 4.4, 15.0$  Hz, 1H, H14 $\alpha$ ), 3.52 (dd,  $J = 4.4, 12.8$  Hz, 1H, H7 $\alpha$ ), 3.72 (dd,  $J = 4.4, 11.4$  Hz, 1H, H5 $\alpha$ ), 3.79 (s, 1H, OH4), 3.86 (d,  $J = 11.0$ , 1H, H20), 3.93 (d,  $J = 11.4$  Hz, 1H, H20), 4.42 (dd,  $J = 5.1, 5.1$  Hz, 1H, H10 $\beta$ ), 4.45 (d,  $J = 4.4$  Hz, 1H, H2 $\beta$ ), 4.66 (dd,  $J = 4.0, 9.2$  Hz, 1H, H13 $\beta$ ).

*p*-Methoxybenzylidene acetal 25b: To a solution of the diol 24 ( $P_5$ =Ac,  $P_7$ =BOM) (6.5 mg, 0.0079 mmol) and anisaldehyde dimethyl acetal (0.013 ml, 0.076 mmol) stirred in  $CH_2Cl_2$  was added a solution of *p*-toluenesulfonic acid (0.002 ml, 0.1M in THF, 0.0002 mmol). The resulting solution was stirred at room temperature for 15 min then triethylamine (0.1 ml) was added and stirring was continued for 10 min. The mixture was rinsed into 30% ethyl acetate in hexanes (15 ml) then the aqueous phase was extracted with 30% ethyl acetate in hexanes (2 x 5 ml). The combined extracts were washed with brine, dried over  $Na_2SO_4$ , and filtered. Concentration of the filtrate under vacuum yielded 12 mg of colorless oil which was purified by silica gel chromatography to yield 6.9 mg (96%) of *p*-methoxybenzylidene acetal 25b as a 5:1 mixture of diasteromers.

25b ( $P_5$ =Ac,  $P_7$ =BOM, major diasteromer):  $^1H$  NMR (500 MHz,  $CDCl_3$ )  $\delta$  -0.05 (s, 3H, TBS  $CH_3$ ), 0.07 (s, 3H, TBS  $CH_3$ ), 0.60 (q,  $J = 7.9$  Hz, 2H, TES  $CH_2$ ), 0.78 (s, 3H,  $CH_3$  19) 0.82 (s, 9H, TBS t-Bu), 0.95(t,  $J = 7.9$  Hz, TES  $CH_3$ ), 1.25 (s, 3H,  $CH_3$  17), 1.37 (s, 3H,  $CH_3$  16), 1.58 (m, H6 $\beta$ ), 1.70 (dd,  $J = 16.8, 5.8$  Hz, H9 $\beta$ ), 1.74 (s, 3H, OAc), 2.26 (s, 3H,  $CH_3$  18), 2.28 (dd,  $J = 16.8, 1.4$  Hz, 1H, H9 $\alpha$ ), 2.38 (dd,  $J = 15.1, 9.7$  Hz, 1H, H14 $\beta$ ), 2.57 (dt,  $J = 5.1, 9.9$  Hz, 1H, H6 $\alpha$ ) 3.10 (dd,  $J = 5.1, 14.7$  Hz, 1H, H14 $\alpha$ ), 3.11 (d,  $J = 4.8$  Hz, 1H, H3 $\alpha$ ), 3.79 (s, 3H,  $OCH_3$ ), 3.84 (dd,  $J = 5.0, 11.5$  Hz, 1H, H7 $\alpha$ ), 4.15 (d,  $J = 8.2$  Hz, 1H, H20), 4.20 (d,  $J = 8.2$  Hz, 1H, H20), 4.48(d,  $J = 12.0$  Hz, 1H,  $OCH_2Ph$ ), 4.55 (d,  $J = 4.8$  Hz, 1H, H2 $\beta$ ), 4.57 (m, 1H, H10 $\beta$ ), 4.71 (d,  $J = 12.0$  Hz, 1H,  $OCH_2Ph$ ), 4.73 (m, 1H, H13 $\beta$ ), 4.78 (dd,  $J = 12.4, 4.9$  Hz, 1H, H5 $\alpha$ ), 4.84 (d,  $J = 6.7$  Hz, 1H,  $OCH_2O$ ), 4.99 (d,  $J = 6.7$  Hz, 1H,  $OCH_2O$ ), 6.05 (s, 1H, acetal CH), 6.80 (d,  $J = 7.5$  Hz, 2H, *p*-MeOPh -o), 7.27-7.36 (m, 7H, *p*-MeOPh -m and Ph).

**Acetonide 26b.** To a solution of the *p*-methoxybenzylidene acetal 25b ( $P_5=Ac$ ,  $P_7=BOM$ ) (11.5 mg, 0.012 mmol) in 0.4 mL of toluene stirred at 0 °C was added a solution of diisobutylaluminum hydride (0.082 ml, 2.0M in toluene, 0.12 mmol). The resulting solution was stirred for 3.5 h then methanol (0.1 ml) was added. The mixture was diluted with ethyl acetate (5 ml) and stirred with saturated aqueous sodium potassium tartrate for 1.5 hours. The aqueous phase was separated and extracted with ethyl acetate (2 x 10 ml) then the combined extracts were washed with brine and dried with  $Na_2SO_4$ . Filtration followed by concentration of the filtrate under vacuum yielded 12 mg of crude material that was purified by silica gel chromatography (30% ethyl acetate in hexanes eluent) to yield 4.7 mg of a mixture of formate acetals, 1.1 mg of 4-MPM-1,2,5,20-tetraol, and 5.2 mg of a mixture of formate *p*-methoxybenzyl ethers.

The mixture of formate acetals was dissolved in methanol (0.1 ml) and 3% aqueous  $NH_4OH$  was added. The cloudy mixture was stirred at room temperature for 30 min then rinsed into ethyl acetate over saturated aqueous  $NaHCO_3$ . The aqueous phase was extracted with ethyl acetate (2 x 10 ml) and the combined extracts were washed with brine, dried over  $Na_2SO_4$ , and filtered. Concentration of the filtrate under vacuum yielded a mixture of *p*-methoxybenzylidene acetals. The mixture of acetals was dissolved in toluene (0.4 ml) and the solution was cooled to 0 °C then a solution of diisobutylaluminum hydride (0.02 ml, 2.0M in toluene, 0.08 mmol) was added. The resulting solution was stirred for 3.5 hours then methanol (0.1 ml) was added. The mixture was diluted with ethyl acetate (5 ml) and stirred with saturated aqueous sodium potassium tartrate for 1.5 hours. The aqueous phase was separated and extracted with ethyl acetate (2 x 10 ml) and the combined extracts were washed with brine and dried over  $Na_2SO_4$ . Filtration followed by concentration of the filtrate under vacuum yielded 4.5 mg of crude material that was purified by silica gel chromatography (30% ethyl acetate in hexanes eluent) to yield 2.8 mg of 4-MPM-1,2,5,20-tetraol.

The mixture of formate *p*-methoxybenzyl ethers was dissolved in methanol (0.1 ml) and 3% aqueous  $NH_4OH$  (0.1 ml) was added. The cloudy mixture was stirred at room temperature for 30 minutes then rinsed into ethyl acetate over saturated aqueous  $NaHCO_3$ . The aqueous phase was extracted with ethyl acetate (2 x 10 ml) and the combined extracts were washed with brine, dried

over  $\text{Na}_2\text{SO}_4$ , and filtered. Concentration of the filtrate under vacuum yielded 4.8mg of crude material which was purified by silica gel chromatography to yield 3.2mg of 4-MPM-1,2,5,20-tetraol. Total combined yield of 4-MPM-1,2,5,20-tetraol: 68% from 25 b.

4-MPM-1,2,5,20-tetraol :  $^1\text{H}$  NMR (500 MHz,  $\text{CDCl}_3$ )  $\delta$  0.13 (s, 3H, TBS  $\text{CH}_3$ ), 0.06 (s, 3H, TBS  $\text{CH}_3$ ), 0.60 (q,  $J$  = 8.0Hz, 2H, TES  $\text{CH}_2$ ), 0.89 (s, 9H, TBS t-Bu), 0.95(t,  $J$  = 8.0 Hz, TES  $\text{CH}_3$ ), 0.97 (s, 3H,  $\text{CH}_3$  19), 1.22 (s, 3H,  $\text{CH}_3$  17), 1.30 (s, 3H,  $\text{CH}_3$  16), 1.83 (dd,  $J$  = 16.8,5.8 Hz, H9 $\alpha$ ), 1.91 (q,  $J$  = 12.4 Hz, 1H, H6 $\beta$ ), 2.12 (m, 2H, H9 $\alpha$  and 14 $\beta$ ), 2.18 (s, 3H,  $\text{CH}_3$  18), 2.55 (m, 2H, H14 $\beta$  and 6 $\alpha$ ), 2.79 (d,  $J$  = 5.3 Hz, 1H, H3 $\alpha$ ), 2.95 (d,  $J$  = 3.0 Hz, 1H, OH5), 3.54 (m, 1H, OH20), 3.66(dd,  $J$  = 10.3, 5.3 Hz, 1H, H2 $\beta$ ), 3.81 (s, 3H,  $\text{OCH}_3$ ), 3.85 (dd,  $J$  = 5.2, 11.6 Hz, 1H, H7 $\alpha$ ), 3.91 (dt,  $J$  = 5.9, 12.4, 1H, H5 $\alpha$ ), 4.18 (s, 1H, OH1), 4.13 (d,  $J$  = 13 Hz, 1H, H20), 4.20 (dd,  $J$  = 7.22, 12.9 Hz, 1H, H20), 4.47 (d,  $J$  = 11.8 Hz, 1H,  $\text{OCH}_2\text{Ph}$ ), 4.58 (m, 1H, H10 $\beta$ ), 4.79 (d,  $J$  = 11.8 Hz, 1H,  $\text{OCH}_2\text{Ph}$ ), 4.85 (m, 1H, H13 $\beta$ ), 4.87 (d,  $J$  = 6.8 Hz, 1H,  $\text{OCH}_2\text{O}$ ), 5.01 (d,  $J$  = 10.6 Hz, 1H, MPM  $\text{CH}_2$ ), 5.10 (d,  $J$  = 6.8 Hz, 1H,  $\text{OCH}_2\text{O}$ ), 5.11(d,  $J$  = 10.6 Hz, 1H, MPM  $\text{CH}_2$ ), 5.49(d,  $J$  = 10.5 Hz, 1H, OH2), 6.87 (d,  $J$  = 8.7 Hz, 2H), 7.30 (d,  $J$  = 8.7 Hz, 2H, *p*-MeOPh-*o*), 7.27-7.36 (m, 5H, *p*-MeOPh-*m* and Ph  $\text{CH}_2$ ).

To a solution of the 4-MPM-1,2,5,20-tetraol (2.0 mg, 0.0023 mmol) stirred in 0.2 ml of  $\text{CH}_2\text{Cl}_2$  and 0.02 ml of 2,2-dimethoxypropane at 0 °C was added a solution of *p*-toluenesulfonic acid (0.002 ml, 0.1M in THF, 0.0002 mmol). The resulting solution was stirred for 20 min then triethylamine (0.1 ml) was added and stirring was continued for 10 min. The mixture was rinsed into ethyl acetate (10 ml) over saturated aqueous  $\text{NaHCO}_3$  then the aqueous phase was extracted with ethyl acetate (2 x 5 ml). The combined extracts were washed with brine, dried with  $\text{Na}_2\text{SO}_4$ , and filtered. Concentration of the filtrate under vacuum yielded 2.1 mg of crude material which was purified by silica gel chromatography to yield 1.1 mg of acetonide 26 b.

26b ( $\text{P}_{520}=\text{C}(\text{CH}_3)_2$ ,  $\text{P}_7=\text{BOM}$ ):  $^1\text{H}$  NMR (500 MHz,  $\text{CDCl}_3$ )  $\delta$  -0.073 (s, 3H, TBS  $\text{CH}_3$ ), 0.008 (s, 3H, TBS  $\text{CH}_3$ ), 0.60 (q,  $J$  = 7.9Hz, 6H, TES  $\text{CH}_2$ ), 0.79 (s, 9H, TBS t-Bu), 0.95(t,  $J$  = 7.9 Hz, 9H, TES  $\text{CH}_3$ ), 1.10 (s, 3H,  $\text{CH}_3$  19), 1.25 (s, 3H,  $\text{CH}_3$  17), 1.34 (s, 3H,  $\text{CH}_3$  16), 1.41 (s, 3H,  $\text{CH}_3$  acetonide), 1.46 (s, 3H,  $\text{CH}_3$  acetonide), 1.88 (dd,  $J$  = 16.7,5.5 Hz, H9 $\beta$ ), 2.08 (dd,  $J$  = 14.3, 9.2 Hz, 1H, H14 $\beta$ ), 2.17 (s, 3H,  $\text{CH}_3$  18), 2.21(dd,  $J$  = 17.1, 1.7 Hz, 1H,

H9 $\alpha$ ), 2.42 (dd,  $J$  = 14.3, 7.2 Hz, 1H, H14 $\alpha$ ), 2.61 (d,  $J$  = 5.1 Hz, 1H, H3 $\alpha$ ), 2.62 (m, 1H, H6 $\beta$ ), 3.71 (dd,  $J$  = 11.3, 5.1 Hz, 1H, H2 $\beta$ ), 3.75 (dd,  $J$  = 5.0, 11.3 Hz, 1H, H7 $\alpha$ ), 3.80 (s, 3H, OCH<sub>3</sub>), 3.99 (dd,  $J$  = 12.0, 6.2 Hz, 1H, H5 $\alpha$ ), 4.01 (d,  $J$  = 14.2 Hz, 1H, H20), 4.17 (s, 1H, OH1), 4.44 (d,  $J$  = 14.2 Hz, 1H, H20), 4.47 (d,  $J$  = 11.6 Hz, 1H, OCH<sub>2</sub>Ph), 4.58 (m, 1H, H10 $\beta$ ), 4.80 (d,  $J$  = 11.6 Hz, 1H, OCH<sub>2</sub>Ph), 4.84 (d,  $J$  = 11.3 Hz, 1H, OH2), 4.85 (m, 1H, H13 $\beta$ ), 4.88 (d,  $J$  = 10.3 Hz, 1H, OCH<sub>2</sub>O), 4.89 (d,  $J$  = 6.8 Hz, 1H, MPM CH<sub>2</sub>), 5.00 (d,  $J$  = 10.3 Hz, 1H, OCH<sub>2</sub>Ph), 5.10 (d,  $J$  = 6.8 Hz, 1H, MPM CH<sub>2</sub>), 6.85 (d,  $J$  = 8.9 Hz, 2H, *p*-MeOPh-*o*), 7.27 (d,  $J$  = 8.9 Hz, 2H, *p*-MeOPh-*m*), 7.27-7.36 (m, 5H, PhCH<sub>2</sub>).

**Diolcarbonate 27 b:** To a solution of the diol 26b ( $P_{520} = C(CH_3)_2$ ,  $P_7 = BOM$ ) (1.1 mg) in 0.2 mL of CH<sub>2</sub>Cl<sub>2</sub> and 0.02 mL of pyridine stirred at -78 °C was added a solution of phosgene (0.010 mL, 2M in toluene, 0.02 mmol). The resulting solution was stirred at -78 °C for 10 min then warmed to 0 °C for 3 h. The mixture was diluted with 30% ethyl acetate in hexanes (5 mL) then poured into 30% ethyl acetate in hexanes (10 mL) over saturated aqueous NaHCO<sub>3</sub>. The aqueous phase was extracted with 30% ethyl acetate in hexanes (2 x 5 mL) then the combined extracts were washed with brine, dried with Na<sub>2</sub>SO<sub>4</sub>, and filtered. Concentration of the filtrate under vacuum yielded 1.3mg of crude material. Purification by silica gel chromatography yielded 0.9 mg of pure 1,2-cyclic carbonate.

To a solution of the carbonate stirred in 0.1 ml of THF and 0.05 mL of methanol was added a solution of pyridinium tosylate (0.005 ml, 0.1M in CH<sub>2</sub>Cl<sub>2</sub>). The mixture was stirred at room temperature for 24 h and partitioned between saturated sodium bicarbonate and ethyl acetate. The ethyl acetate layer was dried over sodium sulfate and evaporated to give 0.9 mg of diol 27b.

**27b (P<sub>7</sub>=BOM):** <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ- 0.24 (s, 3H, TBS CH<sub>3</sub>), -0.038 (s, 3H, TBS CH<sub>3</sub>), 0.58 (q,  $J$  = 8.1 Hz, 6H, TES CH<sub>2</sub>), 0.84 (s, 9H, TBS t-Bu), 0.93 (t,  $J$  = 8.1 Hz, 9H, TES CH<sub>3</sub>), 1.14 (s, 3H, CH<sub>3</sub> 19), 1.19 (s, 3H, CH<sub>3</sub> 17), 1.34 (s, 3H, CH<sub>3</sub> 16), 1.88 (br d,  $J$  = 17 Hz, H9 $\beta$ ), 2.00 (br q,  $J$  = 12 Hz, 1H, H6 $\beta$ ), 2.08 (d,  $J$  = 1.4 Hz, 3H, CH<sub>3</sub> 18), 2.2 (m, 2H, H9 $\alpha$  and 14 $\beta$ ), 2.35 (br s, 1H, H3 $\alpha$ ), 2.39 (dt,  $J$  = 4.8, 13 Hz, H6 $\alpha$ ), 2.74 (br s, 1H, 20 OH), 2.87 (dd,  $J$  = 15.1, 5.1 Hz, 1H, H14 $\alpha$ ), 3.71 (dd,  $J$  = 11.3, 5.1 Hz, 1H, H2 $\beta$ ), 3.58 (br s, 2H, H7 $\alpha$  and 20 OH), 3.78 (s, 3H, OCH<sub>3</sub>), 3.78 (br m, 1H, H5 $\alpha$ ), 4.37 (dd,  $J$  = 13.0, 5.8 Hz, 1H,

H<sub>2</sub>O), 4.39 (dd, *J* = 4.8, 5.8 Hz, 1H, H10 $\beta$ ), 4.47 (m, 2H, H20 and 2 $\beta$ ), 4.59 (d; *J* = 11.6 Hz, 1H, OCH<sub>2</sub>Ph), 4.63 (br m, 1H, H13 $\beta$ ), 4.71 (d, *J* = 11.6 Hz, 1H, OCH<sub>2</sub>Ph), 4.88 (d, *J* = 7.2 Hz, 1H, OCH<sub>2</sub>O), 4.91 (d, *J* = 7.2 Hz, 1H, OCH<sub>2</sub>O), 4.93 (m, 2H, MPM CH<sub>2</sub>), 6.84 (d, *J* = 8.6 Hz, 2H, *p*-MeOPh -*o*), 7.23 (d, *J* = 8.6 Hz, 2H, *p*-MeOPh -*m*), 7.27-7.36 (m, 5H, Ph CH<sub>2</sub>).

**Mesylate 28b.** To a stirred solution of diol 27b (0.9 mg) in pyridine (0.6 mL) under nitrogen at 0° C was added dropwise methanesulfonyl chloride (0.02 mL). After 12 h, a saturated aqueous NaHCO<sub>3</sub> solution (0.05 mL) was added. The mixture was stirred for 10 min, poured into 20 mL of a saturated aqueous NaHCO<sub>3</sub> solution and extracted with 40% ethyl acetate/hexane (20 mL x 3). The combined organic phase was dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure to give 1 mg of 28b as a colorless oil.

**Oxetane 29.** To a stirred solution of mesylate 28b (1 mg) in toluene (0.4 mL) under nitrogen at room temperature was added diisopropyl ethylamine (0.008 mL). The solution was refluxed for 3.5 h, cooled to room temperature, poured into 20 mL of a saturated aqueous NaHCO<sub>3</sub> solution and extracted with ethyl acetate (20 mL x 3). The combined organic phase was dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and concentrated under reduced pressure to give 1.5 mg of a pale yellow oil. The oil was column chromatographed (30% ethyl acetate/hexane) to yield 1 mg of MPM oxetane. This material was dissolved in 1 mL of methylene chloride, 0.1 mL of 0.1 M phosphate buffer and 1 mg of DDQ were added, and the mixture was stirred at ambient temperature for 2h. The mixture was poured into 20 mL of a saturated aqueous NaHCO<sub>3</sub> solution and extracted with ethyl acetate (20 mL x 3). The combined organic phase was dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and concentrated under reduced pressure to give 1.0 mg of an oil. To a stirred solution of this material (1 mg) and dimethyl aminopyridine (1.5 mg) in pyridine (10  $\mu$ L) under nitrogen at room temperature was added acetic anhydride (5  $\mu$ L). The solution was stirred for 15 h, diluted with ethyl acetate, poured into 20 mL of a 10% aqueous CuSO<sub>4</sub> solution and extracted with ethyl acetate (20 mL x 3). The combined organic phase was washed with a saturated aqueous NaHCO<sub>3</sub> solution, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure to give 2 mg of a pale yellow oil. The oil was column chromatographed (25% ethyl acetate/hexane) to yield 0.6 mg of oxetane 29.


100

In view of the above, it will be seen that the several objects of the invention are achieved.

As various changes could be made in the above compositions without departing from the scope of the invention, it is intended that all matter contained in the above description be interpreted as illustrative and not in a limiting sense.

WHAT WE CLAIM IS:

1. An intermediate for use in the preparation of a tricyclic or tetracyclic taxane having the formula:



wherein

5                   R<sub>1</sub> is hydrogen, hydroxy, protected hydroxy or -OCOR<sub>30</sub>, or together with R<sub>2</sub> is a carbonate;

                  R<sub>2</sub> is hydrogen, hydroxy, protected hydroxy, oxo, or -OCOR<sub>31</sub>, or together with R<sub>1</sub> is a carbonate;

10                  R<sub>3</sub> is hydrogen, hydroxy, protected hydroxy, -OCOR<sub>32</sub>, or oxo;

                  R<sub>8</sub> is hydrogen, alkyl, alkenyl, alkynyl, aryl or heteroaryl;

15                  R<sub>9</sub> is hydrogen, hydroxy, protected hydroxy, oxo, or -OCOR<sub>33</sub>, or together with R<sub>10</sub> is a carbonate;

                  R<sub>10</sub> is hydrogen, hydroxy, protected hydroxy, oxo, or -OCOR<sub>29</sub>, or together with R<sub>9</sub> is a carbonate;


                  R<sub>13</sub> is hydrogen, hydroxy, protected hydroxy, -OCOR<sub>35</sub> or MO-;

20                  R<sub>29</sub>, R<sub>30</sub>, R<sub>31</sub>, R<sub>32</sub>, R<sub>33</sub>, and R<sub>35</sub> are independently hydrogen, alkyl, alkenyl, alkynyl, alkoxy, aryloxy, -NX<sub>8</sub>X<sub>10</sub>, -SX<sub>10</sub>, monocyclic aryl or monocyclic heteroaryl;

                  X<sub>8</sub> is hydrogen, alkyl, alkenyl, alkynyl, aryl, or heteroaryl;

25                    $X_{10}$  is alkyl, alkenyl, alkynyl, aryl, or heteroaryl; and  
 M comprises ammonium or is a metal.

2. An intermediate for use in the preparation of a tricyclic or tetracyclic taxane having the formula:



wherein

5                    $R_1$  is hydrogen, hydroxy, protected hydroxy or  $-OCOR_{30}$ , or together with  $R_2$  is a carbonate;

10                   $R_2$  is hydrogen, hydroxy, protected hydroxy, oxo, or  $-OCOR_{31}$ , or together with  $R_1$  is a carbonate;

15                   $R_3$  is hydrogen, hydroxy, protected hydroxy,  $-OCOR_{32}$ , or oxo, or together with  $R_{7b}$  is a carbonate;

20                   $R_{7b}$  is hydrogen, alkyl, cyano, hydroxy, protected hydroxy, or  $-OCOR_{36}$ , or together with  $R_3$  or  $R_9$  is a carbonate;

25                   $R_{7c}$  and  $R_{7d}$  are independently hydrogen, alkyl, alkenyl, alkynyl, aryl or heteroaryl;

30                   $R_9$  is hydrogen, hydroxy, protected hydroxy, oxo, or  $-OCOR_{33}$ , or together with  $R_{7b}$  or  $R_{10}$  is a carbonate;

35                   $R_{10}$  is hydrogen, hydroxy, protected hydroxy, oxo, or  $-OCOR_{29}$ , or together with  $R_9$  is a carbonate;

40                   $R_{13}$  is hydrogen, hydroxy, protected hydroxy,  $-OCOR_{35}$  or  $MO-$ ;


25             $R_{29}$ ,  $R_{30}$ ,  $R_{31}$ ,  $R_{32}$ ,  $R_{33}$ ,  $R_{35}$  and  $R_{36}$  are independently hydrogen, alkyl, alkenyl, alkynyl, alkoxy, aryloxy,  $-NX_8X_{10}$ ,  $-SX_{10}$ , monocyclic aryl or monocyclic heteroaryl;

30             $X_8$  is hydrogen, alkyl, alkenyl, alkynyl, aryl, or heteroaryl;

$X_{10}$  is alkyl, alkenyl, alkynyl, aryl, or heteroaryl; and

              M comprises ammonium or is a metal.

3. An intermediate for use in the preparation of a tricyclic or tetracyclic taxane having the formula:



wherein

5             $R_1$  is hydrogen, hydroxy, protected hydroxy or  $-OCOR_{30}$ , or together with  $R_2$  is a carbonate;

$R_2$  is hydrogen, hydroxy, protected hydroxy, oxo, or  $-OCOR_{31}$ , or together with  $R_1$  is a carbonate;

10             $R_3$  is hydrogen, hydroxy, protected hydroxy, or  $-OCOR_{32}$ ;

$R_{7c}$  and  $R_{7d}$  are independently hydrogen, alkyl, alkenyl, alkynyl, aryl or heteroaryl;

$R_9$  is hydrogen, hydroxy, protected hydroxy, oxo, or  $-OCOR_{33}$ , or together with  $R_{10}$  is a carbonate;

15                     $R_{10}$  is hydrogen, hydroxy, protected hydroxy, oxo, or  $-OCOR_{29}$ , or together with  $R_9$  is a carbonate;

$R_{13}$  is hydrogen, hydroxy, protected hydroxy,  $-OCOR_{35}$  or  $MO^-$ ;


20                     $R_{29}$ ,  $R_{30}$ ,  $R_{31}$ ,  $R_{32}$ ,  $R_{33}$ , and  $R_{35}$  are independently hydrogen, alkyl, alkenyl, alkynyl, alkoxy, aryloxy,  $-NX_8X_{10}$ ,  $-SX_{10}$ , monocyclic aryl or monocyclic heteroaryl;

$X_8$  is hydrogen, alkyl, alkenyl, alkynyl, aryl, or heteroaryl;

25                     $X_{10}$  is alkyl, alkenyl, alkynyl, aryl, or heteroaryl; and

                  M comprises ammonium or is a metal.

4. An intermediate for use in the preparation of a tricyclic or tetracyclic taxane having the formula:



wherein

5                    R is  $C_1 - C_8$  alkyl,

$R_1$  is hydrogen, hydroxy, protected hydroxy or  $-OCOR_{30}$ , or together with  $R_2$  is a carbonate;

$R_2$  is hydrogen, hydroxy, protected hydroxy, oxo, or  $-OCOR_{31}$ , together with  $R_1$  is a carbonate, or together with  $R_{4a}$  is a carbonate;

10                     $R_{4a}$  is hydrogen, alkyl, hydroxy, protected hydroxy, or  $-OCOR_{27}$ , or together with  $R_2$  is a carbonate;

15             $R_{7a}$  is hydrogen, halogen, hydroxy, protected hydroxy,  $-OR_{28}$ , or  $-OCOR_{34}$ , or together with  $R_9$  is a carbonate;

16             $R_9$  is hydrogen, oxo, hydroxy, protected hydroxy,  $-OR_{28}$ , or  $-OCOR_{33}$ , or together with  $R_{7a}$  or  $R_{10}$  is a carbonate;

20             $R_{10}$  is hydrogen, oxo, hydroxy, protected hydroxy,  $-OR_{28}$ , or  $-OCOR_{29}$ , or together with  $R_9$  is a carbonate;

21             $R_{13}$  is hydrogen, hydroxy, protected hydroxy,  $-OCOR_{35}$  or  $MO-$ ;

25             $R_{28}$  is a functional group which increases the solubility of the taxane derivative;


26             $R_{29}$ ,  $R_{30}$ ,  $R_{31}$ ,  $R_{33}$ ,  $R_{34}$  and  $R_{35}$  are independently hydrogen, alkyl, alkenyl, alkynyl, alkoxy, aryloxy,  $-NX_8X_{10}$ ,  $-SX_{10}$ , monocyclic aryl or monocyclic heteroaryl;

30             $X_8$  is hydrogen, alkyl, alkenyl, alkynyl, aryl, or heteroaryl;

31             $X_{10}$  is alkyl, alkenyl, alkynyl, aryl, or heteroaryl; and

32            M comprises ammonium or is a metal.

5. An intermediate for use in the preparation of a tricyclic or tetracyclic taxane having the formula:



wherein

5             $R_1$  is hydrogen, hydroxy, protected hydroxy or  $-OCOR_{30}$ , or together with  $R_2$  is a carbonate;

$R_2$  is hydrogen, hydroxy, protected hydroxy, oxo, or  $-OCOR_{31}$ , or together with  $R_1$  or  $R_{4a}$  is a carbonate;

10           $R_{4a}$  is hydrogen, alkyl, hydroxy, protected hydroxy, or  $-OCOR_{27}$ , together with  $R_{4b}$  is an oxo, or together with  $R_2$ ,  $R_{4b}$ , or  $R_5$  is a carbonate;

$R_{4b}$  is hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl, or cyano, together with  $R_{4a}$  is an oxo, together with  $R_{4a}$  or  $R_5$  is a carbonate, or together with  $R_5$  and the carbons to which they are attached form an oxetane ring;


15           $R_5$  is hydrogen, hydroxy, protected hydroxy,  $-OCOR_{28}$ , oxo, together with  $R_{4a}$  or  $R_{4b}$  is a carbonate, or together with  $R_{4b}$  and the carbons to which they are attached form an oxetane ring;

20           $R_{7a}$  is hydrogen, halogen, hydroxy, protected hydroxy,  $-OR_{28}$ , or  $-OCOR_{34}$ , or together with  $R_9$  is a carbonate;

$R_9$  is hydrogen, oxo, hydroxy, protected hydroxy,  $-OR_{28}$ , or  $-OCOR_{33}$ , or together with  $R_{7a}$  or  $R_{10}$  is a carbonate;

25           $R_{10}$  is hydrogen, oxo, hydroxy, protected hydroxy,  $-OR_{28}$ , or  $-OCOR_{29}$ , or together with  $R_9$  is a carbonate;

$R_{13}$  is hydrogen, hydroxy, protected hydroxy,  $-OCOR_{35}$ ,  $MO-$  or



$R_{28}$  is a functional group which increases the solubility of the taxane derivative;

35             $R_{27}$ ,  $R_{29}$ ,  $R_{30}$ ,  $R_{31}$ ,  $R_{33}$ ,  $R_{34}$ , and  $R_{35}$  are independently hydrogen, alkyl, alkenyl, alkynyl, alkoxy, aryloxy,  $-NX_8X_{10}$ ,  $-SX_{10}$ , monocyclic aryl or monocyclic heteroaryl;

40             $X_1$  is  $-OX_6$ ,  $-SX_7$ , or  $-NX_8X_9$ ;

40             $X_2$  is hydrogen, alkyl, alkenyl, alkynyl, aryl, or heteroaryl;

45             $X_3$  and  $X_4$  are independently hydrogen, alkyl, alkenyl, alkynyl, aryl, or heteroaryl;

45             $X_5$  is  $-COX_{10}$ ,  $-COOX_{10}$ ,  $-COSX_{10}$ ,  $-CONX_8X_{10}$ , or  $-SO_2X_{11}$ ;

50             $X_6$  is hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl, hydroxy protecting group, or a functional group which increases the water solubility of the taxane derivative;

50             $X_7$  is alkyl, alkenyl, alkynyl, aryl, heteroaryl, or sulfhydryl protecting group;

55             $X_8$  is hydrogen, alkyl, alkenyl, alkynyl, aryl, or heteroaryl;

55             $X_9$  is an amino protecting group;

55             $X_{10}$  is alkyl, alkenyl, alkynyl, aryl, or heteroaryl;


60             $X_{11}$  is alkyl, alkenyl, alkynyl, aryl, heteroaryl,  $-OX_{10}$ , or  $-NX_8X_{14}$ ;

60             $X_{14}$  is hydrogen, alkyl, alkenyl, alkynyl, aryl, or heteroaryl; and

60            M comprises ammonium or is a metal.


6. A process for the preparation of an intermediate useful in the synthesis of a tricyclic or tetracyclic taxane comprising reacting a compound having the formula

108



5

with  $\text{BrMgN}(\text{iPr})_2$ , an aldehyde (or ketone), followed by phosgene and an alcohol to form a compound having the formula:



10

wherein

$R_1$  is hydrogen or protected hydroxy;  $R_2$  is hydrogen or protected hydroxy;

$R_3$  is oxo;

$R_{7b}$  is hydrogen, alkyl, cyano, hydroxy, 15 protected hydroxy, or  $-\text{OCOR}_{16}$ , or together with  $R_3$  or  $R_5$  is a carbonate;

$R_{7c}$  and  $R_{7d}$  are independently hydrogen, alkyl, alkenyl, alkynyl, aryl or heteroaryl;

$R_9$  is hydrogen, protected hydroxy, or oxo;


20

$R_{10}$  is  $-\text{OP}_{10}$ ;

$R_{13}$  is  $-\text{OP}_{13}$ ; and


$P_{10}$  and  $P_{13}$  are hydroxy protecting groups.

7. A process for the preparation of an intermediate useful in the synthesis of a tricyclic or tetracyclic taxane comprising reacting a compound having the formula



5

with lithium tetramethylpiperidide to form a compound having the formula:



wherein

10

R<sub>1</sub> is hydrogen or protected hydroxy;

R<sub>7c</sub> is hydrogen, alkyl, alkenyl, alkynyl, aryl or heteroaryl;


R<sub>9</sub> is hydrogen, protected hydroxy, or oxo; and

P<sub>10</sub> and P<sub>13</sub> are hydroxy protecting groups.


15

8. A process for the preparation of an intermediate useful in the synthesis of a tricyclic or tetracyclic taxane comprising reacting a compound having the formula:

110




20 with lithium tetramethylpiperidide and camphosulfonyl oxaziridine to form a compound having the formula:



25 wherein R<sub>9</sub> is hydrogen, protected hydroxy, or oxo; R<sub>7c</sub> is hydrogen, alkyl, alkenyl, alkynyl, aryl or heteroaryl; and P<sub>10</sub> and P<sub>13</sub> are hydroxy protecting groups.


9. A process for the preparation of an intermediate useful in the synthesis of a tricyclic or tetracyclic taxane comprising reacting a compound having the formula:

111



5

with a hydride reducing agent to form a compound having the formula:




10

wherein R<sub>9</sub> is hydrogen, protected hydroxy, or oxo; R<sub>7c</sub> is hydrogen, alkyl, alkenyl, alkynyl, aryl or heteroaryl; and P<sub>10</sub> and P<sub>13</sub> are hydroxy protecting groups.


10. A process for the preparation of an intermediate useful in the synthesis of a tricyclic or tetracyclic taxane comprising reacting a compound having the formula:

112



5


with lithium diisopropylamide to form a compound having the formula:



;


10 wherein R is lower alkyl, R<sub>1</sub> is hydrogen, protected hydroxy or R<sub>1</sub> and R<sub>2</sub> together form a carbonate, R<sub>2</sub> is hydrogen, protected hydroxy or R<sub>1</sub> and R<sub>2</sub> together form a carbonate, R<sub>9</sub> is hydrogen, protected hydroxy, or oxo; R<sub>7c</sub> is hydrogen, alkyl, alkenyl, alkynyl, aryl or heteroaryl; and P<sub>10</sub> and P<sub>13</sub> are hydroxy protecting groups.

11. A process for the preparation of an intermediate useful in the synthesis of a tricyclic or tetracyclic taxane comprising reacting a compound having the formula:



5

with DBU to form a compound having the formula:



wherein

10  $R_1$  is hydrogen, hydroxy, protected hydroxy or  $-OCOR_{30}$ , or together with  $R_2$  is a carbonate;

$R_2$  is hydrogen, hydroxy, protected hydroxy, oxo, or  $-OCOR_{31}$ , or together with  $R_1$  is a carbonate;

15  $R_{4a}$  is hydrogen, alkyl, hydroxy, or protected hydroxy, or together with  $R_2$  is a carbonate;

$R_{4b}$  is hydroxymethylene;

$R_5$  is  $-OMs$ ,  $-OTs$  or a bromide;

20  $R_{7a}$  is hydrogen, protected hydroxy, or  $-OCOR_{34}$ , or together with  $R_9$  is a carbonate;


$R_9$  is hydrogen, oxo, hydroxy, protected hydroxy, or  $-OCOR_{33}$ , or together with  $R_{7a}$  or  $R_{10}$  is a carbonate;

$R_{10}$  is hydrogen, oxo, hydroxy, protected hydroxy, or  $-OCOR_{29}$ , or together with  $R_9$  is a carbonate;

$R_{13}$  is hydrogen, hydroxy, protected hydroxy, or  $-OCOR_{35}$ ;


25  $R_{29}$ ,  $R_{33}$ ,  $R_{34}$  and  $R_{35}$  are independently hydrogen, alkyl, alkenyl, alkynyl, alkoxy, aryloxy,  $-NX_8X_{10}$ ,  $-SX_{10}$ , monocyclic aryl or monocyclic heteroaryl.

12. A process for the preparation of an intermediate useful in the synthesis of a tricyclic or tetracyclic taxane comprising reacting a compound having the formula:




5

with  $KOtBu$  and  $(PhSeO)_2O$  to form a reaction product having the formula:



10 and exposing the reaction product to additional  $KOtBu$ , silica gel, or other acids or bases, or to heat to rearrange the reaction product to a compound having the formula:



wherein

15                     $R_1$  is hydrogen, hydroxy, protected hydroxy, or together with  $R_2$  is a carbonate;

$R_2$  is hydrogen, protected hydroxy, or  $-OCOR_{31}$ , or together with  $R_1$  or  $R_{4a}$  is a carbonate;

20                     $R_{4a}$  is hydrogen, alkyl, hydroxy, protected hydroxy, or  $-OCOR_{27}$ , together with  $R_{4b}$  is an oxo, or together with  $R_2$ ,  $R_{4b}$ , or  $R_5$  is a carbonate;

$R_{4b}$  is hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl, or cyano, together with  $R_{4a}$  is an oxo, together with  $R_{4a}$  or  $R_5$  is a carbonate, or together with  $R_5$  and the carbons to which they are attached form an oxetane ring;

25                     $R_5$  is hydrogen, protected hydroxy,  $-OCOR_{37}$ , together with  $R_{4a}$  or  $R_{4b}$  is a carbonate, or together with  $R_{4b}$  and the carbons to which they are attached form an oxetane ring;

$R_{7a}$  is hydrogen, halogen, protected hydroxy, or  $-OCOR_{34}$ ; and

$R_{27}$ ,  $R_{29}$ ,  $R_{30}$ ,  $R_{31}$ ,  $R_{33}$ ,  $R_{34}$ ,  $R_{35}$  and  $R_3$ , are independently hydrogen, alkyl, alkenyl, alkynyl, alkoxy, aryloxy,  $-NX_8X_{10}$ ,  $-SX_{10}$ , monocyclic aryl or monocyclic heteroaryl;

35                     $X_8$  is hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterosubstituted alkyl, alkenyl, alkynyl, aryl or heteroaryl; and

116


40                    $X_{10}$  is alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterosubstituted alkyl, alkenyl alkynyl, aryl or heteroaryl.

117  
AMENDED CLAIMS

[received by the International Bureau on 6 January 1995 (06.01.95); original claims 3,4,5,11 and 12 amended; other claims unchanged (14 pages)]

and  $X_{10}$  is alkyl, alkenyl, alkynyl, aryl, or heteroaryl;  
M comprises ammonium or is a metal.

3. An intermediate for use in the preparation of a tricyclic or tetracyclic taxane having the formula:



wherein

5  $R_1$  is hydrogen, hydroxy, protected hydroxy or  $-OCOR_{30}$ , or together with  $R_2$  is a carbonate;

$R_2$  is hydrogen, hydroxy, protected hydroxy, oxo, or  $-OCOR_{31}$ , or together with  $R_1$  is a carbonate;

10  $R_3$  is hydrogen, hydroxy, protected hydroxy, or  $-OCOR_{32}$ ;

$R_{7b}$  is hydrogen, alkyl, cyano, hydroxy, protected hydroxy, or  $-OCOR_{36}$ , or together with  $R_3$  or  $R_9$  is a carbonate;

15  $R_{7c}$  is hydrogen, alkyl, alkenyl, alkynyl, aryl or heteroaryl;

$R_9$  is hydrogen, hydroxy, protected hydroxy, oxo, or  $-OCOR_{33}$ , or together with  $R_{10}$  is a carbonate;

$R_{10}$  is hydrogen, hydroxy, protected hydroxy, oxo, or  $-OCOR_{29}$ , or together with  $R_9$  is a carbonate;


20  $R_{13}$  is hydrogen, hydroxy, protected hydroxy,  $-OCOR_{15}$  or  $MO^-$ ;

$R_{29}$ ,  $R_{30}$ ,  $R_{31}$ ,  $R_{32}$ ,  $R_{33}$ ,  $R_{35}$ , and  $R_{36}$  are independently hydrogen, alkyl, alkenyl, alkynyl, alkoxy, aryloxy, - $NX_8X_{10}$ , - $SX_{10}$ , monocyclic aryl or monocyclic heteroaryl;

25  $X_8$  is hydrogen, alkyl, alkenyl, alkynyl, aryl, or heteroaryl;

$X_{10}$  is alkyl, alkenyl, alkynyl, aryl, or heteroaryl; and  $M$  comprises ammonium or is a metal.

4. An intermediate for use in the preparation of a tricyclic or tetracyclic taxane having the formula:



wherein

5  $R$  is  $C_1$  -  $C_8$  alkyl,

$R_1$  is hydrogen, hydroxy, protected hydroxy or - $OCOR_{30}$ , or together with  $R_2$  is a carbonate;

10  $R_2$  is hydrogen, hydroxy, protected hydroxy, oxo, or - $OCOR_{31}$ , together with  $R_1$  is a carbonate, or together with  $R_{4a}$  is a carbonate;

$R_{4a}$  is hydrogen, alkyl, hydroxy, protected hydroxy, or - $OCOR_{27}$ , or together with  $R_2$  is a carbonate;

$R_{7a}$  is hydrogen, halogen, hydroxy, protected hydroxy, - $OR_{28}$ , or - $OCOR_{34}$ , or together with  $R_9$  is a carbonate;

15  $R_9$  is hydrogen, oxo, hydroxy, protected hydroxy, - $OR_{29}$ , or - $OCOR_{33}$ , or together with  $R_{7a}$  or  $R_{10}$  is a carbonate;

20                   R<sub>13</sub> is hydrogen, oxo, hydroxy, protected hydroxy, -OR<sub>28</sub>, or -OCOR<sub>29</sub>, or together with R<sub>9</sub> is a carbonate;


20                   R<sub>13</sub> is hydrogen, hydroxy, protected hydroxy, -OCOR<sub>35</sub> or MO-;

25                   R<sub>28</sub> is a functional group which increases the solubility of the taxane derivative;

25                   R<sub>27</sub>, R<sub>29</sub>, R<sub>30</sub>, R<sub>31</sub>, R<sub>33</sub>, R<sub>34</sub> and R<sub>35</sub> are independently hydrogen, alkyl, alkenyl, alkynyl, alkoxy, aryloxy, -NX<sub>8</sub>X<sub>10</sub>, -SX<sub>10</sub>, monocyclic aryl or monocyclic heteroaryl; X<sub>8</sub> is hydrogen, alkyl, alkenyl, alkynyl, aryl, or heteroaryl;

30                   X<sub>10</sub> is alkyl, alkenyl, alkynyl, aryl, or heteroaryl; and M comprises ammonium or is a metal.

5. An intermediate for use in the preparation of a tricyclic or tetracyclic taxane having the formula:



wherein

5                   R<sub>1</sub> is hydrogen, hydroxy, protected hydroxy or -OCOR<sub>31</sub>, or together with R<sub>2</sub> is a carbonate;

10                  R<sub>2</sub> is hydrogen, hydroxy, protected hydroxy, oxo, or -OCOR<sub>31</sub>, or together with R<sub>1</sub> or R<sub>4a</sub> is a carbonate;

10                  R<sub>4a</sub> is hydrogen, alkyl, hydroxy, protected hydroxy, or -OCOR<sub>27</sub>, together with R<sub>4b</sub> is an oxo, or together with R<sub>1</sub>, R<sub>4b</sub>, or R<sub>5</sub> is a carbonate;

15       $R_{4b}$  is hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl, or cyano, together with  $R_{4a}$  is an oxo, together with  $R_{4a}$  or  $R_5$  is a carbonate, or together with  $R_5$  and the carbons to which they are attached form an oxetane ring;


20       $R_5$  is hydrogen, hydroxy, protected hydroxy,  $-OCOR_{28}$ , oxo, together with  $R_{4a}$  or  $R_{4b}$  is a carbonate, or together with  $R_{4b}$  and the carbons to which they are attached form an oxetane ring;

25       $R_{7a}$  is hydrogen, halogen, hydroxy, protected hydroxy,  $-OR_{28}$ , or  $-OCOR_{34}$ , or together with  $R_9$  is a carbonate;

30       $R_9$  is hydrogen, oxo, hydroxy, protected hydroxy,  $-OR_{28}$ , or  $-OCOR_{33}$ , or together with  $R_{7a}$  or  $R_{10}$  is a carbonate;

35       $R_{10}$  is hydrogen, oxo, hydroxy, protected hydroxy,  $-OR_{28}$ , or  $-OCOR_{29}$ , or together with  $R_9$  is a carbonate;

40       $R_{13}$  is hydrogen, hydroxy, protected hydroxy,  $-OCOR_{35}$ ,  $MO^-$  or



30

45       $R_{26}$  is a functional group which increases the solubility of the taxane derivative;

50       $R_{27}$ ,  $R_{29}$ ,  $R_{30}$ ,  $R_{31}$ ,  $R_{33}$ ,  $R_{34}$ , and  $R_{35}$  are independently hydrogen, alkyl, alkenyl, alkynyl, alkoxy, aryloxy,  $-NX_8X_{10}$ ,  $-SX_{10}$ , monocyclic aryl or monocyclic heteroaryl;

55       $X_1$  is  $-OX_6$ ,  $-SX_7$ , or  $-NX_8X_9$ ;

60       $X_2$  is hydrogen, alkyl, alkenyl, alkynyl, aryl, or heteroaryl;

65       $X_3$  and  $X_4$  are independently hydrogen, alkyl, alkenyl, alkynyl, aryl, or heteroaryl;

70       $X_5$  is  $-COX_{10}$ ,  $-COOX_{10}$ ,  $-COSX_{10}$ ,  $-CONX_8X_{10}$ .

or  $-\text{SC}_2\text{X}_{11}$ ;

45  $\text{X}_6$  is hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl, hydroxy protecting group, or a functional group which increases the water solubility of the taxane derivative;

$\text{X}_7$  is alkyl, alkenyl, alkynyl, aryl, heteroaryl, or sulfhydryl protecting group;

50  $\text{X}_8$  is hydrogen, alkyl, alkenyl, alkynyl, aryl, or heteroaryl;

$\text{X}_9$  is an amino protecting group;


$\text{X}_{10}$  is alkyl, alkenyl, alkynyl, aryl, or heteroaryl;

$\text{X}_{11}$  is alkyl, alkenyl, alkynyl, aryl, heteroaryl,  $-\text{OX}_{10}$ , or  $-\text{NX}_8\text{X}_{14}$ ;


55  $\text{X}_{14}$  is hydrogen, alkyl, alkenyl, alkynyl, aryl, or heteroaryl; and

$\text{M}$  comprises ammonium or is a metal.

6. A process for the preparation of an intermediate useful in the synthesis of a tricyclic or tetracyclic taxane comprising reacting a compound having the formula



5 with  $\text{BrMgN}(\text{iPr})_2$ , an aldehyde (or ketone), followed by phosgene and an alcohol to form a compound having the formula:



wherein

10         $R_1$  is hydrogen or protected hydroxy;  $R_2$  is hydrogen or protected hydroxy;

$R_3$  is oxo;

$R_{7b}$  is hydrogen, alkyl, cyano, hydroxy, protected hydroxy, or  $-OCOR_{16}$ ;

15         $R_{7c}$  and  $R_{7d}$  are independently hydrogen, alkyl, alkenyl, alkynyl, aryl or heteroaryl;

$R_9$  is hydrogen, protected hydroxy, or oxo;

$R_{10}$  is  $-OP_{10}$ ;

$R_{13}$  is  $-OP_{13}$ ;


20         $R_{16}$  is hydrogen, alkyl, alkenyl, alkynyl, alkoxy, aryloxy,  $-NX_8X_{10}$ ,  $-SX_{10}$ , monocyclic aryl or monocyclic heteroaryl;

$X_8$  is hydrogen, alkyl, alkenyl, alkynyl, aryl, or heteroaryl;


25         $X_{10}$  is alkyl, alkenyl, alkynyl, aryl, or heteroaryl; and

$P_{10}$  and  $P_{13}$  are hydroxy protecting groups.

7. A process for the preparation of an intermediate useful in the synthesis of a tricyclic or tetracyclic taxane comprising reacting a compound having the formula



5 with lithium tetramethylpiperidide to form a compound having the formula:



wherein


R<sub>1</sub> is hydrogen or protected hydroxy;

10 R<sub>7c</sub> is hydrogen, alkyl, alkenyl, alkynyl, aryl or heteroaryl;


R<sub>9</sub> is hydrogen, protected hydroxy, or oxo; and

P<sub>10</sub> and P<sub>13</sub> are hydroxy protecting groups.

15 8. A process for the preparation of an intermediate useful in the synthesis of a tricyclic or tetracyclic taxane comprising reacting a compound having the formula:




with lithium tetramethylpiperidide and camphorsulfonyl oxaziridine to form a compound having the formula:




20

wherein R<sub>9</sub> is hydrogen, protected hydroxy, or oxo; R<sub>7c</sub> is hydrogen, alkyl, alkenyl, alkynyl, aryl or heteroaryl; and P<sub>10</sub> and P<sub>13</sub> are hydroxy protecting groups.

9. A process for the preparation of an intermediate useful in the synthesis of a tricyclic or tetracyclic taxane comprising reacting a compound having the formula:




5 with a hydride reducing agent to form a compound having the formula:




10 wherein R<sub>9</sub> is hydrogen, protected hydroxy, or oxo; R<sub>7c</sub> is hydrogen, alkyl, alkenyl, alkynyl, aryl or heteroaryl; and P<sub>10</sub> and P<sub>13</sub> are hydroxy protecting groups.

10. A process for the preparation of an intermediate useful in the synthesis of a tricyclic or tetracyclic taxane comprising reacting a compound having the formula:



5


with lithium diisopropylamide to form a compound having the formula:



10


wherein R is lower alkyl, R<sub>1</sub> is hydrogen, protected hydroxy or R<sub>1</sub> and R<sub>2</sub> together form a carbonate, R<sub>2</sub> is hydrogen, protected hydroxy or R<sub>1</sub> and R<sub>2</sub> together form a carbonate, R, is hydrogen, protected hydroxy, or oxo; R<sub>7</sub> is hydrogen, alkyl, alkenyl, alkynyl, aryl or heteroaryl; and P<sub>10</sub> and P<sub>13</sub> are hydroxy protecting groups.

11. A process for the preparation of an intermediate useful in the synthesis of a tricyclic or tetracyclic taxane comprising reacting a compound having the formula:



5

with DBU to form a compound having the formula:



wherein

10  $R_1$  is hydrogen, hydroxy, protected hydroxy or  $-OCOR_{30}$ , or together with  $R_2$  is a carbonate;

$R_2$  is hydrogen, hydroxy, protected hydroxy, oxo, or  $-OCOR_{31}$ , or together with  $R_1$  is a carbonate;

15  $R_{4a}$  is hydrogen, alkyl, hydroxy, or protected hydroxy, or together with  $R_2$  is a carbonate;

$R_{4b}$  is hydroxymethylene;

$R_5$  is  $-OMs$ ,  $-OTs$  or a bromide;

$R_{7a}$  is hydrogen, protected hydroxy, or  $-OCOR_{34}$ , or together with  $R_9$  is a carbonate;

20  $R_9$  is hydrogen, oxo, hydroxy, protected hydroxy, or  $-OCOR_{33}$ , or together with  $R_7a$  or  $R_{10}$  is a carbonate;

$R_{10}$  is hydrogen, oxo, hydroxy, protected hydroxy, or  $-OCOR_{29}$ , or together with  $R_9$  is a carbonate;


$P_{13}$  is a hydroxy protecting group;

25  $R_{29}$ ,  $R_{30}$ ,  $R_{31}$ ,  $R_{33}$ , and  $R_{34}$  are independently hydrogen, alkyl, alkenyl, alkynyl, alkoxy, aryloxy,  $-NX_8X_{10}$ ,  $-SX_{10}$ , monocyclic aryl or monocyclic heteroaryl;

$X_8$  is hydrogen, alkyl, alkenyl, alkynyl, aryl, or heteroaryl; and


$X_{10}$  is alkyl, alkenyl, alkynyl, aryl, or heteroaryl.

12. A process for the preparation of an intermediate useful in the synthesis of a tricyclic or tetracyclic taxane comprising reacting a compound having the formula:



5


with  $KOtBu$  and  $(PhSeO)_2O$  to form a reaction product having the formula:



10

and exposing the reaction product to additional  $KOtBu$ , silica gel, or other acids or bases, or to heat to

rearrange the reaction product to a compound having the formula:



wherein

15       $R_1$  is hydrogen, hydroxy, protected hydroxy, or together with  $R_2$  is a carbonate;

$R_2$  is hydrogen, protected hydroxy, or  $-OCOR_{21}$ , or together with  $R_1$  or  $R_{4a}$  is a carbonate;

20       $R_{4a}$  is hydrogen, alkyl, hydroxy, protected hydroxy, or  $-OCOR_{27}$ , together with  $R_{4b}$  is an oxo, or together with  $R_2$ ,  $R_{4b}$ , or  $R_5$  is a carbonate;

$R_{4b}$  is hydrogen, alkyl, alkenyl, alkynyl, aryl, heterocaryl, or cyano, together with  $R_{4a}$  is an oxo, together with  $R_{4a}$  or  $R_5$  is a carbonate, or together with  $R_5$  and the carbons to which they are attached form an oxetane ring;

25       $R_5$  is hydrogen, protected hydroxy,  $-OCOR_{33}$ , together with  $R_{4a}$  or  $R_{4b}$  is a carbonate, or together with  $R_{4b}$  and the carbons to which they are attached form an oxetane ring;

30       $R_{7a}$  is hydrogen, halogen, protected hydroxy, or  $-OCOR_{34}$ ;

$R_{13}$  is a hydroxy protecting group;

$R_{27}$ ,  $R_{31}$ ,  $R_{34}$ , and  $R_{37}$  are independently hydrogen, alkyl, alkenyl, alkynyl, alkoxy, aryloxy,  $-NX_8X_{16}$ ,  $-SX_{16}$ , monocyclic aryl or monocyclic heteroaryl;

35       $X_8$  is hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterosubstituted alkyl, alkenyl, alkynyl, aryl or heteroaryl; and

40  $X_{10}$  is alkyl, alkenyl, alkynyl, aryl, heteroaryl, or  
heterosubstituted alkyl, alkenyl alkynyl, aryl or  
heteroaryl.

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US94/08350

## A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) :Please See Extra Sheet.

US CL :Please See Extra Sheet.

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 549/229, 300, 510;  
568/347, 375Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched  
none

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

none

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	JOURNAL OF CHEMICAL SOCIETY, CHEMICAL COMMUNICATION, No. 16, issued August 1992. K.C. Nicolaou et al., "A convergent strategy toward taxol. A facile enantioselective entry into a fully functionalized ring A system", pages 1117-1120.	1-12
X, P	JOURNAL OF AMERICAN CHEMICAL SOCIETY, Volume 116, No. 4, issued 1994, Robert A. Holton et al., "First Total Synthesis of Taxol. 1. Functionalization of the B ring", pages 1597-1598, entire document.	1-12
X, P	JOURNAL OF AMERICAN CHEMICAL SOCIETY, Volume 116, No. 4, issued 1994, Robert A. Holton et al., "First Total Synthesis of Taxol. 2. Completion of the C and D Rings", pages 1599-1600, entire document.	1-12

 Further documents are listed in the continuation of Box C. See patent family annex.

* Special categories of cited documents:	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
*A* document defining the general state of the art which is not considered to be of particular relevance	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
*E* earlier document published on or after the international filing date	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"&"	document member of the same patent family
*O* document referring to an oral disclosure, use, exhibition or other means		
*P* document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search

24 OCTOBER 1994

Date of mailing of the international search report

NOV 07 1994

Name and mailing address of the ISA/US  
Commissioner of Patents and Trademarks  
Box PCT  
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

BA TRINH

Telephone No. (703) 308-1235

**INTERNATIONAL SEARCH REPORT**

International application No.

PCT/US94/08350

**Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)**

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1.  Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
  
2.  Claims Nos.: because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
  
3.  Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

**Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)**

This International Searching Authority found multiple inventions in this international application, as follows:

Please See Extra Sheet.

1.  As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2.  As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3.  As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
  
4.  No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

**Remark on Protest**

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.

**A. CLASSIFICATION OF SUBJECT MATTER:**

IPC (6):

**C07C 45/27, 49/21, 49/203; C07D 305/14, 307/93, 317/70****A. CLASSIFICATION OF SUBJECT MATTER:**

US CL :

**549/229, 300, 510; 568/347, 375****BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING**

This ISA found multiple inventions as follows:

**I.** Claims 1, 2 and 6, drawn to a bicyclic ketone compound and a process of making the same, classified in Class 568, subclasses 347 and 375.**II.** Claim 3, drawn to a tricyclic lactone, and classified in Class 549, subclass 300.**III.** Claim 7, drawn to a process of making tricyclic lactone, classified in Class 549/300.**IV.** Claims 4, 5 and 10, drawn to a tetracyclic carbonate, classified in Class 549, subclass 229.**V.** Claim 8, drawn to a process of making tricyclic lactone, classified in Class 549, subclass 300.**VI.** Claim 9, drawn to a process of making tricyclic lactone, classified in Class 549, subclass 300.**VII.** Claim 11, drawn to a process of making oxetane, classified in Class 549, subclass 510.**VIII.** Claim 12, drawn to a process of making tricyclic ketone, classified in Class 568, subclass 347.

The above delineated groups are distinct because the compounds lack a common core structure and are made by different processes using different reaction conditions and reagents. A search of one compound is not required for the other compound, and vice versa. The processes are distinct because of different starting materials being used to make different final products wherein different reaction conditions and reagents have been used. One process would not suggest and/or render the other prima facie obvious in the absence of secondary teachings. 37 CFR 1.475(d).